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1 Introduction 
Calor, the Latin word for ‘heat’, defines the science of measuring heat as 
calorimetry.[1] The start of calorimetry was the invention of the first thermometer to 
measure heat. Since modern calorimetric instruments are very sensitive and allow to 
detect temperature changes of just a few millionths of a degree,[2] they can be used 
to thermodynamically characterize the heat of biomolecular interactions.[3] The 
thermodynamic fingerprint of a series of compounds can give useful information of 
protein-ligand interactions for structure activity relationship and furthermore for 
decision making in lead discovery.[4]  
 
 
1.1 Thermodynamics of Protein-Ligand Interactions 
1.1.1 The Basics of Thermodynamics in Protein-Ligand Interactions 
In a biomolecular interaction a protein in its native conformation (P) interacts with a 
ligand (L). In a closed thermodynamic system this interaction can be represented as: 
 P + L              PL  (1.1.1.1) 
This equilibrium can be characterized by following equation: 
 
  
KD  [P][L][PL] 
1
KA
  (1.1.1.2) 
where KD is the dissociation constant and KA is the association constant. The change 
in free energy (∆G), under arbitrary conditions, for complex formation (PL) is related 
to the standard free energy change (∆G°), under defined conditions (e.g. 1 M [P] and 
1 M [L] at pH 7 and 25 °C), by the equation: 
   G  GRT lnKD  (1.1.1.3) 
At equilibrium, where ∆G = 0 and equilibrium concentrations of [L], [P], and [PL] are 
reached: 
   G  RT lnKD  RT lnKA  (1.1.1.4) 
where R is the universal gas constant (8.314 J mol–1 K–1) and T the absolute 
temperature in K. Thus, the standard free energy can be directly calculated from KD. 
KD values can be determined using a variety of experimental techniques. Assuming 
that the change in enthalpy (∆H°) is not depending on temperature, the 
measurement of KD at several temperatures (KDT1, KDT2 at T1, T2, respectively), can 
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be used to calculate the van’t Hoff enthalpy (∆H°vH) and entropy (∆S°vH) with the 
van’t Hoff relationship: 
 
  
lnKD  GRT 
HvH
RT
TSvH
RT
 (1.1.1.5) 
However, since the assumption that the enthalpy does not change with the 
temperature is usually incorrect, the non-linear van’t Hoff equation is expected to 
give better results: 
 
  
ln
KDT1
KDT2
 HvHT1Cp
R
1
T1
 1
T2




Cp
R
lnT2
T1
 (1.1.1.6) 
where ∆Cp is the heat capacity change under constant pressure.[5] Nevertheless, 
discrepancies between van’t Hoff and determination of the enthalpy with isothermal 
titration calorimetry (ITC) exist.[6]  
ITC is a direct measurement that allows the values of enthalpy change (∆H°), KD, 
and stoichiometry (N) to be measured in a single experiment. Once these 
parameters are measured, the size of ∆S° can be calculated using the relationship: 
   G  RT lnKD  RT lnKA  H TS  (1.1.1.7) 
This relation is applicable when temperature and pressure are constant. Binding is 
favored if ∆G° is negative, therefore negative values of ∆H° and positive values of 
∆S° promote complex formation.[5]  
A further parameter that can be determined by ITC is the change in heat capacity 
(∆Cp) since both, ∆H° and ∆S°, are related with temperature by the heat capacity 
change: 
 
  
Cp  HT2 HT1(T2 T1)
 ST2 ST1
lnT2
T1
 (1.1.1.8) 
 
1.1.2 The Change in Enthalpy (∆H°) 
The changes in enthalpy (∆H°) and entropy (∆S°) influence the change in free 
energy of binding (∆G°). Negative enthalpy and positive entropy are leading to a 
negative free energy of binding results. 
∆H° of binding is related to the net change in the number and/or strength of non-
covalent bonds going from the free to the bound state. This includes solvent 
reorganization as well as the binding interface as well as other parts of the protein, 
e.g. undergoing conformational changes within the binding process. Before a ligand 
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can bind, the interacting surfaces have to be desolvated. Desolvation of polar groups 
that cannot establish polar non-covalent interaction in the complex will induce an 
enthalpic penalty.[4,7]  
Non-covalent interactions that influence ∆H° are electrostatic interaction like salt 
bridge formation, van-der-Waals interaction, hydrogen bond formation, as well as π-
π and cation-π stacking of aromatic interaction. 
Electrostatic interactions are described with Coulomb’s equation. The potential 
energy (Ui-i) between two point charges q1 and q2 decreases with increasing distance 
r: 
 
  
Uii  q1q24or  (1.1.2.1) 
where o is the permittivity of free space and  is the relative dielectric constant of the 
medium.[8] Charge-charge (or ion-ion) interaction can provide large contribution to 
enthalpy although we have to keep in mind that the desolvation of a charged group 
can compensate the gain by charge-charge interactions. At physiological pH (ca. 
7.40), interactions of the protonated side chain of arginine (pKa = 12.5) and lysine 
(pKa = 10.8), and the deprotonated carboxy groups of aspartic acid (pKa = 3.9) and 
glutamic acid (pKa = 4.1), form important salt bridges. We have, however, to keep in 
mind, that their exact protonation state depends on the local pH.[9]  
When protein and ligand are in close proximity, attractive forces called van-der-
Waals interactions occur. These forces depend on the distance with r–6. Three types 
of van-der-Waals forces can be defined: (i) permanent dipole-dipole interactions, (ii) 
permanent dipole-induced dipole forces, and (iii) induced dipole-induced dipole 
interactions. The latter interaction is called London or dispersion forces[8] and are 
assumed to be the major source of stabilizing energy between two aromatic 
molecules, for example in π-π-stacking or cation-π interaction.[10] The overall van-
der-Waals energy is a sum of the very short-range attraction and the extremely 
short-range steric repulsion between atoms. This relationship can be described with 
following equation: 
  
  
UvdW  Ar m 
B
r 6
  (1.1.2.2) 
where A and B are constants that describe the magnitude of the repulsive and 
attractive terms, respectively, and m is the power of the repulsive term (usually 
between 5 and 12).[1]  
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The formation of hydrogen bonds is the most important interaction in biological 
system. Hydrogen bonds are composed of electrostatic, covalent, as well as 
resonance components, where the electrostatic component is probably dominant.[8] 
Hydrogen bonds consist of an interaction between a hydrogen bond donor (X-H) and 
an acceptor (Y). Generally, X and Y are more electronegative than carbon, i.e. 
heteroatoms as O and N. The bridging distance should be smaller than the van-der-
Waals radii.[8] The length of an optimal hydrogen bond in water is 1.8 Å, whereas the 
interaction is negligible at a distance of 5 Å. Besides the bond length, bond angle, 
temperature, pressure, and environment (characterized by the local dielectric 
constant) influence the quality of a hydrogen bond.[11] The energy of a hydrogen 
bond is in the range of –15 and –30 kJ mol–1 and therefore between a covalent bond 
and a van-der-Waals interaction. When one of the interacting partner is charged, the 
interactional energy can be higher.[8] Accounting for desolvation and the reduction of 
residual motion, the general benefit of a neutral hydrogen bond is in the order of –5 
kJ mol–1 in the free energy change.[12]  
 
1.1.3 The Change in Entropy (∆S°) 
As mentioned in chapter 1.1.2, negative enthalpy of interaction (∆H°) and positive 
entropy of interaction (∆S°) result in high binding affinities. ∆S° is influenced by the 
order of the system such as conformational changes, water molecules released upon 
desolvation of protein and ligand, the loss of rotational and translational degrees of 
freedom, the restriction of rotational bonds, and vibrational modes.[12-14] If the order 
increases, for example the protein gets structured upon binding, the influence on ∆S° 
is unfavorable and negative in sign.[15] In contrast, the release of structured water 
upon binding positively influences ∆S°. The release of a structural water molecule – 
i.e. a water molecule forming three and more geometrically optimal hydrogen bonds 
– can cost up to 10 kJ mol–1 at 298.15 K.[16] Usually, in protein-ligand interactions not 
all motion of ligand, protein, and water are lost upon binding. Therefore, 10 kJ mol–1 
is the upper limit that will be probably not reached in biomolecular interactions.[12,16] 
For the loss of translational and rigid body rotational degrees of freedom upon 
complex formation different ∆S° values exist, ranging from 5.4,[12] the cratic 
contribution 10,[17] 44,[18] up to 62 kJ mol–1[18] (at 298.15 K), whereas the highest 
values might be attributed to a total loss of motion.[12] However, when different 
ligands binding to a target protein are compared, not the absolute but the relative 
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values (∆∆S°) are of importance.[18] Another source of entropic costs are rotatable 
bonds that become restricted upon binding. Again, since in protein-ligand complexes 
vibrational entropy remains, the restriction of one rotatable bond is in the range of 
1.4 kJ mol–1 (T∆S° at 298.15 K) instead of 5 kJ mol–1 for the complete restriction of 
rotations.[12] Therefore, it is an accepted practice in ligand design to introduce 
conformational constraints to pre-organize a ligand in its bioactive conformation to 
reduce entropy costs upon binding.[19] This holds to be true in some cases.[20] 
Whereas other data suggest that constraints can lead to less favorable ∆S° but a 
gain in ∆H° because of additional contacts,[19,21] since additional interactions reduce 
the residual motion.[12,22] On the other side, it was published that flexible ligands bind 
with high affinity because of reduced entropic penalties.[4,23] Overall, it is difficult to 
dissect ∆H° and ∆S°, since they depend on each other.  
 
1.1.4 The Change in Heat Capacity (∆Cp) 
Further information of protein-ligand interactions can be obtained from the change in 
heat capacity (∆Cp) describing the temperature dependence of the change in 
enthalpy (∆H°) and entropy (∆S°) (see 1.1.1). ∆Cp is usually negative in value 
indicating that the complex exhibits a smaller heat capacity then the sum of the heat 
capacities of the two components.[24] ∆Cp effects mostly result from the change in 
hydration of interacting groups.[25] It is known that the desolvation of polar surface 
increases ∆Cp,[7,19,26] whereas non-polar surface desolvation leads to a reduction.[7] 
The inclusion of water molecules upon binding can largely reduce ∆Cp.[26] Other 
influences arise from low frequency vibrational modes.[7,24] Correlation between ∆Cp 
and the surface area that is buried upon complex formation exist for e.g. protein 
folding/unfolding[27] as well as carbohydrate-lectin interactions.[25] These correlations 
differ in their contribution from polar and non-polar surfaces what makes a correct 
extrapolation to other systems difficult. Additionally, discrepancies between 
calculated and experimentally determined ∆Cp values are probably due to other 
effects than the surface buried upon binding.[24] 
  
1.1.5 The Hydrophobic Effect 
Desolvation is a prerequisite for protein-ligand interactions and affects the change in 
enthalpy (∆H°), entropy (∆S°), and heat capacity (∆Cp) of binding. It was previously 
proposed that from 25% up to 100% of the net measured ∆H° accounts for solvent 
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reorganization.[14] The desolvation of non-polar surfaces increases ∆S°, since a 
hydrogen-bond network with high order (low entropy) is disturbed. This process is 
termed the classical hydrophobic effect. Additionally, hydrophobic interactions exhibit 
a small enthalpic contribution that is strongly temperature dependent, leading to a 
large negative change in heat capacity.[10,28] In contrast, the non-classical 
hydrophobic effect is accompanied by a favorable enthalpic term and is related to 
favorable changes in solvent cohesive interactions and to gain in electrostatic 
interaction between non-polar surfaces. In this case, water molecules can form 
stronger interactions to bulk water upon desolvation of non-polar surfaces.[10] This 
behavior is described for protein-ligand interaction dewetting a poorly hydrated non-
polar cavity upon complex formation[28,29] and for ligands of increasing 
lipophilicity.[10,30] 
 
1.1.6 Theory of Isothermal Titration Calorimetry 
Several methods exist to determine heat changes for biomolecular interactions. One 
of the most common techniques is isothermal titration calorimetry (ITC). A scheme of 
a typical calorimetric instrument is shown in Figure 1.1.6.1. 
 
Figure 1.1.6.1. Schematic representation of the power compensation isothermal titration calorimeter. 
A constant power is applied to the reference cell. Over a feedback circuit, a variable power is applied 
to the sample cell. This allows monitoring of very small temperature differences between both cells. 
During an exothermic interaction, heat is generated and less power is applied to the sample cell, vice 
versa for an endothermic interaction. The syringe continuously rotates and a computer-controlled 
plunger injects precise volume of ligand solution. (Picture from Holdgate and Ward.[5]) 
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In an ITC experiment a ligand solution (L) is gradually added to a protein solution (P) 
forming a simple binary complex (PL):  
 P + L              PL  (1.1.6.1) 
The amount of heat absorbed or released by this interaction is monitored. In case of 
an exothermic binding process, heat is released and less power is applied to the 
sample cell resulting in a negative peak. Overall, the amount of energy required to 
maintain constant temperatures of reference cell and sample cell is measured over 
time. The heat released or absorbed (q) for each injection at a given temperature 
(∆H°(T)) depends on the enthalpy the number of moles of complex formed, the 
reaction volume (V) of the sample cell, and the concentration of the complex [PL]: 
   q VH(T )[PL]  (1.1.6.2) 
Initially, the amount of free protein is sufficient to bind ligand according to the 
concentration of the free ligand and protein in solution. With ongoing titration, the 
concentration of unoccupied binding sites decreases, correspondingly, the heat 
released decreases over time as well, ending in dilution effects (Figure 1.1.6.2). The 
integral heat of reaction after the ith addition, qi, will be: 
   qi  N[PT ]VH(T )i  (1.1.6.3) 
where [PT] is the total protein concentration, N is the stoichiometry and  the 
fractional saturation.  
 
Figure 1.1.6.2. A typical result of an isothermal calorimetric titration of a selectin antagonist with E-
selectin/IgG (Chapter 2.1.1.2). The top panel shows the recorded change in heat in units of µcal s–1 
as a function of time for successive injections of antagonist (raw data). The bottom plot shows the 
integrals of the peaks (black squares) from the top plot plotted against the molar ratio of the binding 
process together with a line of best fit, used to estimate ∆H°, KD, and N. 
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The differential heat (Q) of the ith injection is: 
   Q  N[PT ]H(T )V(i i1)  (1.1.6.4) 
A non-linear fit of this sigmoidal curve in the differential heat mode (qi vs. [LT] or vs. 
[LT]/[PT], where [LT] is the total ligand concentration) is then used to estimate the 
parameter KA, ∆H°, and N from a single experiment.[2]  
 
1.1.7 Experimental Setup of an ITC Experiment 
The success of an ITC experiment depends on the thermodynamic characteristics of 
the system (protein-ligand interaction, buffer, temperature, pH). Depending on the 
affinity, an appropriate concentration range can be estimated, where a sigmoidal 
curve reliably fits all three parameter, ∆H°, KD, and N. The dimensionless parameter 
c describes the shape of the curve: 
 
  
c  N[PT ]
KD
  (1.1.7.1) 
The optimal c-values was recently proposed to be 40.[31] Experiments with c-values 
above 500 accurately determine ∆H° and N,[2] whereas KD can only be measured 
correctly if a strong ∆H° contribution allows small injection volumes of the ligand 
solution. On the other side, for reliably determination of KD and ∆H° in experiments 
with c-values below 1, accurate concentrations of protein and ligand solution, a big 
excess of ligand, and a two parameter fit, where N is fixed, are required.[32] 
Another point to consider is the heat related to changes in the protonation state of 
protein and/or ligand upon binding. This heat contributes to the overall heat of 
binding and depends on the ionization enthalpy of the buffer system used (∆H°Ion). 
With this dependency, the deprotonation nH+ (nH+ > 1) or protonation (nH+ < 1) can be 
determined: 
   HObs  nHHIon  HBind    (1.1.7.2) 
where ∆H°Obs is the measured enthalpy and ∆H°Bind is the enthalpy corrected for 
protonation effects.[2] 
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1.2 Lectins 
Lectins are defined as carbohydrate binding proteins, excluding enzymes or 
antibodies, and were first discovered in plants in 1888, when Stillmark found that an 
extract of castor bean seeds contained a protein capable of agglutinating animal red 
blood cells.[33] Lectins are widespread in most living organisms such as animals, 
plants, viruses, and bacteria. The first pure lectin was concanavalin A (Con A) from 
jack beans, used to elucidate the molecular basis for blood group specificity.[34] 
Lectins were shown to be involved in diverse biological processes in many species 
such as clearance of glycoproteins from the circulatory system, adhesion of 
infectious agents to host cells, recruitment of leukocytes to inflammatory sites, cell 
interactions in the immune system, in malignancy and metastasis.[34,35] The major 
types of animal lectins are galectins, C-type, P-type, and I-type lectins (Figure 1.2.1). 
 
 
Figure 1.2.1. Schematic representation of major types of animal lectins with the carbohydrate-binding 
domains (CRD) of C-type lectin CRD (CL), S-type lectin CRD (GL), P-type lectin CRD (MP), I-type 
lectin CRD (IL), EGF-like domain (EG), immunoglobulin C2-set domain (IG2), transmembrane region 
(TM), and complement regulatory repeat (C3) (picture from Varki et al.[33]). 
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Galectins are soluble lectins, previously termed S-type lectins, that recognize -
galactose-containing glycoconjugates and contribute to cell-cell and cell-matrix 
interactions and can modulate cellular function.  
C-type lectins interact with glycans in a Ca2+-dependent manner and share 
homology in their carbohydrate recognition domain (CRD). Collectins, selectins, 
endocytic receptors, and proteoglycans belong to the C-type family which function as 
adhesion signaling receptor in many immune functions such as inflammation and 
immunity to tumor and virally infected cells. Among the C-type lectins, the selectins 
are perhaps the best characterized lectins (chapter 2.1.1).[33] Selectins are 
expressed on vascular endothelial cells, leukocytes, and platelets, and enable the 
adhesive interaction among theses cells. They play a crucial role in leukocyte 
trafficking and are the key players in the early stages of inflammation. Therefore, the 
selectins are promising targets for the development of anti-inflammatory drugs, as 
needed for the treatment of asthma, psoriasis, or rheumatoid arthritis.[36] Another C-
type lectin, DC-SIGN (DC-specific intracellular adhesion molecule-3 (ICAM-3) 
grabbing nonintegrin, chapter 2.1.2), located on dentritic cells (DC), plays a crucial 
role in the defense mechanism against pathogens, however, some pathogens exploit 
this way to infect the host.[37]  
P-type lectins contain a phosphate group and enable the lysosomal trafficking of 
soluble acid hydrolyses to the lysosome.  
Lectins belonging to the immunoglobulin superfamily (IgSF), excluding antibodies 
and T-cell receptors, are called I-type lectins. The largest family within the I-type 
lectins are the sialic acid-binding immunoglobulin-like lectins (siglec), including CD22 
(Siglec-2, chapter 2.2.1) and myelin-associated glycoprotein MAG (Siglec-4, chapter 
2.2.2), both inhibitory proteins in the immune system and the central nervous 
system, respectively.[33]  
Lectins other than plant and animal lectins are lectins that are expressed on viruses, 
bacteria, and protozoa. They exploit host cell-surface glycans as receptors for cell 
attachment and tissue colonization. Several pathogens infect their hosts using 
carbohydrate-lectin interaction, e.g. the influenza virus via hemagglutinin binding to 
sialic acid containing glycans derivatives on the upper respirator tract mucosa, 
Escherichia coli via fimbriae binding to glycans in the urinary tract (chapter 2.3.1) or 
intestinal cells, and Helicobacter pylori via BabA binding to Lewisb in the stomach.[33] 
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1.3 Thermodynamic of Carbohydrate-Lectin Interactions 
Most of the calorimetric studies on lectins so far were made with plant 
lectins[34,35,38,39] although human lectin[34,35,38-41] and bacterial lectin[42,43] 
investigations have recently gained increasing interest. The majority of these studies 
describe carbohydrate-lectin interactions as enthalpically driven processes 
accompanied by an entropic penalty[34,35,38,39] yielding binding affinities in the 
millimolar range for monosaccharides.[34] It is argued that the entropic gain from 
desolvating polar[44] and apolar surfaces[4] is offset by unfavorable conformational 
entropy.[45] However, it is described that the bioactive conformation of carbohydrates 
is a low energy conformation and, moreover, the protein surface is well 
preorganized,[34,38,45] why other than conformational penalty must be the reason for 
the entropic loss. For the example of entropically driven binding processes, which 
are attributed to hydrophobic interactions,[41,46] to the release of structural water upon 
binding,[43,47] to a favorable conformational change of the protein,[48] or to a 
combination of desolvation and preorganization of protein and ligand as reported for 
E-selectin interaction to E-selectin ligand-1 (ESL-1).[49]  
An often observed property of carbohydrate-lectin interactions is the enthalpy-
entropy compensation behavior,[34,38] a common phenomenon for weak 
intermolecular interactions in aqueous solution.[22,50] Enthalpy-entropy compensation 
is a linear behavior in a ∆H° versus –T∆S° plot with several ligands binding to a 
target protein (Figure 1.3.1). A slope of –1 denotes for ligands for which a favorable 
change in enthalpy is completely compensated by an entropic penalty.  
 
Figure 1.3.1.  Correlation of the change in enthalpy (∆H°) versus the change in entropy (–T∆S°) of 
FimH antagonists interacting with FimH-CRD (enthalpy-entropy-compensation plot, chapter 2.3.1.2).  
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The change in heat capacity for carbohydrate-lectin interactions is usually small and 
negative[34,38] and might be attributed to a combination of the desolvation of a polar 
surface and the sequestering of water upon complex formation.[7,26] However, a 
hydrogen bond network with water-mediated hydrogen bonds is another property of 
carbohydrate-lectin interactions[34,39] as well as fast kinetics with half-life times of the 
complex typically below 1 second.[51] 
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2 Results and Discussion 
2.1 Thermodynamics of Glycomimetics Binding to C-type Lectins 
2.1.1 E-selectin  
2.1.1.1 E-selectin Binding to sLex Derivatives 
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Introduction 
Selectins are carbohydrate-binding proteins that belong to the family of C-type 
lectins, as they bind their ligands in a Ca2+-dependent manner. They are key players 
in states of inflammation and metastasis.[1] Selectins are cell-adhesion molecules 
that mediate the earliest stage of leukocyte trafficking[2] which serves to initially slow 
down the leukocytes and allow activation of integrins, which then ensure firm 
adhesion to the endothelial layer. Finally, leukocytes transmigrate through the 
endothelial layer and migrate to the site of inflammation.[3] To date, three selectins 
have been identified, P-, E-, and L-selectin, that bind their natural ligands with fast 
kinetics[4] what is typical for carbohydrate-lectin interactions.[5] The tetrasaccharide 
sialyl Lewisx (sLex, 1) constitutes the minimum binding epitope of all three 
selectins.[6] In this communication we focus on E-selectin. The interactions of sLex 
(1) to E-selectin are depicted in Figure 1.[7] N-Acetylglucosamine (GlcNAc) is not 
directly involved in binding, but serves as a spacer to ensure the correct spatial 
orientation between Fuc and Gal.[8]  
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Figure 1. Schematic presentation of interactions between sLex (1) and E-selectin as observed in the 
crystal structure of Somers et al.[9] The 3- and 4-hydroxyl groups of Fuc directly coordinate to Ca2+ 
and are involved in further hydrogen bonding with protein side chains coordinating to Ca2+. The 2-
hydroxyl group of Fuc forms water mediated hydrogen bonds to the side chains of Asn83 and Glu107. 
The 4- and 6-hydroxyl groups of Gal bind to the side chains of Tyr94 and Glu92, respectively. The 
carboxylate of sialic acid forms a hydrogen bond to the side chain of Tyr48 and a salt bridge to the 
side chain of Arg97. The guanidine moiety of Arg97 furthermore binds to the oxygen of the glycosidic 
bond between Gal and Neu5Ac.  
sc = side chain; bb = backbone; pharmacophoric groups in bold.[7] 
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The binding affinity and kinetics of E-selectin ligand-1 (ESL-1) have been described 
with a dissociation constant KD of 56 M and an off-rate koff of 2.7 s–1 resulting in a 
calculated kon of 4.8·104 M–1s–1. Additionally, the binding was characterized to be 
entropically driven with a weak enthalpic contribution (G° = –24 kJ mol–1, H° = –4 
± 3 kJ mol–1, –TS° = –20 kJ mol–1, at 25 °C). The thermodynamic parameters were 
determined indirectly with a van’t Hoff plot. Vestweber et al. attributed the favorable 
entropy to the desolvation and/or unexpectedly low entropic costs of complex 
formation between E-selectin and ESL-1. The relatively low enthalpic contribution 
was explained by the small number of beneficial interactions and/or disruption of 
favorable interactions upon binding.[10] Such entropy driven binding has been 
reported for other lectins,[11] although carbohydrate-lectin interactions are typically 
enthalpy driven with unfavorable or only weakly favorable change in entropies.[12] 
Later, this entropically driven binding was confirmed for sLex (1) binding to E-selectin 
with isothermal titration calorimetry (ITC), where the enthalpy is measured directly. It 
was argued that the entropy costs caused by the loss of translational and rotational 
degrees of freedom and conformational changes of ligand and protein upon are 
overcompensated by the beneficial entropy arising from the release of bound water. 
However, the interaction exhibits an unfavorable enthalpic contribution related to the 
desolvation penalty that is not compensated by the polar interaction between the 
pharmacophores of sLex (1) and E-selectin.[7]   
One successful strategy of optimizing E-selectin antagonists was the replacement of 
sialic acid by (S)-cyclohexyllactic acid and of GlcNAc by (1R,2R)-cyclohexane-1,2-
diol-3-methyl leading to compound 3 (Figure 2).[7] Here, very polar moieties, like 
sialic acid and GlcNAc that exhibit minor contacts to the protein, were replaced with 
hydrophobic parts. The binding affinity increased from 878 µM to 19 µM, a factor of 
49. Interestingly, only the change in enthalpy became more favorable, whereas the 
entropy remains almost the same, suggesting that the gain in affinity is caused by 
different desolvation penalties for the two compounds. Additionally, a perfect pre-
organization of protein and ligand and/or the release of coordinated water molecules 
from solvation results in a large favorable entropic contribution.[7] To further improve 
pre-organization, parts of the antagonist that do not directly interact with E-selectin 
were modified and their influence on enthalpy and entropy of binding were studied by 
isothermal titration calorimetry. 
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Results and Discussion 
After the successful replacement of sialic acid and GlcNAc leading the E-selectin 
antagonist 3,[7] exhibiting low micromolar affinity, further modifications that were 
expected to not affect the key interactions were introduced. The new antagonists 
(Figure 2) were tested in a competitive binding assay and ITC allowing the 
deconvolution of ∆G° into ∆H° and T∆S° (Table 1). A typical ITC experiment is 
shown in Figure 3.  
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Figure 2. Schematic presentation of the compounds tested in ITC and competitive binding assay with 
E-selectin. 
 
Table 1. IC50 values were determined in a competitive binding assay. KD, G°, H°, and –TS° values 
were obtained from ITC experiments.  
Ligand IC50 [µM] KD [µM] 
∆G° 
[kJ mol–1] 
∆H° 
[kJ mol–1] 
–T∆S° 
[kJ mol–1] 
N 
sLex  (1)[7] 875 ± 138 878 ± 93 –17.5 ± 0.2 +5.4 ± 0.7 –22.9 ± 1.1 1 
2[7] 61.4 ± 13.6 59.0 ± 4.4 –24.2 ± 0.2 –5.3 ± 0.4 –18.9 ± 0.6 0.93 ± 0.08 
3[7] 13.7 ± 3.3 18.5 ± 1.8 –27.1 ± 0.2 –5.8 ± 0.1 –21.3 ± 0.4 0.97 ± 0.01 
4 8.7 ± 0.1 4.8 –30.4 –7.2 –23.2 1.17 
5 6.7 ± 2.0 4.0 ± 0.3 –30.8 ± 0.2 –12.4 ± 0.6 –18.4 ± 0.8 1.00 ± 0.07 
6 7.4 ± 1.5 3.6 –31.1 –11.3 –19.8 1.08 
7 5.2 ± 1.0 8.6 –28.9 –11.6 –17.3 1.04 
8 6.1 ± 1.7 2.1 –32.5 –12.7 –19.8 1.11 
[7] 
[7] 
[7]
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Figure 3. A typical result of an isothermal calorimetric titration with antagonist 5 and E-selectin. The 
top panel shows the recorded change in heat in units of µcal s–1 as a function of time for successive 
injections of inhibitor (raw data). The bottom plot shows the integrals of the peaks (black squares) 
from the top panel plotted against the molar ratio of the binding process together with a line of best fit, 
used to estimate ∆H°, KD, and N. 
 
Both methods gave comparable results, except for compound 3 and 7 were ITC 
revealed 50% lower binding affinity, respectively. The binding affinities and 
thermodynamics of sLex (1), 2, and 3 are already published and discussed by Binder 
et al.[7] In this communication we focus on modifications of the 3’-position (3-OH of 
galactose). Acylation with cyclopropanecarboxylic acid (4) led to a four-fold 
improvement of 3, resulting from both enthalpy and entropy change. Surprisingly, a 
benzoylation of the 3’-hydroxy group (5) revealed similar binding affinity but 
significantly altered thermodynamics (∆∆H° = –5.2 kJ mol–1, –T∆∆S° = +4.8 kJ mol–
1). A change in the electron density of the acyl group by a fluoro substituent in the 
para-position (6) did not alter the thermodynamics. A hydrophobic interaction of 
the benzene ring is expected to be influenced by an electron-withdrawing group 
leading to changes in the thermodynamic fingerprint.[13] Unspecific binding can be 
excluded, since the binding isotherm revealed very good fits with a one-to-one 
binding model and the stoichiometry of all ligands was close to 1. In order to exclude 
an influence of the Fc-part of E-selectin/IgG, a construct without the Fc-part was 
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expressed.[14] This monomeric E-selectin exhibited identical thermodynamics for 
binding to antagonist 5 (Table 2).  
 
Table 2. Results of ITC experiments with different protein construct interacting with antagonist 5. 
E-selectin 
construct KD [µM] 
∆G° 
[kJ mol–1] 
∆H° 
[kJ mol–1] 
–T∆S° 
[kJ mol–1] 
N 
∆Cp [kJ 
mol–1 K–1] 
IgG 4.0 ± 0.3 –30.8 ± 0.2 –12.4 ± 0.6 –18.4 ± 0.7 1.00 ± 0.07 –0.16 
Monomer 3.4 –31.2 –11.8 –19.4 1.14 - 
 
The increased enthalpic contribution of the benzoate compared to the hydroxyl could 
either result from an additional contact with the protein, different desolvation 
properties, and/or an influence on the pre-organization of the core. When identical 
polar interactions for both sLex (1) and the glycomimetics are assumed, the acyl 
group points to water making an interaction with E-selectin unlikely. The bioactive 
conformation and the binding epitope of 2 and sLex (1) determined by tr-NOE-NMR 
and STD-NMR, respectively, strongly suggest a conserved binding mode.[15] To 
account for changes in desolvation, the enthalpy of 1, 2 and 5 interacting with E-
selectin was measured at different temperatures to determine the heat capacity 
change (∆Cp). The ∆Cp value of compound 5 was the lowest (–0.16 kJ mol–1 K–1) 
compared to compound 2 and sLex (1) with –0.11 and –0.06 kJ mol–1 K–1, 
respectively. Since, heat capacity changes are related to different surface area 
buried upon binding they are related to changes in solvation. Hydrophobic surfaces 
are expected to reduce ∆Cp, whereas polar surfaces increase ∆Cp.[16,17] Additionally, 
internal vibrational modes,[17,18] the inclusion of water upon complex formation,[16] as 
well as solvent rearrangements in peripheral solvent layers influences ∆Cp.[18] 
Therefore, the lower ∆Cp value for compound 5 can indicate differences of the 
solvent structure of the ligand, if we assume identical key interactions for all 
compounds. Otherwise, the lower ∆Cp value can indicate greater hydrophobic 
interaction which might be related to a different binding mode were the benzoate 
points toward the protein and not to bulk water.  
Antagonist 5 was additionally tested in different buffer systems to determine 
protonation and deprotonation effects (Table 3).[19] The ∆H° values are almost 
identical in all three different buffer systems which makes protonation and 
deprotonation effects unlikely as far as they are not mutually compensating. 
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Table 3. Results of ITC experiment of antagonist 5 interacting with E-selectin in different buffer 
systems determined at 25 °C. 
Buffer 
∆H°Ion 
[kJ mol–1] KD [µM] 
∆G° 
[kJ mol–1] 
∆H° 
[kJ mol–1] 
–T∆S° 
[kJ mol–1] 
N 
TRIS HCL 46.9 3.8 –30.9 –11.6 –19.3 1.05 
HBS-Ca 21.0 3.8 –31.0 –12.0 –19.0 1.08 
PBS 5.1 3.9 –30.8 –12.0 –18.8 1.02 
 
Other changes in the antagonist were made on the spacer moiety lining Gal and Fuc. 
A methyl group was introduced at the former NAc position of GlcNAc with the 
intention to enhance the pre-organization of the core via steric compression between 
the -face of fucose and the -face of galactose (23).[7] The binding affinity 
increasing by a factor of 3 can be attributed to the enhanced preorganization as has 
been already described for some examples related to more favorable entropic 
term,[20] whereas some other examples are related to an enthalpic gain.[21] Starting 
from 5 (R: Me), the exchange of the ring substituent by cyclopropyl (7) and ethyl 
(8) decreased and increased binding affinity, respectively. 
An entropy-enthalpy compensation plot is shown in Figure 4. The slope is small and 
negative, indicating that most of the differences are related to changes in enthalpy 
and only marginally to changes in entropy. The correlation coefficient is very low and 
there are two clusters of antagonists and one single antagonist visible. One clusters 
of antagonists can be attributed to the benzoates (5-8), the other one to antagonists 
2-4 were little changes in thermodynamics occurred. The single dot is sLex (1) that 
exhibits unique thermodynamics.  
 
Figure 4. Entropy-enthalpy compensation plot of E-selectin antagonists. 
2  Results and Discussion 
- 43 - 
Summary and Conclusion 
New E-selectin antagonists that exhibiting modifications on the GlcNAc replacement 
and the substituent on the 3’-hydroxy, both substitutions that are not expected to 
interact with the protein, were synthesized. The antagonists were investigated by ITC 
whereas the enthalpic part of binding was improved; additional entropy costs only 
partially compensated the gain in affinity.  
 
Experimental Procedure 
 Synthesis of Compounds. Will be published elsewhere. 
E-selectin/IgG Expression, Purification and Competitive Binding Assay. As 
described by Binder et al.[7]  
E-selectin Monomer Expression and Purification. Will be published elsewhere.[14] 
Isothermal Titration Calorimetry. ITC experiments were performed using a VP-ITC 
instrument from MicroCal, Inc. (GE Healthcare, Northampton) after vacuum degassing of the 
samples. The measurements were performed at 25 °C, and for ∆Cp determination 
additionally at 10 and 37 °C. Injections of 5 to 15 µL ligand solutions (0.5 – 1.8 mM) were 
added from a computer controlled 300 µL microsyringe at an interval of 5 min into the 
sample cell solution containing E-selectin/IgG (45 to 83 µM, sample cell volume 1.4037 mL 
or 1.4523 mL) with stirring at 307 rpm. Protein concentration was determined by HPLC-UV 
against a BSA standard.[22] The quantity c = Mt(0) KD–1 where Mt(0) is the initial 
macromolecule concentration, is of importance in titration microcalorimetry. The c-values 
were between 1 and 36. Control experiments injecting ligand solution into buffer without 
protein showed that the heats of dilution were small and constant. The assay buffer was: 10 
mM HEPES, 150 mM NaCl, and 1 mM CaCl2, pH 7.4 (HBS-Ca). Ligand 5 was as well tested 
in TrisHCl and PBS buffer. The first injection was always excluded from data analysis 
because it usually suffers from sample loss during the mounting of the syringe and the 
equilibration preceding the actual titration. Data were evaluated using Origin 7 supplied with 
the instrument (OriginLab, Northampton). A three-parameter data fitting was performed to 
determine N, KD, and ∆H°, that are stoichiometry, dissociation constant, and change in 
enthalpy, respectively. 
Thermodynamic parameters were calculated from the equation (1) and (2),  
   G  H TS  RT lnKD  RT lnKA (1) 
 
  
Cp  HT2  HT1(T2 T1)
    (2) 
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where ∆G°, ∆H°, ∆S°, and ∆Cp are the changes in free energy, enthalpy, entropy, and heat 
capacity of binding, respectively, T is the absolute temperature, and R the universal gas 
constant (8.314 J mol–1 K–1).[23]  
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Introduction 
Immature dentritic cells (DCs) are crucial for the defense against pathogens. They 
monitor pathogens, process, and present them to the immune system. Interestingly, 
some pathogens can escape dendritic cells and the immune surveillance.  
Viruses (e.g. HIV, Ebola virus, cytomegalovirus, Dengue virus, hepatitis C virus), 
bacteria (e.g. Mycobacterium tubercolosis, Helicobacter pylori), and yeasts (e.g. 
Candida albicans) target the C-type lectin DC-SIGN (DC-specific intracellular 
adhesion molecule-3 (ICAM-3) grabbing nonintegrin) and either escape the 
degradation mechanism or alter TLR-mediated (Toll-like receptor) signaling which 
both result in an infection of the host.[1] Endogenous ligands of DC-SIGN are the 
glycoproteins ICAM-2 and ICAM-3 which are involved in DC migration[2] and DC-T-
cell interaction,[3] respectively. The majority of pathogens bind with N-linked high 
mannose oligosaccharides.[1,4] Besides, the fucose-embodying blood group antigens 
Lewisx (Lex) and Lewisa (Lea) are as well common on pathogens and bind to DC-
SIGN.[5] Binding affinities to DC-SIGN are in the low millimolar range for 
monosaccharides, such as mannose and L-Fuc,[6] and Lewis-type structures.[7] 
Multivalent ligands increase the binding affinity.[8] Being a C-type lectin, the binding 
to DC-SIGN is calcium dependent.[1]   
A crystal structure of DC-SIGN complexed with lacto-N-fucopentaose III (LNFP III), 
containing a Lex motif, suggests that 3- and 4-OH of Fuc coordinate the calcium ion, 
Gal contributes to binding via a hydrogen bond to Asp367 (6-OH) and a water-
mediated hydrogen bond to Glu358 (4-OH) (Figure 1). Additionally, van-der-Waals 
contacts exist between the 2-OH of Fuc and Val351 and between 6-OH of Gal and 
Leu371.[9]  
To gain further insights into the binding interaction of glycomimetics we report 
isothermal titration calorimetry experiments that allow the deconvolution of the 
change in free energy of binding (∆G°) into enthalpic (∆H°) and entropic (∆S°) 
contributions.[10,11] Hydrogen bond formation, electrostatic interaction, and dipole-
dipole interaction influence the enthalpy term.[12-15] The entropy term describes the 
change of the order of the system, e.g. the change in the solvation entropy as well 
as translational, rotational, and vibrational entropy of the protein and ligand upon 
complex formation.[13,16] 
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Figure 1. Resolved part of LNFP III and adjacent amino acids in the binding site of DC-SIGN (PDB 
1SL5). The protein backbone is blue, bonds are cyan, and bonds in carbohydrate are yellow. Calcium 
coordination bonds are solid, hydrogen bonds are thin dotted lines, and van-der-Waals contacts are 
thick dotted lines (picture from Guo et al.).[9] 
 
Results and Discussion 
Antagonizing DC-SIGN already demonstrated that it prevents pathogen attachment 
to DCs and inhibits the infection of other immune cells at its earliest steps.[17] 
Although micromolar affinity glycomimetics exist,[6,7] the driving force of the 
interaction is not understood yet. Isothermal titration calorimetry experiments are 
useful to gain insight into the driving force of interaction. 
Figure 3 shows a typical outcome of an ITC experiment. The investigated ligands are 
shown in Figure 2 and accompanying results are shown in Table 1. ITC results are in 
good agreement with those obtained from the competitive binding assay.[18]  
However, the differences in affinity are more pronounced in the competitive binding 
assay. The interactions between DC-SIGN and the antagonists are exothermic and 
partially compensated by unfavorable changes in entropy. This thermodynamic 
signature is a common property of carbohydrate-lectin interactions.[19]  
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Figure 2. Structure of glycomimetics binding to DC-SIGN. 
 
Table 1. Binding thermodynamics of DC-SIGN antagonists determined by ITC. rIC50[18] values were 
calculated against 1 as reference compound. rKD values were calculated relative to phenyl Lea (1). 
The stoichiometry N was set to 1 (see Experimental Procedure).  
Compound rIC50 rKD KD [µM] 
∆G° 
[kJ mol–1] 
∆H° 
[kJ mol–1] 
–T∆S° 
[kJ mol–1] 
1 1 1 583 ± 41 –18.5 ± 0.2 –28.0 ± 2.0 +9.5 ± 1.8 
2 2.9 ± 0.5 1.3 735 –17.9 –27.9 +10.0 
3 3.3 ± 0.2 n.d. n.d. n.d. n.d. n.d. 
4 1.8 ± 0.5 1.1 645 –18.2 -31.4 +13.2 
5 4.7 ± 1.0 2.2 1277 –16.5 –29.7 +13.2 
6 n.d. 1.8 1073 –16.9 –34.7 +17.8 
n.d. - not determined. 
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Figure 3. A typical result of an isothermal calorimetric titration with DC-SIGN antagonist 1 interacting 
and DC-SIGN-CRD-IgG. The top panel shows the recorded change in heat in units of µcal s–1 as a 
function of time for successive injections of inhibitor (raw data). The bottom panel shows the integrals 
of the peaks (black squares) from the top panel plotted against the molar ratio of the binding process 
together with a line of best fit, used to estimate ∆H° and KD. The stoichiometry (N) was set to 1 (see 
Experimental Procedure). 
 
Crystallographic data suggests that GlcNAc has the function of a spacer only 
orienting Fuc and Gal moiety. Therefore, the phenyl moiety in phenyl Lea (1) is as 
well expected to point into bulk water, making no additional contact with the protein. 
However, phenyl Lea (1) exhibited the highest binding affinity towards DC-SIGN 
within this series. It is known that modifications far from binding site can influence 
binding affinity and thermodynamics because of structure rearrangement.[14,20,21] 
Additionally, another binding mode might be possible, where the phenyl moiety 
contacts the protein. Replacing the phenyl by a methyl moiety (12) reduces the 
affinity slightly whereas enthalpy and entropy values are similar to one another. 
Binding affinity of methyl Lex (3) is slightly lower compared to methyl Lea (2) as has 
been previously reported.[8] Since GlcNAc serves as a spacer it was replaced with 
methyl cyclohexanediol. Interestingly, this substituent enhanced the binding affinity 
(34). A better preorganization[15,22] and/or different solvation properties[14] may 
explain this difference. Compound 5, the 6-deoxy Lex mimic, showed the lowest 
binding affinity. It suggests that the 6-OH of the galactose does contribute to binding 
but not essentially. This is in accordance with the published binding mode for Lex 
from crystallography with LNFP III, which supposes hydrogen bond formation for 6-
Molar Ratio (1/DC-SIGN-CRD-IgG) 
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OH.[4] However, a disaccharide mimic without galactose (6) is able to bind with 
similar binding affinity. Nevertheless, studies with deoxy-congeners are important to 
identify key hydroxyl groups. The amount of affinity loss and the change in 
thermodynamics give information about the importance of certain hydroxyl 
groups.[20,23]  
 
Conclusion 
To the best of our knowledge, this was the first thermodynamic characterization of 
DC-SIGN ligand interaction. The millimolar binding affinities are a result of an 
exothermic interaction opposed by an unfavorable entropic penalty.  
 
Experimental Procedures 
Protein Expression, Purification and Competitive Binding Assay and Synthesis 
of Compounds. Will be published elsewhere.[18] 
Isothermal Titration Calorimetry (ITC). ITC experiments were performed using a 
VP-ITC instrument from MicroCal, Inc. (GE Healthcare, Northampton). The measurements 
were performed at 25 °C. Injections of 3 to 5 µL ligand solutions (5.5 - 25 mM) were added at 
an interval of 5 min into the sample cell solution containing DC-SIGN-CRD-IgG (DC-SIGN-
CRD fused to the Fc part of human IgG; 30 to 110 µM, sample cell volume 1.4523 mL) with 
stirring at 307 rpm. Protein concentration was determined by HPLC-UV against a BSA 
standard.[24] Control experiments injecting ligand solution into buffer without protein showed 
that the heats of dilution were small and constant. The assay buffer was: 10 mM HEPES, 150 
mM NaCl, 10 mM CaCl2, pH 7.4 (HBS-Ca). The first injection was always excluded from data 
analysis because it usually suffers from sample loss during the mounting of the syringe and 
the equilibration preceding the actual titration. The experimental data were fitted to a 
theoretical titration curve (one site binding model) using Origin software (version 7, MicroCal). 
The quantity c = Mt(0) KD–1 where Mt(0) is the initial macromolecule concentration, is of 
importance in titration microcalorimetry.[10] The experiments were performed with c-values 
below 1. The stoichiometry was fixed to 1 to allow reliable determination of KD and ∆H°.[25] 
Thermodynamic parameters were calculated from the equation (1),  
  G  H TS  RT lnKD  RT lnKA (1)  
where ∆G°, ∆H°, and ∆S° are the changes in free energy, enthalpy, and entropy of binding, 
respectively, T is the absolute temperature, and R is the universal gas constant (8.314 J 
mol–1 K–1).  
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2.2 Thermodynamics of Glycomimetics Binding to I-type Lectins 
2.2.1 MAG – Siglec-4 
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Introduction 
The central nervous system (CNS) is an inhibitory environment for axon 
regeneration.[1,2] After injury, nerve strands lack the ability for regeneration due to the 
presence of several inhibitory proteins.[3] In the last decade, three inhibitor proteins 
have been identified, one of them being the myelin-associated glycoprotein (MAG).[4] 
MAG interacts with several neuronal receptors, such as proteins of the Nogo 
receptor family and gangliosides, primarily GD1a, GT1b and GQ1b.[5] Although the 
relative role of Nogo receptors and gangliosides as MAG ligands has yet to be 
resolved, it is supposed that their binding to MAG leads to the activation of RhoA 
kinase and finally to growth cone collapse.[6] 
Our focus is on the inhibitory cascade mediated by gangliosides, because it was 
shown that sialidase treatment results in enhanced neural outgrowth.[7] Therefore, 
blocking MAG with sialic acid derivatives offers a valuable therapeutic approach to 
enhance axon regeneration. Extensive SAR studies resulted in sialic acid derivatives 
with - compared to gangliosides, which are the physiological players in the inhibitory 
cascade - almost 1000-fold improved potencies.[8-11] To further enhance affinity for 
MAG (Siglec-4) and selectivity versus other Siglecs, a fragment-based approach was 
applied.[12] Thus, Shelke et al.[13] identified fragments binding to MAG in the close 
proximity of sialic acid binding site.[14] When these fragments were linked with a 
micromolar sialic acid derivative the lead structure 1 was identified.[13] (Figure 1). In 
this report, we present the optimization of lead 1 and the biological evaluation of the 
newly obtained MAG antagonists. 
 
Results and Discussion 
Second-site NMR screening with a spin-labeled first-site ligand allows detecting 
ligands that bind to the target protein simultaneously with and in the vicinity of the 
first-site ligand. The paramagnetic relaxation enhancement on protons by the 
unpaired electron of the spin label is depending on the distance between spin label 
and the proton of interest and therefore reveals precious information for the design of 
the spacer to link the two ligands.[15] In the case of MAG, Shelke et al. identified 5-
nitroindole as second-site ligand.[13] The optimal spacer length was evaluated by in 
situ click chemistry,[16] leading to antagonist 1 with an affinity of 190 nM (Figure 1, 
Table 1).[13] 
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Figure 1. Lead identification by NMR-based screening followed by lead optimization. 
 
In this communication, we modified substituents of the indole moiety (R1 to R4), the 
5-position of sialic acid (R5) and the para-position of the terminal benzamide (R6). 
For the indole moiety, the effect of electron density as well as the enlargement of the 
hydrophobic surface was studied. The 5-position of sialic acid was modified to 
optimize the hydrophobic contact with tryptophane. Finally, para-substituted 
benzamides in the terminal position of the gycerol side chain of sialic acid have 
previously been shown to enhance the affinity of MAG antagonists.[11,17] The binding 
affinities of antagonists 2-20 were determined by surface plasmon resonance 
experiments. Furthermore, molecular mechanic studies were conducted to 
rationalize the binding process and the effect of indole substituents was scrutinized 
by testing the ligands with a MAG mutant with a hapten binding assay.[9-11] Finally, 
the thermodynamic profile of the most potent antagonists was investigated by 
isothermal titration calorimetry (ITC). 
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Synthesis 
For the linking of the first- (sialosides 21 and 22) and the second-site ligands (indoles 
26a-o, 33 & 34) a copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition was applied 
(Schemes 4 & 5).[18] Sialoside 21[13] was synthesized according to a reported 
procedure. The synthesis of sialosides 22a & 22b is summarized in Scheme 5. The 
synthesis of the various indoles was accomplished by following three different 
approaches (Schemes 1-3). 
 
Synthesis of indoles 25a-o, 33 and 34. In more detail, 3- and 3,5-substituted 
indoles were synthesized by reacting hydrazine derivatives 23a-e with 3,4-dihydro-
2H-pyran under modified Fisher indolization conditions ( 24a-e) as earlier 
described by Campos et al.[19] Applying similar conditions yielded the indoles 24f-k. 
Afterwards, the primary alcohols were converted into the corresponding azides 26a-k 
by using the Appel reaction (Scheme 1).[20,21] 
N
H
NH2
HCl
N
H
R4
R4
23a-k
R3
R2
R3
R2
X
N
H
R4
R3
R2
N3
24a-k (X = OH)
25a-k (X = Br)
26a-k
a)
N
H
R4
OAc
27j,k
d)
e)
b)
c)
2
3
4
5
6
7
 
 
26 a b c d e F g h i j k 
R2 H H H H Me H H H Cl H H 
R3 H H H H H Cl H H2C
H2C
H2C
H H H 
R4 H OMe Cl F H H iPr H CN SO2Me 
 
Scheme 1. a) 3,4-Dihydro-2H-pyran, DMAc, 4% aq. H2SO4, 100 °C (11-90%); b) 3,4-dihydro-2H-
pyran, AcOH, conc. aq. HCl; c) NaOMe/MeOH (24j: 27%; 24k: 42%); d) PPh3, CBr4, CH3CN; e) NaN3, 
DMF (16-85%, 2 steps). 
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Starting from intermediate 24a, 3,6-disubstituted indoles were obtained after 
protection of the free alcohol ( 28[22]) and the indole-amine ( 29) by performing 
Friedel-Crafts acylation. Subsequent deprotection ( 24l, m) and conversion of the 
primary alcohol into the azide yielded the desired indole derivatives ( 26l, m) for 
click chemistry (Scheme 2). 
 
24a
2822
b)
N
OAc
Ts
c)
N
H
X
R
O
e)
N
H
N3
R
O
29
24l,m (X = OH)
25l,m (X = Br)
26l:   R = cyclopropyl
26m: R = 4-chlorophenyl
N
H
X
a)
d)
(X = OH)
(X = OAc)
 
Scheme 2. a) Ac2O, DMAP, pyridine (92%); b) TsCl, NaH, THF (70%); c) (i) RCOCl, AlCl3, CH3NO2, 
(ii) 6 M NaOH, MeOH (24l: 61%; 24m: 47%, yields refer to inseparable mixtures of 5- and 6-
substituted indoles); d) PPh3, CBr4, DMF, 50 °C; e) DMF, NaN3, 50 °C (26l: 36%; 26m: 37%, two 
steps). 
 
In the case of 1,3,5- and 3,5-substituted indoles, having electron-withdrawing 
substituents in 5'-position (Scheme 3), azide 26n was synthesized by reacting 2-
iodo-aniline derivative 30n with 31 under Larock indole conditions[21,23] ( 32n). 
After removal of the silyl protecting group, the alcohol ( 24n) was converted into 
the desired azide ( 26n). Starting from 26o[13] N-alkylation was performed using 
the corresponding alkyl iodides and potassium hydroxide as base to obtain 33 and 
34. 
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I
NH2
F3C
N
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N
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F3C
N
H
F3C
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b)
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31
32n
24n (X = OH)
25n (X = Br)
OTBS
X N3
30n
OTBS
Me3Si
c)
N
H
O2N
26o13
N3
d)
NR1
O2N
33 (R1 = Me)
34 (R1 = Et)
N3
e)
 
Scheme 3. a) Pd(OAc)2, LiCl, KOAc, DMF, 70 °C; b) 48% HF, CH3CN, rt (69%, 2 steps); c) PPh3, 
CBr4, CH3CN; d) DMF, NaN3, rt (80%, 2 steps); e) R2I, KOH, DMF (33: 94%; 34: 92%). 
 
Copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition. Finally, with 
sialoside 21[13] and the various substituted indole derivatives in hand, the final 
compounds 2-8 were synthesized applying Cu(I)-catalyzed click-conditions as shown 
in Scheme 4. 
a)
2113 26a,b,l-n
33, 34
NR1
R4
R3
N3
O
COONa
O
HO
AcHN
OH
OH
N
H
O
O
COONa
O
HO
AcHN
OH
OH
N
H
O
N N
N
NR1
R4
R3
+
2-8  
Triazole 2 3 4 5 6 7 8 
Indole 26a 26b 26l 26m 26n 33 34 
R1 H H H H H Me Et 
R3 H H 
O  
O
Cl H H H 
R4 H OMe H H CF3 NO2 NO2 
Scheme 4. a) CuSO4·5H2O, sodium ascorbate, H2O/t-BuOH 1:1, rt (47-80%). 
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Earlier SAR studies showed that introduction of fluoroacetamide in 5-position leads 
to a distinct improvement of the binding affinity[5e,11,17] and therefore we decided to 
incorporate this modification into compound 1 (Scheme 5). Intermediate 36 was 
obtained from 35[13] by cleavage of the N-acetate in 5-position followed by Boc-
protection. After deprotection ( 37), selective fluoroacetylation was performed to 
give 38. Afterwards, the azide was transformed into benzylamide or p-
chlorobenzylamide, respectively, under modified Staudinger conditions ( 39a, b). 
After deprotection ( 22a, b) the test compounds 9-20 were obtained by click 
reaction with indole derivatives 26b-k, o. 
O
COONa
O
HO
FAcHN
OH
OHH
N
O
N N
N
N
H
R6
O
COOMe
O
AcO
R5HN
OAc
OAc
N3
b)
3513
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f)
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38 (R5 = FAc)
39a (X = Ac, Y = Me, R6 = H)
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d)
O
COOMe
O
AcO
R5HN
OAc
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N3
O
COOY
O
XO
FAcHN
OX
OX
N
H
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O
R4
R3
R2
NH
R4
R3
N3 R2
26b-k, o
a) c)
22a (X = H,  Y = Li, R6 =H)
22b (X = H, Y = Li, R6 = Cl)
e)
e)
9-20
(R5 = Ac)
(R5 = Boc)
 
Triazole 9 10 11 12 13 14 15 16 17 18 19 20 
Indole 26b 26c 26d 26e 26f 26g 26h 26i 26j 26k 26o 26o
R2 H H H Me H H H Cl H H H H 
R3 H H H H Cl H H2C
H2C
H2C
H H H H H 
R4 OMe Cl F H H iPr H CN SO2Me NO2 NO2 
R6 Cl Cl Cl Cl Cl Cl Cl Cl Cl Cl H Cl 
 
Scheme 5. a) i. Boc2O, DMAP, THF; ii. N2H4H2O, MeOH; iii. Ac2O, DMAP, pyridine (50%); b) PhOH, 
TMSCl, DCM, rt (70%); c) FCH2COCl, NEt3, DMAP, THF (43%); d) PPh3, RCOCl, DCE, rt (39a: 52%; 
39b: 65%); e) 10% aq. LiOH, THF/H2O (22a: 80%); 22b: 50%); f) i. (26b-k, o), CuSO4·5H2O, sodium 
ascorbate, H2O/tBuOH 1:1, rt; ii. Dowex 50X8 (Na+ form) (9-20: 16-80%). 
 
Biological evaluation of antagonists 1-20. To evaluate the binding 
properties of the MAG antagonists surface plasmon resonance (SPR) experiments[11] 
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and a hapten inhibition assay[24] were used. For SPR experiments, recombinant 
protein, consisting of the three N-terminal domains of MAG and the Fc part of human 
IgG (MAGd1-3-Fc)[24] was immobilized on polyclonal anti-Fc antibody, which was 
covalently bound to the chip surface. A reference cell, providing only antibody was 
used for compensation of unspecific binding to the matrix. The test compounds were 
dissolved in running buffer and injected over the surface. The obtained sensorgrams 
were fitted according to a 1:1 binding model. 
 
Critical micelle concentration (CMC). Concerns that our test compounds 
might form micelles in aqueous solution or show surface activity were addressed by 
determining the critical micelle concentration (CMC) with surface tension 
measurements using a wire probe tensiometer on a series of different analyte 
concentrations. The expended energy to pull the wire probes out of a solution 
corresponds to the surface pressure (mN/m), which is inversely proportional to the 
surface tension. Due to the fact that the surface tension changes strongly with 
raising concentrations of a surface-active analyte and remains relatively constant as 
soon as micelles are being formed, the CMC can be obtained with a dilution series. 
In the case of our MAG antagonists no activity up to 1 mM was observed, thus 
excluding a possible influence of micelles formed by the test compounds on the 
affinity measurements. 
The affinities (Table 1) revealed that N-alkylation of 5'-nitroindole with methyl ( 7, 
entry 2) or ethyl ( 8, entry 3) led to a slight decrease in affinity, whereas 
substituents in the 6- and 7-position of the indole moiety (entries 18-20) improved 
affinity by a factor of 2. 
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N
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Table 1. Overview on affinities of antagonists 1-20, determined by surface plasmon resonance. 
Entry Compound R1 R2 R3 R4 R5 R6 KD [nM] 
1 1 H H H NO2 Ac H 190 
2 7 Me H H NO2 Ac H 445 
3 8 Et H H NO2 Ac H 333 
4 2 H H H H Ac H 267 
5 3 H H H OMe Ac H 322 
6 6 H H H CF3 Ac H 354 
7 4 H H 
O
 
H Ac H 300 
8 5 H H 
O
Cl 
H Ac H 75 
9 19 H H H NO2 FAc H 50 
10 20 H H H NO2 FAc Cl 53 
11 10 H H H Cl FAc Cl 48 
12 11 H H H F FAc Cl 67 
13 17 H H H CN FAc Cl 66 
14 18 H H H SO2Me FAc Cl 33 
15 9 H H H OCH3 FAc Cl 79 
16 14 H H H CH(CH3)2 FAc Cl 101 
17 15 H H -CH2CH2CH2- FAc Cl 98 
18 13 H H Cl H FAc Cl 57 
19 16 H Cl H H FAc Cl 92 
20 12 H CH3 H H FAc Cl 96 
 
The replacement of the nitro group by hydrogen ( 3, entry 5), trifluoromethyl ( 6, 
entry 6) or by the electron-donating methoxy-group decreased the affinity. These 
observations suggest that the nitro group’s contribution to affinity is not related to its 
electron withdrawing capacity but rather a beneficial polar interaction with the 
protein. Next, substituents with increased lipophilic surfaces were introduced at the 
6'-position of the indole moiety. No beneficial effect was observed for 
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cyclopropanecarbonyl ( 4, entry 7), however a gain in affinity by a factor of 3 
resulted for 4-chlorobenzoyl ( 5, entry 8). However, due to the low solubility of 
antagonist 4 and 5, modifications in the 6’-position were discontinued. 
Earlier studies have shown an improvement in binding affinity upon insertion of 
fluoroacetamide in the 5-position of sialic acid derivatives.[11,17] This modification 
turned out to be successful when applied to lead compound 1, leading to a three-fold 
improved affinity ( 19, entry 9). However, the reported beneficial effect for the 
replacement of the benzamide in the 9-position of the Neu5Ac moiety by para-
chlorobenzamide[9] ( 20, entry 10) could not be observed. Based on antagonist 20, 
we revisited our search for the replacement of the nitro group exhibiting a toxic 
potential[25] and substituents in the 6- and 7-position of the indole moiety. From the 
many explored substituents (see entries 11 to 20) methyl sulfone yielded the most 
active MAG antagonist with a KD of 33 nM. 
 
Isothermal titration calorimetry (ITC). We performed ITC measurements of 
lead 1 and two of the most active compounds 5 and 19 in order to gain further insight 
into the thermodynamic parameters ∆H°, ∆S°, and ∆G° of the binding event (Table 
2). A solution of the ligands (1, 5, and 19) in HBS-E buffer was injected into a 
solution of MAGd1-3-Fc[24] (HBS-E buffer) at 25 °C. The experimental data were fitted 
to a theoretical titration curve (one site binding model) using Origin version 7 
software (MicroCal). ∆H° and KD are measured and ∆S° and ∆G° calculated 
according to equation (1) 
 G  HTS  RT lnKD  RT lnKA   (1) 
With ITC, the high affinity of the antagonists could be reproduced, however, 
compared to SPR, the affinities were consistently weaker. As in most cases of 
carbohydrate-lectin interactions, the binding is enthalpy driven.[26]  
 
Table 2. The thermodynamic parameters of 1, 5, and 19 are shown. ∆G° and –T∆S° were calculated 
according to equation 1. N represents the stoichiometry. 
Compound N KD [nM] ∆G° [kJ mol–1] ∆H° [kJ mol–1] –T∆S° [kJ mol–1] 
1 0.91 ± 0.07 589 ± 30 –35.6 ± 0.2 –34.0 ± 0.9 –1.6 ± 0.7 
5 0.91 ± 0.04 132 ± 20 –39.3 ± 0.4 –51.9 ± 0.1 +12.6 ± 0.2 
19 1.05 ± 0.11 171 ± 50 –38.7 ± 0.7 –32.5 ± 0.6 –6.2 ± 1.3 
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When comparing compound 1 and 5, the difference ∆G° results from ∆S°, whereas 
the ∆H° values are almost equal. This could be the result, at least partially, of a more 
favorable desolvation entropy as 5 is more lipophilic than 1. In contrast, the 
enhanced affinity of compound 19 compared to compound 1 is related to a more 
favorable enthalpy that is partially compensated by an unfavorable entropy term. 
Since 4-chlorbenzylacyl in 6’-position of the indole forms additional interactions, 
enthalpy is increased but partially compensated because of the reduced 
conformational freedom of the ligand.[27] 
 
Molecular modeling studies. For an improved understanding of the 
biological data, compounds 2 and 19 and were docked to a homology model of 
MAG[10,11] and a molecular-dynamics simulation in aqueous solution was performed 
(4 ns at 300 K) using Desmond.[28] In both antagonist-protein complexes, the sialic 
acid core established the crucial interactions responsible for recognition and binding, 
i.e. a salt bridge of the carboxylate with Arg118[17] and a hydrophobic contact of the 
N-acetate/N-fluoroaceate in the 5-position with Trp22.[17] In addition, hydrogen bonds 
between 5-NH and the carbonyl of Gln126, 8-OH and Thr128 and 9-NH and Tyr125 
are present in both antagonist-protein complexes. These interactions are in full 
agreement with those observed by X-ray crystallography of synthetic sialosides 
complexed with Siglec-1[29] and Siglec-7.[30] 
In the case of 19, the 5'-nitroindole is embedded in a hydrophobic pocket lined by the 
residues Tyr60, Tyr69 and Tyr116. The indole-moiety is sandwiched by Tyr69 and 
Tyr116, displaying an angle to Tyr69 of 17° and to Tyr116 an angle of 39° (Figure 2). 
It is noteworthy, that the - interactions are maintained during the whole simulation. 
Furthermore, the nitro substituent interacts with Lys67 by dipolar interactions and 
seems to stabilize the position of the indole. The nitro group is in a distance range of 
2.6 to 5.0 Å, a value also found in other protein-ligand complexes.[31] In the case of 
the unsubstituted indole 2 no π-π interactions were observed (Figure 2B). The 
angles of both tyrosines are around 70-90° and the dispersion is clearly higher. 
Furthermore, the mobility of the linker was strikingly increased during the dynamic 
simulation. The nevertheless good binding affinity might be explained that no 
constraints raise from the linker positioning and that the core interactions might be 
slightly better established. 
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Figure 2. Conformations of the antagonists 2 and 19 and the position of Tyr69 and Tyr116 during the dynamic 
simulation were clustered. A) 5'-Nitroindole interacts via π-π interactions with Tyr69 and Tyr116 resulting in a 
locked conformation of the linker. In addition, a dipolar interactions with Lys67 can be established. B) Antagonist 
2, lacking the 5'-nitro substituent, is not sandwiched and consequently shows increased mobility of the linker. 
 
In summary, these findings are in agreement with the observation that replacement 
of the 5'-nitro group by other substituents decreases the affinity (e.g.  6, entry 6), 
as the polar interaction with Lys67 is no longer possible. Furthermore, modifications 
in the 6'-position could be aligned into the hydrophobic cleft and additional 
hydrophobic interactions ( 5, entry 8) contribute to the binding affinity. 
 
MAG mutant K67A. In order to elucidate the role of the nitro group 
experimentally, compounds 1 and 2 were tested with the MAG mutant where Lys67 
is replaced by alanine (K67A) in a hapten inhibition assay.[24] The molecular docking 
experiments of sialoside 19 suggested an interaction of the nitro group of 5'-
nitroindole with Lys67. To elucidate this interaction, affinities of the sialosides 1 and 
2 for MAGd1-3-Fc wt and the MAG mutant K67A were compared in hapten inhibition 
assays. The concentration of 1 and 2 required for 50 % inhibition (IC50) was 
determined in microtiter plates coated with fetuin as the binding target for MAGd1-3 
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Fc-chimeras.[24] Relative inhibitory potencies (rIP) were calculated as ratio of the IC50 
of the compound of interest, i.e. 1 and 2 and the IC50 of 2 used as reference 
compound. For each compound at least three independent titrations were performed 
with seven or eight concentrations in triplicates (Figure 3 & Table 3). Both 
substances exhibit IC50 values in the low nanomolar range. The presence of the nitro 
group in sialoside 1 leads to a 4.25-fold stronger inhibition compared to 2 for MAGd1-
3-Fc wt, whereas for MAGd1-3-Fc K67A this increase is only 2.14-fold. This supports 
the hypothesis that Lys67 contributes to binding via a polar interaction with the nitro 
group of compound 1, as suggested in Figure 2A. However, additional parameters 
are likely to support binding, since the introduction of the nitro group also enhances 
affinity of the K67A mutant. 
 
 
Figure 3. A) Inhibition curves of MAGd1-3-Fc wild type (wt) and mutant K67A for the determination of 
IC50-values by hapten inhibition assay. B) rIP of sialosides 1 and 2 for both Fc-chimeras MAG wt and 
K67A. Sialoside 2 (without nitro residue) was used as reference compound (rIP = 1) to obtain a factor 
of enhanced affinity related to the introduction of the nitro group. 
 
Table 3. Comparison of the half maximal inhibitory concentrations (IC50) and relative inhibitory 
potencies (rIP) for MAGd1-3-Fc wild type (wt) and mutant K67A inhibited by sialosides 1 and 2 
determined by hapten inhibition assay.[24] 
Compound MAGd1-3-Fc wt MAGd1-3-Fc K67A 
 IC50 [nM] rIP IC50 [nM] rIP 
1 13 ± 2 4.25 ± 0.19 41 ± 5 2.14 ± 0.21
2 53 ± 9 1.00 ± 0.00 88 ± 4 1.00 ± 0.00
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Summary and Conclusions 
The lead compound 1 of our study showed nanomolar binding affinity (Table 1, entry 
1), however, suffers from two metabolic soft spots, i.e. the unsubstituted benzamide 
prone to oxidation and the nitro group exhibiting a toxic potential.[27] We therefore 
replaced the benzamide by p-chlorobenzamide, which showed a comparable binding 
affinity as indicated by the antagonists 19 and 20 (entries 9 &10). Furthermore, we 
examined a series of ligands (entries 11-20) where the nitro group in the 5'-position 
of the nitroindole moiety was replaced by either halogen-, cynano-, methoxy-, alkyl- 
and methylsulfonyl-substituents. In agreement with our findings with the MAG-mutant 
K67A, i.e. that the nitro group establishes a polar interaction with Lys67, the 
methylsulfonyl substituent ( 18) yielded the most active antagonist. Surprisingly, 
antagonists 10, 11 and 17 (entries 11-13) showed comparable binding affinities (48-
67 nM), probably also related to polar interactions with Lys67. Finally, introduction of 
substituents in the 7'-position (entries 19 & 20) or lipophilic substituents in the 5'-
position (entries 16 & 17) led to a decreased binding affinity. Overall, we have 
identified with compound 18 a low nanomolar MAG antagonist ready for extended 
cellular and in vivo evaluation. 
 
Experimental Procedure 
 Chemistry. NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) 
spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D methods 
(COSY, HSQC, TOCSY). Chemical shifts are expressed in ppm using residual CHCl3, 
CHD2OD and HDO as references. Optical rotations were measured using Perkin-Elmer 
Polarimeters 241 and 341. MS analyses were carried out using a Waters Micromass ZQ 
Detector system. The spectra were recorded in positive or negative ESI mode. The 
HPLC/HRMS analyses were carried out using an Agilent 1100 equipped with a photodiode 
array detector and a Micromass QTOF I equipped with a 4 GHz digital-time converter. All 
target compounds exhibit a purity of  95%. Reactions were monitored by TLC using glass 
plates coated with silica gel 60 F254 (Merck) and visualized by using UV light and/or by 
charring with a molybdate solution (a 0.02 M solution of ammonium cerium sulfate dihydrate 
and ammonium molybdate tetrahydrate in aqueous 10% H2SO4). Column chromatography 
was performed on silica gel (Uetikon, 40-60 mesh). Methanol was dried by refluxing with 
sodium methoxide and distilled immediately before use. Pyridine was freshly distilled under 
argon over CaH2. Dichloromethane (DCM), dichloroethane (DCE), acetonitrile (MeCN), 
nitromethane, toluene, and benzene were dried by filtration over Al2O3 (Fluka, type 5016 A 
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basic). Molecular sieves (3 Å) were activated under vacuum at 500 °C for 2 h immediately 
before use. If not stated otherwise, all starting materials were commercially available. 
General procedure A: Synthesis of indoles (24f-i). To a solution of hydrazine-HCl 
23f-i (2.50 mmol) and N,N-dimethylacetamide (DMAc, 10 mL) in aq. 4% H2SO4 (4 mL), 3,4 
dihydro-2H-pyran (2.50 mmol) was added dropwise. The reaction was stirred for 2 h, then 
cooled to rt, extracted with EtOAc (20 mL) and washed with water (3  20 mL). The 
combined aqueous layers were extracted with EtOAc (20 mL) and the combined organic 
layers were dried over Na2SO4, filtered and evaporated. The crude product was purified by 
chromatography on silica (petroleum ether/EtOAc). 
General procedure B: Appel reaction (26a-n). The alcohol 24a-n (1.0 eq) was 
dissolved in dry MeCN and cooled to 0 °C. Afterwards, triphenylphosphine (1.2-1.5 eq) was 
added, followed by successive addition of CBr4 (1.2-1.5 eq). The mixture was stirred at rt for 
2 h and then diluted with EtOAc, washed with H2O and brine, and dried over Na2SO4. The 
solvents were removed in vacuo and the residue was purified by chromatography on silica 
(petroleum ether/EtOAc) to yield the corresponding bromide 25a-n. Afterwards, to a solution 
of bromide (1.0 eq) in dry DMF, NaN3 (2.0-5.0 eq) was added at rt and stirring was continued 
overnight. The solvent was removed under reduced pressure and the residue was purified 
by chromatography on silica (petroleum ether/EtOAc) to afford azides 26a-n. 
General procedure C: Triazole formation by click reaction (2-20). To a solution of 
acetylene 21 or 22a, b (1.0 eq) in degassed tBuOH:H2O (v/v, 1:1), azide 26a-o, 33 or 34 
(1.2-1.5 eq), CuSO4·5H2O (0.25 eq) and sodium ascorbate (0.5 eq) were added. The 
reaction mixture was stirred at rt overnight. Then, the solvents were removed under reduced 
pressure and the residue was purified by reversed phase chromatography (Merck 
LiChroprep RP-18, 5% gradient of MeOH in water), Dowex 50X8 (Na+ type) ion-exchange 
chromatography and P2 size-exclusion chromatography to afford the pure test compounds 
2-20 after a final lyophilization from water. 
The indoles 24f-k were synthesized according to the procedure published by Campos et al. 
[19] 
 3-(6-Chloro-1H-indol-3-yl)-propan-1-ol (24f). Prepared from 23f (400 mg, 2.23 mmol) 
according to general procedure A. Yield: 53 mg, 11%. 1H NMR (500 MHz, CDCl3): δ = 1.94-
2.03 (m, 2H, CH2), 3.01-3.09 (m, 2H, CH2), 3.73 (t, J = 6.5 Hz, 2H, CH2), 6.95 (s, 1H, CHar), 
7.00-7.08 (m, 2H, CHar), 7.16-7.23 (m, 1H, CHar), 8.27 (s, 1H, NH); 13C NMR (126 MHz, 
CDCl3): δ = 22.7, 34.6, 62.7 (3 CH2), 110.1, 116.5, 120.5, 122.6, 123.1, 124.3, 126.6, 138.1 
(C-Ar); ESI-MS: m/z calcd for C11H13ClNO M+H+: 210.1, found: 209.9. 
3-(5-Isopropyl-1H-indol-3-yl)-propan-1-ol (24g). Prepared from 23g (300 mg, 1.61 
mmol) according to general procedure A. Yield: 152 mg, 43%. 1H NMR (500 MHz, CDCl3): δ 
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= 1.34 (d, J = 6.9 Hz, 6H, 2 CH3), 1.94-2.07 (m, 2H, CH2), 2.88 (t, J = 7.5 Hz, 2H, CH2), 3.05 
(hept, J = 6.9 Hz, 1H, CH), 3.77 (t, J = 6.4 Hz, 2H, CH2), 6.98 (s, 1H, CHar), 7.12 (dd, J = 1.4, 
8.4 Hz, 1H, CHar), 7.30 (d, J = 8.4 Hz, 1H, CHar), 7.46 (s, 1H, CHar); 13C NMR (126 MHz, 
CDCl3): δ = 21.6 (CH2), 24.9 (2C, 2 CH3), 33.1 (CH2), 34.5 (CH), 63.0 (CH2), 111.1, 115.9, 
116.0, 121.4, 121.6, 127.7, 135.2, 140.2 (C-Ar); ESI-MS: m/z calcd for C14H20NO M+H+: 
218.2, found: 218.0. 
 3-(1,5,6,7-Tetrahydrocyclopenta[f]indol-3-yl)-propan-1-ol (24h). Prepared from 23h 
(200 mg, 1.08 mmol) according to general procedure A. Yield: 140 mg, 60%. 1H NMR (500 
MHz, CDCl3): δ = 1.86-1.94 (m, 2H, CH2), 2.04 (p, J = 7.3 Hz, 2H, Cyc-CH2), 2.74 (t, J = 7.4 
Hz, 2H, CH2), 2.90 (t, J = 7.3 Hz, 4H, 2 Cyc-CH2), 3.64 (t, J = 6.4 Hz, 2H, CH2), 6.82 (d, J = 
2.0 Hz, 1H, CHar), 7.09 (s, 1H, CHar), 7.34 (s, 1H, CHar), 7.70 (s, 1H, NH); 13C NMR (126 
MHz, CDCl3): δ = 22.7 (CH2), 26.9, 32.6, 32.7 (3 Cyc-CH2), 33.1 (CH2), 63.0 (CH2), 106.7, 
113.9, 118.9, 121.0, 126.8, 136.1, 136.1, 139.4 (C-Ar); ESI-MS: m/z calcd for C14H18NO 
M+H+: 216.1, found: 215.9. 
 3-(7-Chloro-1H-indol-3-yl)-propan-1-ol (24i). Prepared from 23i (300 mg, 1.68 mmol) 
according to general procedure A. Yield: 80 mg, 22%. 1H NMR (500 MHz, CDCl3): δ = 1.91-
2.02 (m, 2H, CH2), 2.84 (t, J = 7.4 Hz, 2H, CH2), 3.71 (t, J = 6.4 Hz, 2H, CH2), 6.92-7.13 (m, 
2H, CHar), 7.17 (d, J = 7.3 Hz, 1H, CHar), 7.50 (d, J = 7.9 Hz, 1H, CHar), 8.16 (s, 1H, NH); 13C 
NMR (126 MHz, CDCl3): δ = 21.6, 33.1, 62.7 (3 CH2), 116.8, 117.4, 117.8, 120.2, 121.6, 
122.1, 129.2, 133.8 (C-Ar); ESI-MS: m/z calcd for C11H13ClNO M+H+: 210.1, found: 209.9. 
3-(3-Azidopropyl)-1H-indole (26a). Prepared from 24a (494 mg, 2.82 mmol) 
according to general procedure B. Yield: 277 mg, 50% (two steps), yellow oil. 1H NMR 
(CDCl3, 500 MHz): δ = 2.02 (m, 2H, CH2), 2.88 (t, J = 7.5 Hz, 2H, CH2), 3.34 (t, J = 7.0 Hz, 
2H, CH2), 7.01 (s, 1H, CHar), 7.15 (t, J = 7.0 Hz, 1H, CHar), 7.22 (t, J = 7.0 Hz, 1H, CHar), 
7.37 (d, J = 8.0 Hz, 1H, CHar), 7.61 (d, J = 7.5 Hz, 1H, CHar), 7.99 (s, 1H, NH); 13C NMR 
(CDCl3, 126 MHz): δ = 22.1, 29.2, 50.9 (3 CH2), 111.1, 115.0, 118.8, 119.3, 121.5, 122.1, 
127.3, 136.3 (C-Ar); IR (film):  = 3415, 2929, 2097, 1456, 742 cm-1.  
3-(3-Azidopropyl)-5-methoxy-1H-indole (26b). Prepared from 24b (523 mg, 2.55 
mmol) according to general procedure B. Yield: 396 mg, 68% (two steps), yellow oil. 1H 
NMR (CDCl3, 500 MHz): δ = 2.01 (m, 2H, CH2), 2.85 (t, J = 7.0 Hz, 2H, CH2), 3.36 (t, J = 7.0 
Hz, 2H, CH2), 3.89 (s, 3H, OMe), 6.88 (dd, J = 9.0, 2.5 Hz, 1H, CHar), 7.00 (d, J = 2.5 Hz, 
1H, CHar), 7.05 (d, J = 2.0 Hz, 1H, CHar), 7.27 (d, J = 3.5 Hz, 1H, CHar), 7.87 (s, 1H, NH); 13C 
NMR (CDCl3, 126 MHz): δ = 22.1, 29.1, 50.8 (3 CH2), 55.9 (OMe), 100.6, 111.8, 112.2, 
114.7, 122.3, 127.7, 131.5, 153.9 (C-Ar); IR (film):  = 3415, 2938, 2097, 1485, 1214 cm-1. 
3-(3-Azidopropyl)-5-chloro-1H-indole (26c). Prepared from 24c (99.4 mg, 0.474 
mmol) according to general procedure B. Yield: 86 mg, 77% (two steps). 1H NMR (500 MHz, 
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CDCl3): δ = 1.94 (p, J = 7.0 Hz, 2H, CH2), 2.78 (t, J = 7.4 Hz, 2H, CH2), 3.28 (t, J = 6.7 Hz, 
2H, CH2), 6.99 (d, J = 1.9 Hz, 1H, CHar), 7.12 (m, 1H, CHar), 7.22 (d, J = 3.8 Hz, 1H, CHar), 
7.51 (d, J = 1.6 Hz, 1H, CHar), 7.95 (s, 1H, NH); 13C NMR (126 MHz, CDCl3): δ = 22.2, 29.4, 
51.0 (3 CH2), 112.4, 115.1, 118.6, 122.6, 123.2, 125.4, 128.7, 134.9 (C-Ar); IR (film):  = 
3435, 2929, 2098, 1463 cm-1; ESI-MS: m/z calcd for C11H12ClN4 M+H+: 235.1, found: 
234.8. 
3-(3-Azidopropyl)-5-fluoro-1H-indole (26d). Prepared from 24d (65.7 mg, 0.340 
mmol) according to general procedure B. Yield: 54 mg, 73% (two steps). 1H NMR (500 MHz, 
CDCl3): δ = 1.83-1.94 (m, 2H, CH2), 2.70 (t, J = 7.4 Hz, 2H, CH2), 3.21 (t, J = 6.7 Hz, 2H, 
CH2), 6.85 (td, 3J1,2 = 2.5 Hz, 3JH,F = 9.0 Hz, 1H, CHar), 6.92 (s, 1H, CHar), 7.14 (m, 2H, CHar), 
7.85 (s, 1H, NH); 13C NMR (126 MHz, CDCl3): δ = 22.2, 29.2, 51.0 (3 CH2), 103.9 (d, 2JC,F = 
23.3 Hz, C-4), 110.6 (d, 2JC,F = 26.4 Hz, C-6), 112.0 (d, 3JC,F = 9.7 Hz, C-7), 115.4 (d, 4JC,F = 
4.8 Hz, C-8), 123.6 (C-Ar), 127.9 (d, 3JC,F = 9.5 Hz, C-3), 133.0 (C-Ar), 157.9 (d, 1JC,F = 234 
Hz, C-5); IR (film):  = 3429, 2927, 2098, 1485 cm-1; ESI-MS: m/z calcd for C11H12FN4 
M+H+: 219.1, found: 218.9. 
3-(3-Azidopropyl)-7-methyl-1H-indole (26e). Prepared from 24e (82.0 mg, 0.433 
mmol) according to general procedure B. Yield: 64 mg, 70% (two steps). 1H NMR (500 MHz, 
CDCl3): δ = 1.96-2.08 (m, 2H, CH2), 2.49 (s, 3H, CH3), 2.88 (t, J = 7.3 Hz, 2H, CH2), 3.33 (t, 
J = 6.7 Hz, 2H, CH2), 6.97-7.05 (m, 2H, CHar), 7.08 (td, J = 2.0, 7.4 Hz, 1H, CHar), 7.47 (d, J 
= 7.8 Hz, 1H, CHar), 7.86 (s, 1H, NH); 13C NMR (126 MHz, CDCl3): δ = 16.7 (CH3), 22.4, 
29.5, 51.1 (3 CH2), 115.7, 116.7, 119.8, 120.5, 121.5, 122.8, 127.0, 136.2 (C-Ar); IR (film):  
= 3418, 2930, 2097 cm-1; ESI-MS: m/z calcd for C12H15N4 M+H+: 215.1, found: 214.9. 
3-(3-Azidopropyl)-6-chloro-1H-indole (26f). Prepared from 24f (43.0 mg, 0.205 mmol) 
according to general procedure B. Yield: 35 mg, 75% (two steps). 1H NMR (500 MHz, 
CDCl3): δ = 2.00-2.14 (m, 2H, CH2), 3.10 (t, J = 7.5 Hz, 2H, CH2), 3.37 (t, J = 6.8 Hz, 2H, 
CH2), 7.03 (d, J = 1.9 Hz, 1H, CHar), 7.09-7.15 (m, 2H, CHar), 7.24-7.31 (m, 1H, CHar), 8.07 
(s, 1H, NH); 13C NMR (126 MHz, CDCl3): δ = 23.5, 30.9, 51.1 (3 CH2), 110.1, 115.8, 120.7, 
122.8, 123.3, 124.3, 126.6, 138.1 (C-Ar); IR (film):  = 3429, 2929, 2097, 1437 cm-1; ESI-
MS: m/z calcd for C11H12ClN4 M+H+: 235.1, found: 234.8. 
3-(3-Azidopropyl)-5-isopropyl-1H-indole (26g). Prepared from 24g (152 mg, 0.700 
mmol) according to general procedure B. Yield: 144 mg, 85% (two steps). 1H NMR (500 
MHz, CDCl3): δ = 1.32 (d, J = 6.9 Hz, 6H, 2 CH3), 2.01 (p, J = 6.9 Hz, 2H, CH2), 2.86 (t, J = 
7.3 Hz, 2H, CH2), 3.03 (hept, J = 6.9 Hz, 1H, CH), 3.34 (t, J = 6.8 Hz, 2H, CH2), 6.95 (s, 1H, 
CHar), 7.11 (dd, J = 1.5, 8.4 Hz, 1H, CHar), 7.28 (d, J = 8.4 Hz, 1H, CHar), 7.42 (s, 1H, CHar), 
7.83 (s, 1H, NH); 13C NMR (126 MHz, CDCl3): δ = 22.3 (CH2), 24.9 (2C, 2 CH3), 29.4 (CH2), 
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34.5 (CH), 51.1 (CH2), 111.1, 115.0, 115.9, 121.5, 121.9, 127.6, 135.2, 140.3 (C-Ar); IR 
(film):  = 3412, 2957, 2096 cm-1; ESI-MS: m/z calcd for C14H18N4 M+: 242.2, found: 242.1. 
3-(3-Azidopropyl)-1,5,6,7-tetrahydrocyclopenta[f]indole (26h). Prepared from 24h 
(36.0 mg, 0.167 mmol) according to general procedure B. Yield: 10 mg, 25% (two steps). 1H 
NMR (500 MHz, CDCl3): δ = 1.98 (p, J = 7.0 Hz, 2H, CH2), 2.12 (dq, J = 7.3, 14.6 Hz, 2H, 
Cyc-CH2), 2.82 (t, J = 7.3 Hz, 2H, CH2), 2.98 (td, J = 2.1, 7.2 Hz, 4H, 2 Cyc-CH2), 3.31 (t, J = 
6.8 Hz, 2H, CH2), 6.90 (d, J = 2.1 Hz, 1H, CHar), 7.18 (s, 1H, CHar), 7.40 (s, 1H, CHar), 7.75 
(s, 1H, NH); 13C NMR (126 MHz, CDCl3): δ = 22.4 (CH2), 26.9 (Cyc-CH2), 29.4 (CH2), 32.7, 
33.1 (2 Cyc-CH2), 51.1 (CH2), 106.7, 113.8, 114.7, 121.3, 126.7, 136.2, 136.3, 139.5 (C-Ar); 
IR (film):  = 3401, 2934, 2094, 1646 cm-1; ESI-MS: m/z calcd for C14H17N4 M+H+: 241.1, 
found: 241.0. 
3-(3-Azidopropyl)-7-chloro-1H-indole (26i). Prepared from 24i (80.0 mg, 0.382 mmol) 
according to general procedure B. Yield: 10 mg, 16% (two steps). 1H NMR (500 MHz, 
CDCl3): δ = 1.91-2.02 (m, 2H, CH2), 2.84 (t, J = 7.4 Hz, 2H, CH2), 3.31 (t, J = 6.7 Hz, 2H, 
CH2), 7.04 (t, J = 7.8 Hz, 2H, CHar), 7.18 (d, J = 7.6 Hz, 1H, CHar), 7.48 (d, J = 7.9 Hz, 1H, 
CHar), 8.17 (s, 1H, NH); 13C NMR (126 MHz, CDCl3): δ = 22.4, 29.4, 51.0 (3 CH2), 116.5, 
116.9, 117.7, 120.4, 121.7, 122.4, 129.0, 133.9 (C-Ar); IR (film):  = 3427, 2925, 2098, 1437 
cm-1; ESI-MS: m/z calcd for C11H12ClN4 M+H+: 235.1, found: 235.8. 
 3-(5-Cyano-1H-indol-3-yl)-propyl acetate (27j). To a mixture of 3,4-dihydro-2H-pyran 
(242 L, 2.65 mmol) in AcOH (6 mL) and conc. aq. HCl (2 mL) was added 23j (150 mg, 
0.883 mmol) at rt, and the reaction mixture was stirred for 3 h at 100°C. After cooling to rt 
the reaction mixture was diluted with EtOAc (50 mL) and washed with water (40 mL) and 
brine (40 mL). The aqueous layers were extracted with EtOAc (40 mL) and the combined 
organic layers were dried over Na2SO4, filtered and evaporated to dryness. Chromatography 
(petroleum ether/EtOAc, 2:1) of the residue gave 27j (66 mg, 32%). 1H NMR (500 MHz, 
CDCl3): δ = 1.97-2.10 (m, 2H, CH2), 2.06 (s, 3H, CH3), 2.82 (t, J = 7.4 Hz, 2H, CH2), 4.11 (t, 
J = 6.5 Hz, 2H, CH2), 7.11 (m, 1H, CHar), 7.39 (s, 2H, CHar), 7.92 (s, 1H, CHar), 8.40 (s, 1H, 
NH); 13C NMR (126 MHz, CDCl3): δ = 21.1, 21.2 (CH2, CH3), 44.3 (CH2), 63.9 (CH2), 102.5, 
112.2, 116.6, 121.0, 123.7, 124.7, 125.1, 127.5, 138.2 (C-Ar, CN), 171.4 (CO); IR (film):  = 
3343, 2924, 2219, 1734, 1246 cm-1; ESI-MS: m/z calcd for C14H14NaN2O2 M+Na+: 265.1, 
found: 264.9. 
3-(5-Cyano-1H-indol-3-yl)-propan-1-ol (24j). A solution of 27j (80.0 mg, 0.330 mmol) 
in MeOH (2 mL) was treated with freshly prepared NaOMe/MeOH (1.0 eq) for 2 h. Then, the 
reaction mixture was neutralized with AcOH and evaporated to dryness. Chromatography 
(petroleum ether/EtOAc, 3:2) of the residue gave 24j (18 mg, 27%). 1H NMR (500 MHz, 
CDCl3): δ = 1.92-1.99 (m, 2H, CH2), 2.84 (t, J = 7.5 Hz, 2H, CH2), 3.71 (t, J = 6.3 Hz, 2H, 
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CH2), 7.10 (s, 1H, CHar), 7.38 (d, J = 0.8 Hz, 2H, CHar), 7.93 (s, 1H, CHar), 8.49 (s, 1H, NH); 
13C NMR (126 MHz, CDCl3): δ = 21.2, 33.0, 62.5 (3 CH2), 102.4, 112.2, 117.2, 121.1, 123.6, 
124.9, 125.1, 127.6, 138.2 (CN, C-Ar); IR (film):  = 3339, 2932, 2220, 1472, 1056 cm-1; ESI-
MS: m/z calcd for C12H12NaN2O M+Na+: 223.1, found: 222.8. 
3-(3-Azidopropyl)-5-cyano-1H-indole (26j). Prepared from 24j (30.0 mg, 0.150 mmol) 
according to general procedure B. Yield: 25 mg, 70% (two steps). 1H NMR (500 MHz, 
CDCl3): δ = 1.90-2.01 (m, 2H, CH2), 2.84 (t, J = 7.4 Hz, 2H, CH2), 3.32 (t, J = 6.7 Hz, 2H, 
CH2), 7.12 (d, J = 2.0 Hz, 1H, CHar), 7.33-7.56 (m, 2H, CHar), 7.92 (s, 1H, CHar), 8.47 (s, 1H, 
NH); 13C NMR (126 MHz, CDCl3): δ = 22.0, 29.3, 50.9 (3 CH2), 102.5, 112.3, 116.2, 121.0, 
123.9, 124.7, 125.2, 127.4, 138.2 (CN, C-Ar); IR (film):  = 3333, 2926, 2217, 2093 cm-1; 
ESI-MS: m/z calcd for C12H11NaN5 M+Na+: 248.1, found: 247.9. 
 3-(5-Methylsulfonyl-1H-indol-3-yl)-propyl acetate (27k). Prepared from 23k (150 mg, 
0.593 mmol) according to the procedure described for 27j. Yield: 65 mg, 37%. 1H NMR (500 
MHz, CD3OD): δ = 2.00-2.09 (m, 2H, CH2), 2.05 (s, 3H, CH3), 2.90 (t, J = 7.4 Hz, 2H, CH2), 
3.11 (s, 3H, CH3), 4.10 (t, J = 6.4 Hz, 2H, CH2), 7.27 (s, 1H, CHar), 7.54 (d, J = 8.5 Hz, 1H, 
CHar), 7.65 (dd, J = 1.8, 8.6 Hz, 1H, CHar), 8.17 (d, J = 1.5 Hz, 1H, CHar); 13C NMR (126 
MHz, CD3OD): δ = 21.0 (CH3), 22.1, 30.7 (2 CH2), 45.5 (CH3), 65.2 (CH2), 113.2, 117.6, 
120.4, 120.8, 126.3, 128.6, 131.8, 140.6 (C-Ar), 173.3 (CO); ESI-MS: m/z calcd for 
C14H17NaNO4S M+Na+: 318.1, found: 318.0. 
 3-(5-Methylsulfonyl-1H-indol-3-yl)-propan-1-ol (24k). Prepared from 27k (102 mg, 
0.3454 mmol) according to the procedure described for 24j. Yield: 37 mg, 42%. 1H NMR 
(500 MHz, CDCl3): δ = 1.90-2.01 (m, 2H, CH2), 2.88 (t, J = 7.5 Hz, 2H, CH2), 3.07 (s, 3H, 
CH3), 3.72 (t, J = 6.3 Hz, 2H, CH2), 7.15 (s, 1H, CHar), 7.46 (d, J = 8.5 Hz, 1H, CHar), 7.70 
(dd, J = 1.7, 8.5 Hz, 1H, CHar), 8.24 (d, J = 1.6 Hz, 1H, CHar), 8.35 (s, 1H, NH); 13C NMR 
(126 MHz, CDCl3): δ = 21.1, 32.9 (2 CH2), 45.2 (CH3), 61.8 (CH2), 112.1, 117.3, 119.6, 
119.7, 124.5, 127.2, 130.1, 139.0 (C-Ar); ESI-MS: m/z calcd for C12H15NaNO3S M+Na+: 
276.1, found: 275.9. 
3-(3-Azidopropyl)-5-methylsulfonyl-1H-indole (26k). Prepared from 24k (37.0 mg, 
0.146 mmol) according to general procedure B. Yield: 22 mg, 55% (two steps). 1H NMR (500 
MHz, CDCl3): δ = 1.91-2.02 (m, 2H, CH2), 2.85 (t, J = 7.4 Hz, 2H, CH2), 3.08 (s, 3H, CH3), 
3.30 (t, J = 6.7 Hz, 2H, CH2), 7.14 (d, J = 2.1 Hz, 1H, Indole), 7.46 (d, J = 8.6 Hz, 1H, CHar), 
7.68 (dd, J = 1.7, 8.6 Hz, 1H, CHar), 8.20 (d, J = 1.5 Hz, 1H, CHar), 8.68 (s, 1H, NH); 13C 
NMR (126 MHz, CDCl3): δ = 22.0, 29.4 (2 CH2), 45.5 (CH3), 50.9 (CH2), 112.2, 116.9, 119.8, 
120.6, 124.4, 127.3, 131.3, 138.9 (C-Ar); IR (film):  = 3351, 2925, 2098, 1293, 1142 cm-1; 
ESI-MS: m/z calcd for C12H14NaN4O2S M+Na+: 301.1, found: 301.0. 
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3-(1H-Indol-3-yl)-propyl acetate (28). To a solution of 24a (3.90 g, 22.3 mmol) and 
DMAP (133 mg, 1.1 mmol) in pyridine (30 mL), Ac2O (20 mL) was added and the reaction 
mixture was stirred at rt overnight. The solvents were co-evaporated with toluene and the 
residue purified by chromatography on silica (petroleum ether/EtOAc, 6:1 to 4:1) to yield 28 
(4.44 g, 92%) as a colourless solid. The analytic data were in accordance with published 
data.[22] 
3-(1-Tosyl-1H-indol-3-yl)-propyl acetate (29). A solution of 28 (2.34 g, 10.8 mmol) in 
THF (15 mL) was added to an ice-cold slurry of NaH (60% in oil, 1.31 g, 32.7 mmol) in THF 
(5 mL). After stirring for 1 h at 0 °C, tosyl chloride (6.15 g, 32.3 mmol) was added over a 
period of 1 h in three portions and the reaction mixture was stirred for another 2 h at 0 °C. 
After quenching with sat. aq. NH4Cl (10 mL) the mixture was transferred into a separation 
funnel, diluted with EtOAc (100 mL) and washed with sat. aq. NH4Cl (100 mL) and water 
(100 mL). The aqueous layers were extracted with EtOAc (100 mL). The combined organic 
layers were dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified 
by chromatography on silica (toluene/EtOAc, 1:0 to 2:1) to yield 29 (2.81 g, 70%) as 
colorless oil. 1H NMR (CDCl3, 500 MHz): δ = 2.01 (m, 2H, CH2), 2.05 (s, 3H, OAc), 2.33 (s, 
3H, CH3), 2.74 (t, J = 7.5 Hz, 2H, CH2), 4.10 (t, J = 6.4 Hz, 2H, CH2), 7.20-7.26 (m, 3H, 
CHar), 7.29-7.34 (m, 2H, CHar), 7.46 (m, 1H, CHar), 7.74 (m, 1H, CHar), 7.98 (m, 1H, CHar); 
13C-NMR (CDCl3, 125 MHz): δ = 20.9 (OAc), 21.4 (CH2), 21.5 (CH3), 27.9, 63.7 (2 CH2), 
113.8, 119.3, 122.0, 122.9, 123.0, 124.6, 126.7, 129.8, 130.8, 135.3, 135.4, 144.7 (C-Ar), 
171.1 (CO); ESI-MS: m/z calcd for C20H21NaNO4S M+Na+: 394.1, found: 394.0. 
3-(6-Cyclopropanecarbonyl-1H-indol-3-yl)-propan-1-ol (24l). To an ice-cold solution 
of 29 (302 mg, 0.80 mmol) in nitromethane (6 mL), cyclopropanecarbonyl chloride (340 µL, 
3.7 mmol) and AlCl3 (545 mg, 4.1 mmol) were added. After stirring for 1.5 h at 0 °C, the 
reaction mixture was quenched with water (10 mL). The mixture was transferred into a 
separation funnel, diluted with EtOAc (40 mL) and subsequently washed with water (40 mL) 
and brine (40 mL). The aqueous layers were extracted with EtOAc (40 mL). The combined 
organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. 
The residue was dissolved in MeOH (5 mL) and treated with aq. NaOH (6 M, 5 mL). After 
refluxing for 1 h, the mixture was transferred into a separation funnel with DCM (40 mL), 
neutralized with aq. HCl and washed with water (2  40 mL). The organic layers were 
extracted with DCM (2  40 mL). The combined organic layers were dried over Na2SO4, 
filtered and evaporated to dryness. The residue was purified by chromatography on silica 
(toluene/EtOAc, 2:1 to 1:2) to yield a inseparable mixture of 24l and the 5-regioisomer (121 
mg, 61%) as a white solid. The mixture was directly used in the next step. 
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3-(3-Azidopropyl)-6-cyclopropanecarbonyl-1H-indole (26l). A mixture of 24l and its 5-
regioisomer (112 mg, 0.460 mmol), CBr4 (231 mg, 0.70 mmol) and triphenylphosphine (145 
mg, 0.55 mmol) in dry DMF (1 mL) was shaken in an Eppendorf tube (2 mL) at 50 °C and 
900 rpm for 30 min to give the intermediate bromide 25l. NaN3 (60.0 mg, 0.923 mmol) was 
added and the reaction mixture was shaken overnight at 50 °C. The reaction was quenched 
by addition of a few drops of water and directly purified by preparative LCMS to yield 26l 
(44.4 mg, 36%, two steps) and the 5-regioisomer (15 mg, 12%, two steps) as colorless 
solids. 1H NMR (500 MHz, CDCl3):  = 0.93-1.10 (m, 2H, CH2) 1.21-1.32 (m, 2H, CH2), 2.01 
(p, J = 7.0 Hz, 2H, CH2), 2.72-2.80 (m, 1H, CH), 2.89 (t, J = 7.4 Hz, 2H, CH2), 3.34 (t, J = 6.7 
Hz, 2H, CH2), 7.20 (d, J = 1.9 Hz, 1H, CHar), 7.65 (d, J = 8.4 Hz, 1H CHar), 7.75-7.90 (m, 1H 
CHar), 8.10 (s, 1H, CHar), 8.25 (s, 1H, NH); 13C NMR (126 MHz, CDCl3):  = 11.3 (CH2), 17.1 
(CH), 22.0, 29.3, 50.8 (3 CH2), 111.9, 115.5, 118.4, 119.5, 125.3, 130.8, 132.4, 135.9 (C-Ar), 
200.6 (CO); IR (film):  = 3312, 2924, 2097, 1651, 1387 cm-1; ESI-MS: m/z calcd for 
C15H17N4O M+H+: 269.2, found: 268.9. 
3-(6-(4-Chlorobenzoyl)-1H-indol-3-yl)-propan-1-ol (24m). To an ice-cold solution of 
29 (408 mg, 1.10 mmol) in nitromethane (12 mL), 4-chlorobenzoyl chloride (560 µL, 4.40 
mmol) and AlCl3 (732 mg, 5.50 mmol) were added. After stirring for 2 h at 0 °C, the reaction 
mixture was quenched with water (10 mL). The mixture was transferred into a separation 
funnel, diluted with EtOAc (40 mL) and subsequently washed with water (40 mL) and brine 
(40 mL). The aqueous layers were extracted with EtOAc (40 mL). The combined organic 
layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The 
residue was dissolved in methanol (8 mL) and treated with aq. NaOH (6 M, 8 mL). After 
stirring for 1.5 h at rt, the mixture was neutralized with aq. HCl, transferred into a separation 
funnel with DCM (40 mL), and washed with water (2  40 mL). The organic layers were 
extracted with DCM (40 mL). The combined organic layers were dried over Na2SO4, filtered 
and evaporated to dryness. The residue was purified by chromatography on silica 
(toluene/DCM/iPrOH, 25:5:1 to 4:5:1) to yield a inseparable mixture of 24m and the 5-
regioisomer (163 mg, 47%). The mixture was directly used in the next step. 
3-(3-Azidopropyl)-6-(4-chlorobenzoyl)-1H-indole (26m). A mixture of 24m and its 5-
regioisomer (104 mg, 0.33 mmol), CBr4 (165 mg, 0.50 mmol) and triphenylphosphine (106 
mg, 0.40 mmol) in dry DMF (1 mL) was shaken in an Eppendorf tube (2 mL) at 50 °C and 
900 rpm for 15 min to give the intermediate bromide 25m. NaN3 (44 mg, 0.68 mmol) was 
added and the reaction mixture was shaken overnight at 50 °C. The reaction was quenched 
by addition of a few drops of water and directly purified by LCMS to yield 26m (42 mg, 37%, 
two steps) and the 5-regioisomer (4.5 mg, 4%, two steps) as yellow solids. 1H NMR (500 
MHz, CDCl3): δ = 2.02 (p, J = 7.0 Hz, 2H, CH2), 2.90 (t, J = 7.4 Hz, 2H, CH2), 3.35 (t, J = 6.7 
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Hz, 2H, CH2), 7.22 (d, J = 2.0 Hz, 1H, CHar), 7.45 (d, J = 8.4 Hz, 2H, CHar), 7.58 (dd, J = 0.9, 
8.3 Hz, 1H, CHar), 7.65 (d, J = 8.3 Hz, 1H, CHar), 7.76 (d, J = 8.4 Hz, 2H, CHar), 7.88 (s, 1H, 
CHar), 8.42 (s, 1H, NH); 13C NMR (126 MHz, CDCl3): δ = 22.1 (CH2), 29.4 (CH2), 50.9 (CH2), 
114.5, 115.9, 118.6, 121.7, 125.8, 128.6, 131.1, 131.3, 131.5, 135.7, 137.2, 138.3 (14 C-Ar), 
196.1 (CO); IR (film):  = 3271, 2918, 2096, 1611, 1334 cm-1.  
3-(3-(tert-Butyldimethylsilyl)oxy)propyl-5-trifluoromethyl-2-trimethylsilyl-1H-indole 
(32n). A mixture of 30n (1.20 g, 4.20 mmol), 3113 (2.30 g, 8.40 mmol), potassium acetate 
(2.10 g, 21.0 mmol), lithium chloride (178 mg, 4.20 mmol) and palladium(II) acetate (77 mg, 
0.42 mmol) in dry DMF (10 mL) was heated at 70-75 °C under argon for 2.5 h. After cooling 
to rt, the reaction mixture was diluted with ether and ice-water, the aqueous layer was 
separated and extracted with EtOAc (50 mL). The combined organic layers were washed 
with water (50 mL) and brine (50 mL), dried over Na2SO4 and evaporated. The residue was 
purified by chromatography on silica (petroleum ether/EtOAc, 8:1) to give 32n (1.70 g, 89%) 
as yellow oil.1 H NMR (CDCl3, 500 MHz): δ = 0.12 (s, 6H, 2 CH3), 0.43 (s, 9H, C(CH3)3), 0.97 
(s, 9H, C(CH3)3), 1.89 (m, 2H, CH2), 2.95 (m, 2H, CH2), 3.77 (t, J = 6.0 Hz, 2H, CH2), 7.42 
(m, 2H, CHar), 7.92 (s, 1H, CHar), 8.06 (s, 1H, NH); 13C NMR (CDCl3, 126 MHz): δ = -5.3 
(CH3), -0.7 (CH3), 18.4 (C(CH3)3), 22.4 (CH2), 35.2 (C(CH3)3), 62.9 (CH2), 107.1, 111.0, 
116.7 (q, J = 4.3 Hz), 118.9 (q, J = 3.3 Hz), 126.4, 128.2, 135.1, 139.4 (C-Ar, CF3). 
3-(5-Trifluoromethyl-1H-indol-3-yl)-propan-1-ol (24n). To a solution of 32n (1.70 g, 
4.00 mmol) in MeCN (20 mL) was added in portions 48% aq. HF (2 mL). The mixture was 
stirred at rt for 48 h. Then, the reaction mixture was cautiously basified with sat. aq. Na2CO3 
and extracted with EtOAc. The organic extract was washed with brine, dried over Na2SO4 
and evaporated to give a viscous solid. Purification by chromatography on silica (petroleum 
ether/EtOAc, 1:1) gave 24n (671 mg, 65%) as yellow oil. 1H NMR (CDCl3, 500 MHz): δ = 
2.01 (m, 2H, CH2), 2.89 (t, J = 7.5 Hz, 2H, CH2), 3.75 (t, J = 6.5 Hz, 2H, CH2), 7.11 (t, J = 1.0 
Hz, 1H, CHar), 7.42 (d, J = 1.5 Hz, 2H, CHar), 7.90 (s, 1H, CHar), 8.17 (s, 1H, NH); 13C NMR 
(CDCl3, 125 MHz): δ = 21.1, 32.8, 62.4 (3 CH2), 111.3, 116.6 (q, J = 4.3 Hz), 117.1, 118.8 
(q, J = 3.5 Hz), 121.7 (q, J = 31.8 Hz), 122.9, 126.5, 126.9, 137.6 (C-Ar, CF3); ESI-MS: m/z 
calcd for C12H13F3NO M+H+: 244.1, found: 243.9. 
3-(3-Azidopropyl)-5-trifluoromethyl-1H-indole (26n). Prepared from 24n (607 mg, 
2.50 mmol) according to general procedure B. Yield: 533 mg, 80% (two steps), yellow oil. 1H 
NMR (CDCl3, 500 MHz): δ = 2.02 (m, 2H, CH2), 2.90 (t, J = 7.5 Hz, 2H, CH2), 3.36 (t, J = 6.5 
Hz, 2H, CH2), 7.12 (d, J = 2.0 Hz, 1H, CHar), 7.44 (m, 2H, CHar), 7.89 (s, 1H, CHar), 8.17 (s, 
1H, NH); 13C NMR (CDCl3, 125 MHz): δ = 21.9, 29.1, 50.8 (3 CH2), 111.4, 116.1, 116.5 (q, J 
= 4.3 Hz), 118.9 (q, J = 3.5 Hz), 121.9 (q, J = 31.5 Hz), 123.1, 124.3, 126.7, 137.6 (C-Ar, 
CF3); IR (film):  = 3440, 2940, 2101, 1432, 1329, 1111 cm-1.  
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3-(3-Azidopropyl)-1-methyl-5-nitro-1H-indole (33). To a stirred solution of 26o[13] 
(48.5 mg, 0.198 mmol) in DMF (2 mL), powdered KOH (112 mg, 2.00 mmol) was added. 
Iodomethane (125 µL, 2.00 mmol) was added drop-wise and the reaction was stirred at rt for 
2 h. The reaction mixture was quenched by addition of water (2 mL), transferred into a 
separation funnel with DCM (20 mL) and extracted with water (2  20 mL). The aqueous 
layers were extracted with DCM (20 mL). The combined organic layers were dried over 
Na2SO4, filtered and co-evaporated with toluene to dryness. The residue was purified by 
chromatography on silica (petroleum ether/EtOAc, 9:1 to 1:1) to yield 33 (48 mg, 94%) as 
yellow oil. 1H NMR (500 MHz, CDCl3): δ = 1.87-2.08 (m, 2H, CH2), 2.88 (t, J = 7.4 Hz, 2H, 
CH2), 3.35 (t, J = 6.7 Hz, 2H, CH2), 3.81 (s, 3H, CH3), 7.01 (s, 1H, CHar), 7.31 (t, J = 9.5 Hz, 
1H, CHar), 8.13 (dd, J = 2.2, 9.0 Hz, 1H, CHar), 8.55 (d, J = 2.1 Hz, 1H, CHar); 13C NMR (126 
MHz, CDCl3): δ = 21.8, 29.4 (2 CH2), 33.2 (CH3), 50.7 (CH2), 109.2, 116.4, 117.5, 129.5 (C-
Ar). IR (film):  = 2941, 2098, 1515, 1334 cm-1. 
3-(3-Azidopropyl)-1-ethyl-5-nitro-1H-indole (34). According to the procedure 
described for 33, compound 26o (56.0 mg, 0.230 mmol) was treated with KOH (129 mg, 
2.30 mmol) and iodoethane (185 µL, 2.30 mmol) in DMF (2 mL) at rt for 2 h. After work-up, 
the residue was purified by chromatography on silica (petroleum ether/EtOAc, 1:0 to 3:1) to 
yield 34 (57 mg, 92%) as yellow oil. 1H NMR (500 MHz, CDCl3):  = 1.48 (t, J = 7.3 Hz, 3H, 
CH3), 1.96-2.04 (m, 2H, CH2), 2.88 (t, J = 7.5 Hz, 2H, CH2), 3.35 (t, J = 6.7 Hz, 2H, CH2), 
4.18 (q, J = 7.3 Hz, 2H, CH2), 7.07 (s, 1H, CHar), 7.32 (d, J = 9.1 Hz, 1H, CHar), 8.11 (dd, J = 
2.2, 9.1 Hz, 1H, CHar), 8.54 (d, J = 2.1 Hz, 1H, CHar); 13C NMR (126 MHz, CDCl3):  = 15.4 
(CH3), 21.9, 29.4, 41.4, 50.8 (4 CH2), 109.1, 116.5, 117.3, 127.7 (C-Ar); IR (film):  = 2937, 
2097, 1514, 1332 cm-1.   
Methyl [2-propynyl 4,7,8-tri-O-acetyl-9-azido-5-(tert-butoxycarbonylamino)-3,5,9-
trideoxy-D-glycero--D-galacto-2-nonulopyranosid]onate (36). Compound 35[13] (39.0 mg, 80 
µmol) was reacted with Boc2O (33 mg, 0.15 mmol) and DMAP (2.5 mg, 20 µmol) at 50 °C for 
5 h. After addition of N2H4H2O (24 µL, 0.49 mmol), stirring was continued for 16 h. The 
mixture was diluted with CHCl3 (20 mL) and washed successively with 1 M aq. HCl (5.0 mL), 
0.5 M aq. CuSO4 (5.0 mL) and sat. aq. NaHCO3 (3  10 mL). The organic layer was dried 
over Na2SO4, filtered and concentrated under reduced pressure to give an yellow oil. The 
crude product was dissolved in dry pyridine (1.0 mL) and treated with acetic anhydride (0.5 
mL) for 3 h at rt. The reaction mixture was diluted with CHCl3 (10 mL) and washed with 0.5 
M aq CuSO4 (3  3 mL) and sat. aq. NaHCO3 (3  5 mL). The organic layer was dried over 
Na2SO4, filtered and concentrated. The residue was purified by chromatography on silica 
(petroleum ether/EtOAc, 1:1) to yield 36 (14 mg, 34%) as white foam. D20 +7.6 (c 0.90, 
DCM); 1H NMR (500 MHz, CD3OD):  = 1.40 (s, 9H, C(CH3)3), 1.77 (t, J = 12.4 Hz, 1H, H-
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3a), 2.00, 2.13, 2.16 (3s, 9H, 3 OAc), 2.67 (dd, J = 4.7, 12.6 Hz, 1H, H-3b), 2.86 (t, J = 2.4 
Hz, 1H, CCH), 3.35 (dd, J = 6.0, 13.5 Hz, 1H, H-9a), 3.56-3.70 (m, 2H, H-5, H-9b), 3.83 (s, 
3H, OMe), 4.03 (dd, J = 2.0, 10.7 Hz, 1H, H-6), 4.19, 4.35 (A, B of ABX, J = 2.5, 15.8 Hz, 
2H, H-1'), 4.79 (ddd, J = 4.7, 10.4, 12.0 Hz, 1H, H-4), 5.30-5.41 (m, 2H, H-7, H-8); 13C NMR 
(CD3OD, 126 MHz):  = 20.8, 20.9, 21.2 (3 OAc), 28.7 (C(CH3)3), 39.0 (C-3), 51.4 (C-5), 52.2 
(C-9), 53.4 (OMe), 53.5 (C-1'), 69.5 (C-7), 70.8 (2C, C-4, C-8), 73.8 (C-6), 75.8 (CCH), 80.1 
(CCH), 80.6 (C(CH3)3), 99.4 (C-2), 157.7 (CONH), 169.1, 171.5, 171.7, 171.8 (4 CO); ESI-
MS: m/z calcd for C29H33Cl2F2N2NaO9 [M+Na]+: 593.2, found: 593.3.  
Methyl [2-propynyl 4,7,8-tri-O-acetyl-5-amino-9-azido-3,5,9-trideoxy-D-glycero--D-
galacto-2-nonulopyranosid]onate (37). Compound 36 (177 mg, 0.31 mmol) was dissolved in 
4 M PhOH (5 mL, in dry DCM). After addition of 4 M TMSCl (5 mL, in dry DCM), the reaction 
mixture was stirred at rt for 2 h. CHCl3 was added and the organic layer was washed with 
sat. aq. NaHCO3 (3  10 mL) and water (10 mL). The organic layer was dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude product was purified by 
chromatography on silica (EtOAc/petroleum ether, 1:2; then EtOAc/acetone, 9:1) to yield 37 
(98 mg, 67%) as colorless oil. D20 +8.2 (c 1.00, DCM); 1H NMR (500 MHz, CD2Cl2):  = 
1.63 (t, J = 12.2 Hz, 1H, H-3a), 1.97, 2.08, 2.10 (3s, 9H, 3 OAc), 2.42 (t, J = 2.4 Hz, 1H, 
CCH), 2.49 (dd, J = 8.3, 10.9 Hz, 1H, H-5), 2.58 (dd, J = 4.5, 12.6 Hz, 1H, H-3b), 3.26 (dd, 
J = 5.0, 13.6 Hz, 1H, H-9a), 3.57 (dd, J = 2.8, 13.6 Hz, 1H, H-9b), 3.63 (dd, J = 1.0, 10.1 Hz, 
1H, H-6), 4.04, 4.27 (A, B of ABX, J = 2.5, 15.5 Hz, 1H, H-1'), 4.53 (ddd, J = 4.6, 10.0, 11.9 
Hz, 1H, H-4), 5.29 (m, 1H, H-8), 5.42 (dd, J = 1.1, 8.5 Hz, 1H, H-7); 13C NMR (CD2Cl2, 126 
MHz):  = 21.1, 21.3, 21.4 (3 OAc), 37.2 (C-3), 52.3 (C-9), 52.9 (C-1'), 53.2 (C-5), 53.4 
(OMe), 69.6 (2C, C-7, C-8), 71.8 (C-4), 72.1 (CCH), 74.8 (CCH), 75.9 (C-6), 117.2 (C-2), 
170.4, 170.8, 170.9, 171.0 (4 CO); ESI-MS: m/z calcd for C19H26N4NaO10 [M+Na]+: 493.2, 
found: 493.2. 
Methyl [2-propynyl 4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-5-fluoroacetamido-D-
glycero--D-galacto-2-nonulopyranosid]onate (38). Compound 37 (130 mg, 0.27 mmol) was 
dissolved in dry THF (3 mL) and cooled to 0 °C. Fluoroacetyl chloride (60 µL, 0.83 mmol) 
was added, followed by the addition of NEt3 (190 µL, 1.35 mmol). The reaction mixture was 
allowed to reach rt and stirring was continued for 24 h. DCM (10 mL) was added and the 
organic layer was washed with sat. aq. NaHCO3 (3  2 mL) and water (2 mL). The organic 
layer was dried over Na2SO4, filtered and the solvent removed under reduced pressure. The 
crude product was purified by chromatography on silica (petroleum ether/EtOAc, 1:1) to yield 
38 (63 mg, 43%). []D20 +8.0 (c = 0.40, DCM); 1H NMR (500 MHz, CDCl3):  = 1.98 (t, J = 
12.5 Hz, 1H, H-3a), 2.03, 2.15, 2.19 (3s, 9H, 3 OAc), 2.46 (t, J = 2.1 Hz, 1H, CCH), 2.69 
(dd, J = 4.5, 12.8 Hz, 1H, H-3b), 3.26 (dd, J = 5.4, 13.5 Hz, 1H, H-9a), 3.56 (dd, J = 2.6, 13.5 
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Hz, 1H, H-9b), 3.83 (s, 3H, OMe), 4.08-4.20 (m, 3H, H-5, H-6, H-1'a), 4.40 (dd, J = 2.3, 15.6 
Hz, 1H, H-1'b), 4.57-4.86 (m, 2H, CH2F), 4.93 (m, 1H, H-4), 5.25-5.40 (m, 2H, H-7, H-8), 
6.19 (d, J = 8.6 Hz, 1H, NH); 13C NMR (CDCl3, 126 MHz):  = 21.0, 21.1, 21.2 (3 OAc), 38.1 
(C-3), 48.7 (C-5), 51.1 (C-9), 53.3 (2C, OMe, C-1'), 67.9 (C-4), 68.7 (C-7), 69.4 (C-8), 72.7 
(C-6), 74.8 (CCH), 79.0 (CCH), 79.5, 81.0 (d, J = 186 Hz, CH2F), 98.3 (C-2), 168.3, 168.4, 
170.3, 170.4, 170.9 (5 CO); ESI-MS: m/z calcd for C21H27FNaN4O11 [M+Na]+: 553.2, found: 
553.1. 
Methyl [2-propynyl 4,7,8-tri-O-acetyl-9-benzamido-3,5,9-trideoxy-5-fluoroacetamido-
D-glycero--D-galacto-2-nonulopyranosid]onate (39a). Compound 38 (63 mg, 0.12 mmol) 
was dissolved in dry DCE (2 mL). Benzoyl chloride (55 L, 0.47 mmol) and 
triphenylphosphine (70 mg, 0.26 mmol) were added successively with stirring. After 24 h 
DCM (5 mL) was added and the organic layer was washed with sat. aq. NaHCO3 (3  2 mL) 
and water (2 mL). The organic layer was dried over Na2SO4, filtered and the solvent 
removed under reduced pressure. The crude product was purified by chromatography on 
silica (0.5% gradient of MeOH in DCM) to yield 39a (37 mg, 52%). D20 +12.8 (c 1.00, 
DCM); 1H NMR (500 MHz, CD2Cl2):  = 1.97 (m, 1H, H-3a) 2.08, 2.15, 2.21 (3s, 9H, 3 OAc), 
2.53 (t, J = 2.4 Hz, 1H, CCH), 2.75 (dd, J = 4.7, 12.7 Hz, 1H, H-3b), 3.08 (td, J = 4.3, 15.2 
Hz, 1H, H-9a), 3.79 (s, 3H, OMe), 4.14-4.33 (m, 4H, H-5, H-6, H-9b, H-1'a), 4.43 (dd, J = 
2.5, 15.6 Hz, 1H, H-1'b), 4.75 (m, 2H, CH2F), 4.99 (ddd, J = 4.7, 10.4, 12.1 Hz, 1H, H-4), 
5.24 (d, J = 9.5 Hz, 1H, H-7), 5.33 (m, 1H, H-8), 6.64 (d, J = 9.9 Hz, 1H, 5-NH), 7.04 (dd, J = 
4.4, 7.4 Hz, 1H, 9-NH), 7.48 (m, 2H, CHar), 7.58 (m, 1H, CHar), 7.69 (m, 2H, CHar); 13C NMR 
(CD2Cl2, 126 MHz):  = 21.0, 21.3, 21.4 (3 OAc), 38.2 (C-3), 38.5 (C-9), 48.9 (C-5), 53.1 
(OMe), 53.3 (C-1'), 68.3 (C-7), 68.9 (C-8), 69.1 (C-4), 72.4 (C-6), 72.8 (CCH), 74.8 (CCH), 
79.9 (CH2F), 98.5 (C-2), 128.9, 129.0, 132.4, 134.8 (C-Ar), 167.9, 168.4, 168.6, 168.9, 
170.8, 172.3 (6 CO); ESI-MS: m/z calcd for C28H33FNaN2O12 [M+Na]+: 631.2, found: 631.2. 
Methyl [2-propynyl 4,7,8-tri-O-acetyl-9-(4-chlorobenzamido)-3,5,9-trideoxy-5-
fluoroacetamido-D-glycero--D-galacto-2-nonulopyranosid]onate (39b). Prepared from 38 
(400 mg, 0.753 mmol) and 4-chlorobenzoyl chloride (385 L, 3.01 mmol) according to the 
procedure described for 39a. Yield: 313 mg, 65%. D20 -11.5 (c 1.41, DCM); 1H NMR (500 
MHz, CDCl3): δ = 1.96 (m, 1H, H-3a), 2.01, 2.11, 2.21 (3s, 9H, 3 OAc), 2.42 (t, J = 2.4 Hz, 
1H, CCH), 2.68 (dd, J = 4.6, 12.8 Hz, 1H, H-3b), 2.97 (dt, J = 4.0, 15.1 Hz, 1H, H-9a), 3.78 
(s, 3H, OMe), 4.08 (m, 1H, H-6), 4.14 (dd, J = 2.4, 15.6 Hz, 1H, H-1'a), 4.17-4.30 (m, 2H, H-
9b, H-5), 4.39 (dd, J = 2.5, 15.6 Hz, 1H, H-1'b), 4.58-4.79 (m, 2H, CH2F), 4.86 (m, 1H, H-4), 
5.13 (dd, J = 2.2, 9.8 Hz, 1H, H-7), 5.29 (m, 1H, H-8), 6.12 (dd, J = 3.2, 10.2 Hz, 1H, 5-NH), 
6.89 (dd, J = 4.4, 8.0 Hz, 1H, 9-NH), 7.38 (d, J = 8.5 Hz, 2H, C6H4), 7.71 (d, J = 8.5 Hz, 2H, 
C6H4); 13C NMR (126 MHz, CDCl3): δ = 21.0, 21.3, 21.3 (3 OAc), 38.1 (C-3), 38.9 (C-9), 48.9 
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(C-5), 53.13, 53.14 (C-1', OMe), 67.9 (C-7), 68.4 (C-8), 68.8 (C-4), 72.3 (C-6), 74.8 (CCH), 
79.0 (CCH), 80.2 (d, J = 186 Hz, CH2F), 98.2 (C-2), 128.6, 129.0, 132.9, 138.0 (6C, C6H4), 
166.6, 167.7, 170.6, 170.9, 172.5 (6C, 6 CO); ESI-MS: m/z calcd for C28H32ClFN2NaO12 
M+Na+: 665.1, found: 665.2. 
Lithium [2-propynyl 9-benzamido-3,5,9-trideoxy-5-fluoroacetamido-D-glycero--D-
galacto-2-nonulopyranosid]onate (22a). Compound 39a (25 mg, 41 µmol) was dissolved in 
THF (4.5 mL) and LiOH (6.0 mg, 0.25 mmol in 0.5 mL water) was added. The reaction 
mixture was stirred at rt for 7 h. After neutralization with 7% aq. HCl the solvents were 
removed under reduced pressure and the crude product was purified by chromatography 
(1% gradient of water in DCM/MeOH, 5:1) to yield 22a (15 mg, 80%). D20 -19.8 (c 1.34, 
MeOH); 1H NMR (500 MHz, CD3OD):  = 1.59 (t, J = 11.6 Hz, 1H, H-3a), 2.70 (s, 1H, 
CCH), 2.80 (dd, J = 3.6, 11.9 Hz, 1H, H-3b), 3.42 (d, J = 8.7 Hz, 1H, H-7), 3.65 (m, 1H, H-
9a), 3.68-3.85 (m, 4H, H-4, H-5, H-6, H-9b), 4.00 (m, 1H, H-8), 4.13, 4.40 (A, B of AB, J = 
14.1 Hz, 2H, H-1'), 4.78 (m, 2H, CH2F), 7.41 (t, J = 7.3 Hz, 2H, CHar), 7.48 (t, J = 7.1 Hz, 1H, 
CHar), 7.80 (d, J = 7.6 Hz, 2H, CHar); 13C NMR (CD3OD, 126 MHz):  = 42.2 (C-3), 44.3 (C-
9), 53.2 (C-1'), 53.7 (C-5), 69.2 (C-4), 71.6 (C-8), 72.1 (C-7), 73.8 (C-6), 75.0 (CCH), 80.9 
(d, J = 181 Hz, CH2F), 81.0 (CCH), 101.7 (C-2), 128.4, 129.6, 132.7, 135.6 (C-Ar), 172.0, 
178.5 (2 CO); ESI-MS: m/z calcd for C21H24FN2O9 [M-H]-: 467.2, found: 467.2. 
Lithium [2-propynyl 9-(4-chlorobenzamido)-3,5,9-trideoxy-5-fluoroacetamido-D-
glycero--D-galacto-2-nonulopyranosid]onate (22b). Prepared from 39b (313 mg, 0.487 
mmol) according to the procedure described for 22a. Yield: 123 mg, 50%, white solid. D20 
-17.4 (c 1.10, MeOH); 1H NMR (500 MHz, CD3OD): δ = 1.64 (t, J = 11.8 Hz, 1H, H-3a), 2.72 
(t, J = 2.4 Hz, 1H, CCH), 2.85 (dd, J = 4.5, 12.3 Hz, 1H, H-3b), 3.45 (dd, J = 1.4, 8.9 Hz, 
1H, H-7), 3.52 (m, 1H, H-9a), 3.73-3.92 (m, 4H, H-9b, H-4, H-5, H-6), 4.04 (td, J = 3.0, 8.4 
Hz, 1H, H-8), 4.18 (dd, J = 2.3, 15.0 Hz, 1H, H-1'a), 4.44 (dd, J = 2.4, 15.0 Hz, 1H, H-1'b), 
4.83 (d, J = 46.9 Hz, 2H, CH2F), 7.46 (d, J = 8.5 Hz, 2H, C6H4), 7.82 (d, J = 8.5 Hz, 2H, 
C6H4), 8.35 (d, J = 5.1 Hz, 1H, NH); 13C NMR (126 MHz, CD3OD): δ = 42.4 (C-3), 44.6 (C-9), 
53.3 (C-1'), 53.7 (C-5), 69.5 (C-4), 71.6 (C-8), 72.3 (C-7), 74.0 (C-6), 75.1 (CCH), 81.1 (d, J 
= 183 Hz, CH2F), 81.1 (CCH), 129.8, 130.2, 134.6, 138.8 (6C, C6H4), 169.5, 172.2, 172.3 (3 
CO); ESI-MS: m/z calcd for C21H24ClFN2NaO9 M+Na+: 525.1, found: 525.0. 
Sodium [3-(1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 5-acetamido-9-
benzamido-3,5,9-trideoxy-D-glycero--D-galacto-2-nonulopyranosid]onate (2). Prepared 
from 21[13] (8.0 mg, 20 µmol) and 26a (4.1 mg, 20 µmol) according to general procedure C. 
Yield: 7.7 mg, 68%, white solid. []D20 -15.9 (c 0.20, MeOH); 1H NMR (CD3OD, 500 MHz): δ 
= 1.62 (t, J = 11.5 Hz, 1H, H-3a), 1.99 (s, 3H, NHAc), 2.28 (m, 2H, H-2"), 2.75 (t, J = 7.0 Hz, 
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2H, H-3"), 2.88 (dd, J = 4.5, 12.5 Hz, 1H, H-3b), 3.44 (d, J = 9.0 Hz, 1H, H-7), 3.51 (dd, 1H, 
J = 8.0, 13.5 Hz, H-9a), 3.67 (d, J = 9.0 Hz, 1H, H-6), 3.69-3.75 (m, 2H, H-4, H-5), 3.79 (dd, 
J = 3.0, 13.5 Hz, 1H, H-9b), 4.05 (dt, J = 3.0, 8.0 Hz, 1H, H-8), 4.38 (t, J = 7.0 Hz, 2H, H-1"), 
4.68, 4.95 (A, B of AB, J = 12.5 Hz, 2H, H-1'), 6.98 (t, J = 7.5 Hz, 1H, CHar), 7.04-7.08 (m, 
2H, CHar), 7.32 (d, J = 8.0 Hz, 1H, CHar), 7.41-7.49 (m, 4H, CHar), 7.81 (d, J = 7.5 Hz, 2H, 
CHar), 7.94 (s, 1H, triazole-H); 13C NMR (CD3OD, 125 MHz): δ = 22.6 (NHAc), 22.9 (C-3"), 
31.8 (C-2"), 42.6 (C-3), 44.6 (C-9), 50.9 (C-1"), 54.1 (C-5), 58.9 (C-1'), 69.7 (C-4), 71.2 (C-
8), 72.6 (C-7), 74.4 (C-6), 102.0 (C-2), 112.2, 112.8, 114.6, 119.2, 119.5, 122.3, 123.3, 
125.3, 128.3, 129.5, 132.5, 135.9, 146.7 (C-Ar), 170.3, 174.1, 175.4 (3 CO); HRMS: m/z 
calcd for C32H37N6Na2O9 M+Na+: 695.2412, found: 695.2413. 
Sodium [3-(5-methoxy-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 5-acetamido-
9-benzamido-3,5,9-trideoxy-D-glycero--D-galacto-2-nonulopyranosid]onate (3). Prepared 
from 21 (10 mg, 20 µmol) and 26b (5.8 mg, 30 µmol) according to general procedure C. 
Yield: 8.2 mg, 70%, white solid. []D20 -24.3 (c 0.23, MeOH); 1H NMR (CD3OD, 500 MHz): δ 
= 1.63 (t, J = 11.5 Hz, 1H, H-3a), 2.0 (s, 3H, NHAc), 2.27 (m, 2H, H-2"), 2.72 (t, J = 7.0 Hz, 
2H, H-3"), 2.88 (dd, J = 4.0, 13.5 Hz, 1H, H-3b), 3.44 (d, J = 9.0 Hz, 1H, H-7), 3.52 (dd, 1H, 
J = 8.0, 13.5 Hz, H-9a), 3.66 (d, J = 9.0 Hz, 1H, H-6), 3.80 (s, 3H, OMe), 3.73-3.80 (m, 3H, 
H-4, H-5, H-9b), 4.05 (m, 1H, H-8), 4.39 (t, J = 7.0 Hz, 2H, H-1"), 4.68, 4.95 (A, B of AB, J = 
12.5 Hz, 2H, H-1'), 6.73 (d, J = 8.5 Hz, 1H, CHar), 6.95 (s, 1H, CHar), 7.02 (s, 1H, CHar), 7.20 
(d, J = 8.5 Hz, 1H, CHar), 7.42-7.50 (m, 3H, CHar), 7.81 (d, J = 7.5 Hz, 2H, CHar), 7.95 (s, 1H, 
triazole-H); 13C NMR (CD3OD, 125 MHz): δ = 22.6 (NHAc), 22.9 (C-2"), 31.7 (C-3"), 42.6 (C-
3), 44.5 (C-9), 50.9 (C-1"), 54.0 (C-5), 56.3 (OCH3), 58.9 (C-1'), 69.7 (C-4), 71.2 (C-8), 72.5 
(C-7), 74.4 (C-6), 101.1 (C-Ar), 102.0 (C-2), 111.4, 112.6, 112.9, 114.3, 124.1, 125.4, 128.3, 
128.8, 129.5, 132.5, 133.4, 135.8, 146.7, 154.9 (C-Ar), 170.3, 174.1, 175.4 (3 CO); HRMS: 
m/z calcd for C33H39N6Na2O10 M+Na+: 725.2518, found: 725.2522. 
Sodium [3-(6-cyclopropanecarbonyl-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 
5-acetamido-9-benzamido-3,5,9-trideoxy-D-glycero--D-galacto-2-nonulopyranosid]onate 
(4). Prepared from 21 (6 mg, 10 µmol) and 26l (4 mg, 20 µmol) according to general 
procedure C. Yield: 6.1 mg, 65%, white solid. []D20 -15.3 (c 0.17, MeOH); 1H NMR (CD3OD, 
500 MHz): δ = 1.07-1.15 (m, 4H, CH(CH2)2), 1.63 (t, J = 11.5 Hz, 1H, H-3a), 2.09 (s, 3H, 
NHAc), 2.30 (m, 2H, H-2"), 2.79 (t, J = 7.0 Hz, 2H, H-3"), 2.88-2.94 (m, 2H, CH(CH2)2, H-3b), 
3.44 (dd, J = 1.5, 9.0 Hz, 1H, H-7), 3.51 (dd, 1H, J = 8.0, 14.0 Hz, H-9a), 3.68 (m, 1H, H-6), 
3.72-3.78 (m, 2H, H-4, H-5), 3.80 (dd, J = 3.5, 13.5 Hz, 1H, H-9b), 4.05 (td, J = 3.0, 8.0 Hz, 
1H, H-8), 4.42 (t, J = 7.0 Hz, 2H, H-1"), 4.69, 4.96 (A, B of AB, J = 12.5 Hz, 2H, H-1'), 7.32 
(s, 1H, CHar), 7.42 (t, J = 7.5 Hz, 1H, CHar), 7.50 (t, J = 7.5 Hz, 2H, CHar), 7.60 (d, J = 8.5 
Hz, 1H, CHar), 7.75 (dd, J = 1.5, 8.5 Hz, 1H, CHar), 7.82 (m, 2H, CHar), 7.98 (s, 1H, CHar), 
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8.12 (s, 1H, triazole-H); 13C NMR (CD3OD, 126 MHz): δ = 11.9 (CH(CH2)2), 17.8 (CH(CH2)2), 
22.6 (NHAc), 22.7 (C-3"), 31.8 (C-2"), 42.6 (C-3), 44.6 (C-9), 50.8 (C-1"), 54.1 (C-4), 59.0 
(C-1'), 69.7 (C-5), 71.2 (C-8), 72.5 (C-7), 74.4 (C-6), 102.0 (C-2), 113.5, 115.3, 119.2, 119.7, 
125.4, 128.1, 128.3, 129.5, 132.4, 132.5, 135.8, 137.6, 146.9 (C-Ar), 170.3, 174.2, 175.4, 
203.5 (4 CO); HRMS: m/z calcd for C36H41N6Na2O10 M+Na+: 763.2674, found: 763.2673. 
Sodium [3-(4-chlorobenzoyl)-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 5-
acetamido-9-benzamido-3,5,9-trideoxy-D-glycero--D-galacto-2-nonulopyranosid]onate (5). 
Prepared from 21 (6 mg, 15 mol) and 26m (6.8 mg, 20 mol) according to general 
procedure C. Yield: 4.8 mg, 47%, pale yellow solid. []D20 -12.0 (c 0.21, MeOH); 1H NMR 
(CD3OD, 500 MHz): δ = 1.62 (t, J = 11.5 Hz, 1H, H-3a), 2.07 (s, 3H, NHAc), 2.31 (m, 2H, H-
2"), 2.80 (t, J = 7.0 Hz, 2H, H-3"), 2.89 (dd, J = 4.0, 12.0 Hz, 1H, H-3b), 3.42 (dd, J = 2.0, 9.0 
Hz, 1H, H-7), 3.51 (dd, 1H, J = 8.0, 13.5 Hz, H-9a), 3.66 (m, 1H, H-6), 3.71-3.75 (m, 2H, H-
4, H-5), 3.79 (dd, J = 3.0, 13.5 Hz, 1H, H-9b), 4.04 (td, J = 3.0, 8.0 Hz, 1H, H-8), 4.42 (t, J = 
7.0 Hz, 2H, H-1"), 4.69, 4.96 (A, B of AB, J = 12.5 Hz, 2H, H-1'), 7.35 (s, 1H, CHar), 7.41 (m, 
2H, CHar), 7.48-7.51 (m, 2H, CHar), 7.56 (d, J = 8.5 Hz, 2H, CHar), 7.64 (d, J = 8.5 Hz, 1H, 
CHar), 7.75-7.84 (m, 5H, CHar), 7.98 (s, 1H, triazole-H); 13C NMR (CD3OD, 125 MHz): δ = 
22.6 (NHAc), 22.7 (C-3"), 31.7 (C-2"), 42.6 (C-3), 44.6 (C-9), 50.8 (C-1"), 54.1 (C-5), 59.0 
(C-1'), 69.7 (C-4), 71.2 (C-8), 72.6 (C-7), 74.4 (C-6), 102.1 (C-2), 115.5, 116.1, 119.3, 121.6, 
125.4, 128.3, 129.5, 131.0, 135.6, 137.2, 138.7, 139.1, 147.0 (C-Ar), 170.4, 174.1, 175.4, 
198.2 (4 CO); HRMS: m/z calcd for C39H40ClN6Na2O10 M+Na+: 833.2284, found: 833.2284. 
Sodium [3-(5-trifluoromethyl-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 5-
acetamido-9-benzamido-3,5,9-trideoxy-D-glycero--D-galacto-2-nonulopyranosid]onate (6). 
Prepared from 21 (10 mg, 20 µmol) and 26n (7 mg, 30 µmol) according to general 
procedure C. Yield: 7.7 mg, 67%, white solid. []D20 -21.4 (c 0.14, MeOH); 1H NMR (CD3OD, 
500 MHz): δ = 1.62 (t, J = 11.5 Hz, 1H, H-3a), 2.08 (s, 3H, NHAc), 2.29 (m, 2H, H-2"), 2.79 
(t, J = 7.0 Hz, 2H, H-3"), 2.87 (dd, J = 3.5, 11.5 Hz, 1H, H-3b), 3.44 (dd, J = 2.0, 9.0 Hz, 1H, 
H-7), 3.50 (dd, 1H, J = 8.0, 13.5 Hz, H-9a), 3.66 (m, 1H, H-6), 3.68-3.77 (m, 2H, H-4, H-5), 
3.80 (dd, J = 3.5, 13.5 Hz, 1H, H-9b), 4.05 (td, J = 3.0, 8.5 Hz, 1H, H-8), 4.41 (t, J = 7.0 Hz, 
2H, H-1"), 4.69, 4.95 (A, B of AB, J = 12.0 Hz, 2H, H-1'), 7.21 (s, 1H, CHar), 7.33 (m, 1H, 
CHar), 7.41-7.50 (m, 4H, CHar), 7.81 (m, 3H, CHar), 7.97 (s, 1H, triazole-H); 13C NMR 
(CD3OD, 125 MHz): δ = 22.6 (C-2"), 22.6 (NHAc) 31.6 (C-3"), 42.6 (C-3), 44.5 (C-9), 50.8 
(C-1"), 54.1 (C-5), 58.9 (C-1'), 69.7 (C-4), 71.2 (C-8), 72.6 (C-7), 74.4 (C-6), 102.0 (C-2), 
112.7, 115.8, 116.9 (q, J = 4.3 Hz), 118.8 (q, J = 3.5 Hz), 121.9 (q, J = 31.3 Hz), 125.4, 
125.6, 127.9, 128.2, 129.5, 132.5, 135.8, 139.6, 146.8 (C-Ar), 170.3, 174.2, 175.4 (3 CO); 
HRMS: m/z calcd for C33H36F3N6Na2O9 M+Na+: 763.2286, found: 763.2295. 
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Sodium [3-(1-methyl-5-nitro-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 5-
acetamido-9-benzamido-3,5,9-trideoxy-D-glycero--D-galacto-2-nonulopyranosid]onate (7). 
Prepared from 21 (10 mg, 20 µmol) and 33 (6.5 mg, 30 µmol) according to general 
procedure C. Yield: 12.3 mg, 80%, yellow solid. []D20 -19.8 (c 0.30, MeOH); 1H NMR 
(CD3OD, 500 MHz): δ = 1.62 (t, J = 11.5 Hz, 1H, H-3a), 2.0 (s, 3H, NHAc), 2.30 (m, 2H, H-
2"), 2.80 (t, J = 7.0 Hz, 2H, H-3"), 2.88 (dd, J = 3.0, 11.5 Hz, 1H, H-3b), 3.43 (d, J = 9.0 Hz, 
1H, H-7), 3.48 (dd, 1H, J = 8.0, 13.5 Hz, H-9a), 3.66 (d, J = 9.0 Hz, 1H, H-6), 3.82 (s, 3H, 
NCH3), 3.71-3.81 (m, 3H, H-4, H-5, H-9b), 4.03 (dt, J = 2.5, 8.5 Hz, 1H, H-8), 4.43 (t, J = 7.0 
Hz, 2H, H-1"), 4.67, 4.94 (A, B of AB, J = 12.5 Hz, 2H, H-1'), 7.20 (s, 1H, CHar), 7.40-7.50 
(m, 4H, CHar), 7.80 (d, J = 8.0 Hz, 2H, CHar), 7.96 (s, 1H, triazole-H), 8.06 (dd, J = 4.0, 1.5 
Hz, 1H, CHar), 8.48 (d, J = 1.5 Hz, 1H, CHar); 13C NMR (CD3OD, 125 MHz): δ = 22.5 (NHAc), 
22.6 (C-3"), 31.6 (C-2"), 33.2 (NCH3), 42.6 (C-3), 44.6 (C-9), 50.8 (C-1"), 54.0 (C-5), 59.0 (C-
1'), 69.6 (C-4), 71.3 (C-8), 72.5 (C-7), 74.4 (C-6), 102.0 (C-2), 110.6, 116.8, 117.3, 117.9, 
125.4, 128.3, 131.6, 132.1, 135.8, 141.3, 142.2, 146.9 (C-Ar), 170.3, 174.1, 175.4 (3 CO); 
HRMS: m/z calcd for C33H38N7Na2O11 M+Na+: 754.2419, found: 754.2419. 
Sodium [3-(1-ethyl-5-nitro-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 5-
acetamido-9-benzamido-3,5,9-trideoxy-D-glycero--D-galacto-2-nonulopyranosid]onate (8). 
Prepared from 21 (10 mg, 20 µmol) and 34 (6.8 mg, 30 µmol) according to general 
procedure C. Yield: 11 mg, 71%, yellow solid. []D20 -18.9 (c 0.27, MeOH); 1H NMR (CD3OD, 
500 MHz): δ = 1.43 (t, J = 7.5 Hz, 3H, NCH2CH3), 1.62 (t, J = 11.5 Hz, 1H, H-3a), 2.0 (s, 3H, 
NHAc), 2.32 (m, 2H, H-2"), 2.81 (t, J = 7.5 Hz, 2H, H-3"), 2.88 (dd, J = 4.0, 12.5 Hz, 1H, H-
3b), 3.43 (d, J = 9.0 Hz, 1H, H-7), 3.48 (dd, 1H, J = 8.0, 13.5 Hz, H-9a), 3.66 (m, 1H, H-6), 
3.71-3.74 (m, 2H, H-5, H-4), 3.81 (dd, J = 3.0, 13.5 Hz, 1H, H-9b), 4.04 (td, J = 3.0, 8.0 Hz, 
1H, H-8), 4.23 (q, J = 7.0 Hz, 2H, NCH2), 4.44 (t, J = 7.0 Hz, 2H, H-1"), 4.67, 4.94 (A, B of 
AB, J = 12.5 Hz, 2H, H-1'), 7.28 (s, 1H, CHar), 7.40-7.49 (m, 4H, CHar), 7.81 (d, J = 7.5 Hz, 
2H, CHar), 7.96 (s, 1H, triazole-H), 8.06 (dd, J = 2.0, 9.0 Hz, 1H, CHar), 8.49 (d, J = 1.5 Hz, 
1H, CHar); 13C NMR (CD3OD, 126 MHz): δ = 15.8 (NCH2CH3), 22.6 (C-3"), 22.6 (NHAc), 31.6 
(C-2"), 42.2 (NCH2), 42.6 (C-3), 44.6 (C-9), 50.8 (C-1"), 54.1 (C-5), 59.0 (C-1'), 69.6 (C-4), 
71.2 (C-8), 72.6 (C-7), 74.4 (C-6), 102.0 (C-2), 110.6, 116.9, 117.5, 117.8, 125.3, 128.3, 
128.4, 129.5, 129.9, 132.5, 135.8, 140.4, 142.2, 146.9 (C-Ar), 170.3, 174.1, 175.4 (3 CO); 
HRMS: m/z calcd for C34H40N7Na2O11 M+Na+: 768.2576, found: 768.2580. 
Sodium [3-(5-methoxy-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 9-(4-chloro-
benzamido)-3,5,9-trideoxy-5-fluoroacetamido-D-glycero--D-galacto-2-
nonulopyranosid]onate (9). Prepared from 22b (10 mg, 20.0 µmol) and 26b (6.9 mg, 30.0 
µmol) according to general procedure C. Yield: 8.6 mg, 61%. D20 -20.5 (c 0.67, MeOH); 1H 
NMR (500 MHz, CD3OD): δ = 1.64 (t, J = 11.9 Hz, 1H, H-3a), 2.27 (p, J = 7.1 Hz, 2H, H-2"), 
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2.72 (t, J = 7.3 Hz, 2H, H-3"), 2.88 (dd, J = 4.7, 12.2 Hz, 1H, H-3b), 3.43-3.53 (m, 2H, H-7, 
H-9a), 3.81 (s, 3H, OCH3), 3.77-3.87 (m, 3H, H-4, H-6, H-9b), 3.91 (m, 1H, H-5), 4.04 (td, J 
= 3.1, 8.4 Hz, 1H, H-8), 4.40 (t, J = 6.9 Hz, 2H, H-1"), 4.68 (A of AB, J = 12.2 Hz, 1H, H-1'a), 
4.84 (d, J = 47.0 Hz, 2H, CH2F), 4.96 (B of AB, J = 12.2 Hz, 1H, H-1'b), 6.73 (dd, J = 2.4, 8.8 
Hz, 1H, CHar), 6.95 (d, J = 2.3 Hz, 1H, CHar), 7.02 (s, 1H, CHar), 7.21 (d, J = 8.8 Hz, 1H, 
CHar), 7.42 (d, J = 8.5 Hz, 2H, CHar), 7.80 (t, J = 7.1 Hz, 2H, CHar), 7.94 (s, 1H, CHar); 13C 
NMR (126 MHz, CD3OD): δ = 23.0 (C-3"), 31.9 (C-2"), 42.7 (C-3), 44.7 (C-9), 51.0 (C-1"), 
53.7 (C-5), 56.5 (OCH3), 59.1 (C-1'), 69.7 (C-4), 71.7 (C-8), 72.5 (C-7), 74.0 (C-6), 81.1 (d, J 
= 183 Hz, CH2F), 101.3 (C-2), 112.8, 113.1, 114.4, 124.3, 125.5, 129.0, 129.8, 130.2, 133.6, 
134.6, 138.7, 155.1 (C-Ar), 169.4, 172.2, 172.3 (3 CO); HRMS: m/z calcd for 
C33H37ClFN6Na2O10 M+Na+: 777.2039, found: 777.2039. 
Sodium [3-(5-chloro-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 9-(4-chloro-
benzamido)-3,5,9-trideoxy-5-fluoroacetamido-D-glycero--D-galacto-2-
nonulopyranosid]onate (10). Prepared from 22b (30.0 mg, 59.1 µmol) and 26c (20.8 mg, 
88.6 µmol) according to general procedure C. Yield: 27 mg, 60%. D20 -21.0 (c 1.08, 
MeOH); 1H NMR (500 MHz, CD3OD): δ = 1.61 (m, 1H, H-3a), 2.23 (p, J = 7.1 Hz, 2H, H-2"), 
2.69 (t, J = 7.3 Hz, 2H, H-3"), 2.88 (dd, J = 4.6, 12.2 Hz, 1H, H-3b), 3.39-3.59 (m, 2H, H-7, 
H-9a), 3.74-3.97 (m, 4H, H-4, H-5, H-6, H-9b), 4.03 (td, J = 3.0, 8.5 Hz, 1H, H-8), 4.37 (t, J = 
7.0 Hz, 2H, H-1"), 4.68 (A of AB, J = 12.2 Hz, 1H, H-1'a), 4.84 (d, J = 46.7 Hz, 2H, CH2F), 
4.95 (B of AB, J = 12.2 Hz, 1H, H-1'b), 7.02 (dd, J = 2.0, 8.6 Hz, 1H, CHar), 7.09 (s, 1H, 
CHar), 7.28 (d, J = 8.6 Hz, 1H, CHar), 7.40 (d, J = 8.6 Hz, 2H, CHar), 7.44 (d, J = 1.9 Hz, 1H, 
CHar), 7.79 (d, J = 8.6 Hz, 2H, CHar), 7.91 (s, 1H, CHar); 13C NMR (126 MHz, CD3OD): δ = 
22.9 (C-3"), 31.8 (C-2"), 42.6 (C-3), 44.6 (C-9), 51.0 (C-1"), 53.7 (C-5), 59.0 (C-1'), 69.6 (C-
4), 71.8 (C-8), 72.4 (C-7), 74.0 (C-6), 81.1 (d, J = 183 Hz, CH2F), 102.2 (C-2), 113.6, 114.5, 
118.8, 122.6, 125.3, 125.4, 125.5, 129.8, 130.2, 134.5, 136.7, 138.7, 146.8 (C-Ar), 169.4, 
172.1, 172.3 (3 CO); HRMS: m/z calcd for C32H35Cl2FN6NaO9 M+Na+: 781.1544, found: 
781.1547. 
Sodium [3-(5-fluoro-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 9-(4-chloro-
benzamido)-3,5,9-trideoxy-5-fluoroacetamido-D-glycero--D-galacto-2-
nonulopyranosid]onate (11). Prepared from 22b (13 mg, 25.7 µmol) and 26d (8.4 mg, 38.5 
µmol) according to general procedure C. Yield: 10 mg, 50%. D20 -17.6 (c 0.68, MeOH); 1H 
NMR (500 MHz, CD3OD): δ = 1.65 (t, J = 12.0 Hz, 1H, H-3a), 2.26 (p, J = 7.2 Hz, 2H, H-2"), 
2.71 (t, J = 7.3 Hz, 2H, H-3"), 2.88 (dd, J = 4.8, 12.3 Hz, 1H, H-3b), 3.42-3.54 (m, 2H, H-7, 
H-9a), 3.75-3.87 (m, 3H, H-4, H-6, H-9b), 3.91 (m, 1H, H-5), 4.04 (td, J = 3.1, 8.1 Hz, 1H, H-
8), 4.39 (t, J = 7.0 Hz, 2H, H-1"), 4.68 (A of AB, J = 12.2 Hz, 1H, H-1'a), 4.84 (d, J = 47.0 Hz, 
2H, CH2F), 4.95 (B of AB, J = 12.2 Hz, 1H, H-1'b), 6.83 (td, J = 2.5, 9.1 Hz, 1H, CHar), 7.11 
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(s, 1H, CHar), 7.14 (dd, J = 2.5, 9.9 Hz, 1H, CHar), 7.27 (dd, J = 4.4, 8.8 Hz, 1H, CHar), 7.39-
7.46 (m, 2H, CHar), 7.76-7.84 (m, 2H, CHar), 7.94 (s, 1H, CHar); 13C NMR (126 MHz, 
CD3OD): δ = 23.0 (C-3"), 31.8 (C-2"), 42.8 (C-3), 44.7 (C-9), 51.0 (C-1"), 53.8 (C-5), 59.1 (C-
1'), 69.7 (C-4), 71.7 (C-8), 72.5 (C-7), 74.0 (C-4), 81.1 (d, J = 183 Hz, CH2F), 102.2 (C-2), 
104.0 (d, J = 23.4 Hz, Ind-C4), 110.5 (d, J = 26.5, Ind-C6), 113.2 (d, J = 9.7 Hz, Ind-C7), 
114.9 (d, J = 4.8 Hz, Ind-C8), 125.5, 125.6 (C-Ar), 129.0 (d, J = 9.6 Hz, Ind-C3), 129.8, 
130.2, 134.7, 135.0, 138.8, 146.9 (C-Ar), 159.0 (d, J = 232 Hz, Ind-C5), 169.5, 172.2, 172.3 
(3 CO); HRMS: m/z calcd for C32H34ClF2N6Na2O9 M+Na+: 765.1839, found: 765.1842. 
Sodium [3-(7-methyl-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 9-(4-chloro-
benzamido)-3,5,9-trideoxy-5-fluoroacetamido-D-glycero--D-galacto-2-
nonulopyranosid]onate (12). Prepared from 22b (16.0 mg, 32.7 µmol) and 26e (10.6 mg, 
49.0 µmol) according to general procedure C. Yield: 18 mg, 75%. D20 -23.2 (c 1.00, 
MeOH); 1H NMR (500 MHz, CD3OD): δ = 1.65 (t, J = 11.9 Hz, 1H, H-3a), 2.25-2.29 (m, 2H, 
H-2"), 2.46 (s, 3H, CH3), 2.74 (t, J = 7.3 Hz, 2H, H-3"), 2.88 (dd, J = 4.7, 12.3 Hz, 1H, H-3b), 
3.44-3.53 (m, 2H, H-7, H-9a), 3.76-3.87 (m, 3H, H-4, H-6, H-9b), 3.95 (m, 1H, H-5), 4.03 (td, 
J = 2.9, 8.5 Hz, 1H, H-8), 4.37 (t, J = 7.0 Hz, 2H, H-1"), 4.67 (A of AB, J = 12.2 Hz, 1H, H-
1'a), 4.84 (d, J = 46.9 Hz, 2H, CH2F), 4.95 (B of AB, J = 12.2 Hz, 1H, H-1'b), 6.83-6.94 (m, 
2H, CHar), 7.05 (s, 1H, CHar), 7.31 (d, J = 7.5 Hz, 1H, CHar), 7.41 (d, J = 8.5 Hz, 2H, CHar), 
7.79 (d, J = 8.5 Hz, 2H, CHar), 7.92 (s, 1H, CHar); 13C NMR (126 MHz, CD3OD): δ = 17.0 
(CH3), 23.2 (C-3"), 32.0 (C-2"), 42.7 (C-3), 44.7 (C-9), 51.0 (C-1"), 53.7 (C-5), 59.0 (C-1'), 
69.6 (C-4), 71.7 (C-8), 72.4 (C-7), 74.0 (C-6), 81.1 (d, J = 183 Hz, CH2F), 102.1 (C-2), 115.0, 
117.1, 120.0, 121.8, 123.0, 123.3, 125.5, 128.3, 129.8, 130.2, 134.6, 137.8, 138.7 (C-Ar), 
169.4, 172.2, 172.3 (3 CO); HRMS: m/z calcd for C33H37ClFN6Na2O9 M+Na+: 761.2090, 
found: 761.2091. 
Sodium [3-(6-chloro-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 9-(4-chloro-
benzamido)-3,5,9-trideoxy-5-fluoroacetamido-D-glycero--D-galacto-2-
nonulopyranosid]onate (13). Prepared from 22b (16.0 mg, 32.7 µmol) and 26f (11.3 mg, 
48.2 µmol) according to general procedure C. Yield: 19 mg, 79%). D20 -24.3 (c 1.07, 
MeOH); 1H NMR (500 MHz, CD3OD): δ = 1.65 (t, J = 12.0 Hz, 1H, H-3a), 2.28 (p, J = 7.1 Hz, 
2H, H-2"), 2.88 (dd, J = 4.7, 12.3 Hz, 1H, H-3b), 2.95 (t, J = 7.4 Hz, 2H, H-3"), 3.40-3.57 (m, 
2H, H-7, H-9a), 3.77-3.87 (m, 3H, H-4, H-6, H-9b), 3.92 (m, 1H, H-5), 4.04 (td, J = 3.1, 8.4 
Hz, 1H, H-8), 4.41 (t, J = 6.9 Hz, 2H, H-1"), 4.67 (A of AB, J = 12.2 Hz, 1H, H-1'a), 4.84 (d, J 
= 47.0 Hz, 2H, CH2F), 4.95 (B of AB, J = 12.2 Hz, 1H, H-1'b), 6.92 (d, J = 7.5 Hz, 1H, CHar), 
6.98 (t, J = 7.8 Hz, 1H, CHar), 7.08 (s, 1H, CHar), 7.25 (d, J = 8.0 Hz, 1H, CHar), 7.41 (d, J = 
8.5 Hz, 2H, CHar), 7.79 (d, J = 8.5 Hz, 2H, CHar), 7.95 (s, 1H, CHar); 13C NMR (126 MHz, 
CD3OD): δ = 24.3 (C-3"), 33.7 (C-2"), 42.7 (C-3), 44.7 (C-9), 51.0 (C-1"), 53.7 (C-5), 59.0 (C-
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1'), 69.7 (C-4), 71.7 (C-8), 72.5 (C-7), 74.0 (C-6) 81.1 (d, J = 183 Hz, CH2F), 102.2 (C-2), 
111.5, 115.1, 120.7, 123.0, 125.2, 125.5, 125.6, 126.9, 129.8, 130.2, 134.6, 138.7, 140.0, 
146.9 (C-Ar), 169.4, 172.2, 172.3 (3 CO); HRMS: m/z calcd for C32H34Cl2FN6Na2O9 M+Na+: 
781.1544, found: 781.1548. 
Sodium [3-(5-isopropyl-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 9-(4-chloro-
benzamido)-3,5,9-trideoxy-5-fluoroacetamido-D-glycero--D-galacto-2-
nonulopyranosid]onate (14). Prepared from 22b (17.5 mg, 34.9 µmol) and 26g (12.7 mg, 
52.4 µmol) according to general procedure C. Yield: 13 mg, 50%. D20 -18.5 (c 0.97, 
MeOH); 1H NMR (500 MHz, CH3OD): δ = 1.28 (d, J = 6.9 Hz, 6H, 2 CH3), 1.65 (t, J = 11.8 
Hz, 1H, H-3a), 2.28 (p, J = 7.1 Hz, 2H, H-2"), 2.74 (t, J = 7.3 Hz, 2H, H-3"), 2.89 (dd, J = 3.3, 
11.8 Hz, 1H, H-3b), 2.95 (m, 1H, CH), 3.43-3.52 (m, 2H, H-7, H-9a), 3.77-3.87 (m, 3H, H-4, 
H-6, H-9b), 3.91 (m, 1H, H-5), 4.04 (td, J = 2.3, 8.3 Hz, 1H, H-8), 4.39 (t, J = 6.9 Hz, 2H, H-
1"), 4.68 (A of AB, J = 11.9 Hz, 1H, H-1'a), 4.84 (d, J = 47.0 Hz, 2H, CH2F), 4.95 (B of AB, J 
= 11.9 Hz, 1H, H-1'b), 6.98 (dd, J = 1.3, 8.4 Hz, 1H, CHar), 7.01 (s, 1H, CHar), 7.24 (d, J = 8.4 
Hz, 1H, CHar), 7.29 (s, 1H, CHar), 7.41 (d, J = 8.5 Hz, 2H, CHar), 7.79 (d, J = 8.5 Hz, 2H, 
C6H4), 7.95 (s, 1H, CHar); 13C NMR (126 MHz, CD3OD): δ = 23.1 (C-3"), 25.4 (2C, 2 CH3), 
31.9 (C-2"), 35.7 (CH), 42.7 (C-3), 44.7 (C-9), 51.1 (C-1"), 53.7 (C-5), 59.1 (C-1'), 69.7 (C-4), 
71.7 (C-8), 72.5 (C-7), 74.0 (C-6), 81.1 (d, J = 183 Hz, CH2F), 102.1 (C-2), 112.2, 114.4, 
116.2, 121.6, 123.6, 128.8, 129.8, 130.2, 134.6, 137.0, 138.7, 140.4 (C-Ar), 169.4, 172.2, 
172.3 (3 CO); HRMS: m/z calcd for C35H41ClFN6Na2O9 M+Na+: 789.2403, found: 789.2406. 
Sodium [3-(1,5,6,7-tetrahydrocyclopenta[f]indole-3-yl)-propyl-[1,2,3]triazole-4-yl-
methyl 9-(4-chlorobenzamido)-3,5,9-trideoxy-5-fluoroacetamido-D-glycero--D-galacto-2-
nonulopyranosid]onate (15). Prepared from 22b (10 mg, 19.1 µmol) and 26h (6.9 mg, 28.7 
µmol) according to general procedure C. Yield: 9 mg, 64%. D20 -24.5 (c 0.57, MeOH); 1H 
NMR (500 MHz, CD3OD): δ = 1.65 (t, J = 11.9 Hz, 1H, H-3a), 2.07 (p, J = 7.2 Hz, 2H, Cyc-
CH2), 2.26 (p, J = 6.9 Hz, 2H, H-2"), 2.71 (t, J = 7.2 Hz, 2H, H-3"), 2.89 (dd, J = 4.7, 12.3 Hz, 
1H, H-3b), 2.93 (t, J = 7.2 Hz, 4H, 2 Cyc-CH2), 3.43-3.53 (m, 2H, H-7, H-9a), 3.76-3.86 (m, 
3H, H-4, H-6, H-9b), 3.91 (m, 1H, H-5), 4.03 (td, J = 3.0, 8.4 Hz, 1H, H-8), 4.38 (t, J = 7.0 
Hz, 2H, H-1"), 4.68 (A of AB, J = 12.2 Hz, 1H, H-1'a), 4.84 (d, J = 47.0 Hz, 2H, CH2F), 4.96 
(B of AB, J = 12.2 Hz, 1H, H-1'b), 6.94 (s, 1H, CHar), 7.14 (s, 1H, CHar), 7.26 (s, 1H, CHar), 
7.41 (d, J = 8.5 Hz, 2H, CHar), 7.79 (d, J = 8.5 Hz, 2H, CHar), 7.93 (s, 1H, CHar); 13C NMR 
(126 MHz, CD3OD): δ = 23.2 (C-3"), 27.9 (Cyc-CH2), 31.9 (C-2"), 33.6, 33.9 (2 Cyc-CH2), 
42.7 (C-3), 44.7 (C-9), 51.1 (C-1"), 53.7 (C-5), 59.0 (C-1'), 69.7 (C-4), 71.7 (C-8), 72.5 (C-7), 
74.0 (C-6), 81.1 (d, J = 183 Hz, CH2F), 101.9 (C-2), 107.6, 114.1, 114.1, 122.9, 125.5, 128.0, 
129.8, 130.2, 134.6, 136.2, 138.1, 138.7, 139.5 (C-Ar), 169.4, 172.2, 172.3 (3 CO); HRMS: 
m/z calcd for C35H39ClFN6Na2O9 M+Na+: 787.2246, found: 787.2248. 
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Sodium [3-(7-chloro-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 9-(4-chloro-
benzamido)-3,5,9-trideoxy-5-fluoroacetamido-D-glycero--D-galacto-2-
nonulopyranosid]onate (16). Prepared from 22b (12.0 mg, 24.1 µmol) and 26i (8.5 mg, 30.2 
µmol) according to general procedure C. Yield: 15 mg, 83%. D20 -22.6 (c 1.00, MeOH); 1H 
NMR (500 MHz, CD3OD): δ = 1.65 (t, J = 11.9 Hz, 1H, H-3a), 2.28 (p, J = 7.2 Hz, 2H, H-2"), 
2.74 (t, J = 7.4 Hz, 2H, H-3"), 2.88 (dd, J = 4.7, 12.3 Hz, 1H, H-3b), 3.43-3.53 (m, 2H, H-7, 
H-9a), 3.74-3.88 (m, 3H, H-4, H-6, H-9b), 3.92 (m, 1H, H-5), 4.03 (td, J = 3.1, 8.4 Hz, 1H, H-
8), 4.40 (t, J = 7.0 Hz, 2H, H-1"), 4.69 (A of AB, J = 12.3 Hz, 1H, H-1'a), 4.84 (d, J = 47.0 Hz, 
2H, CH2F), 4.96 (B of AB, J = 12.2 Hz, 1H, H-1'b), 6.97 (t, J = 7.7 Hz, 1H, CHar), 7.09 (d, J = 
7.5 Hz, 1H, CHar), 7.14 (s, 1H), 7.38-7.47 (m, 3H, CHar), 7.76-7.83 (m, 2H, CHar), 7.96 (s, 
1H, CHar); 13C NMR (126 MHz, CD3OD): δ = 23.0 (C-3"), 31.9 (C-2"), 42.7 (C-3), 44.7 (C-9), 
51.0 (C-1"), 53.7 (C-5), 59.1 (C-1'), 69.7 (C-4), 71.7 (C-8), 72.5 (C-7), 74.0 (C-6), 81.1 (d, J = 
183 Hz, CH2F), 102.0 (C-2), 116.0, 117.8, 118.4, 120.6, 121.9, 124.7, 125.5, 129.8, 130.2, 
130.6, 134.6, 135.2, 138.7 (C-Ar), 169.4, 172.2, 172.3 (3 CO); HRMS: m/z calcd for 
C32H34Cl2FN6Na2O9 M+Na+: 781.1544, found: 781.1544. 
Sodium [3-(5-cyano-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 9-(4-chloro-
benzamido)-3,5,9-trideoxy-5-fluoroacetamido-D-glycero--D-galacto-2-
nonulopyranosid]onate (17). Prepared from 22b (15.3 mg, 30.5 µmol) and 26j (10.3 mg, 45.7 
µmol) according to general procedure C: Yield: 16 mg, 72%. D20 -22.1 (c 1.07, MeOH); 1H 
NMR (500 MHz, CD3OD): δ = 1.65 (t, J = 11.9 Hz, 1H, H-3a), 2.28 (p, J = 7.1 Hz, 2H, H-2"), 
2.73-2.83 (m, 2H, H-3"), 2.88 (dd, J = 4.8, 12.3 Hz, 1H, H-3b), 3.48 (dd, J = 8.1, 13.9 Hz, 2H, 
H-7, H-9a), 3.76-3.88 (m, 3H, H-4, H-6, H-9b), 3.91 (m, 1H, H-5), 4.03 (td, J = 3.1, 8.3 Hz, 
1H, H-8), 4.41 (t, J = 6.9 Hz, 2H, H-1"), 4.68 (A of AB, J = 12.3 Hz, 1H, H-1'a), 4.84 (d, J = 
47.0 Hz, 2H, CH2F), 4.95 (B of AB, J = 12.3 Hz, 1H, H-1'b), 7.23 (s, 1H, CHar), 7.35 (dd, J = 
1.4, 8.4 Hz, 1H, CHar), 7.42 (d, J = 8.6 Hz, 2H, CHar), 7.46 (d, J = 8.4 Hz, 1H, CHar), 7.79 (d, 
J = 8.6 Hz, 2H, CHar), 7.95 (s, 2H, CHar); 13C NMR (126 MHz, CD3OD): δ = 22.7 (C-3"), 31.7 
(C-2"), 42.7 (C-3), 44.7 (C-9), 50.9 (C-1"), 53.7 (C-5), 59.0 (C-1'), 69.7 (C-4), 71.7 (C-8), 
72.5 (C-7), 74.0 (C-6), 81.1 (d, J = 183 Hz, CH2F), 102.2, 102.3 (C-2, C-Ar), 113.6, 116.1, 
122.2, 125.3, 125.4, 125.5, 126.3, 128.6, 129.8, 130.2, 134.6, 138.7, 140.1, 146.9 (CN, C-
Ar), 169.4, 172.2, 172.3 (3 CO); HRMS: m/z calcd for C33H34ClFN7Na2O9 M+Na+: 772.1886, 
found: 772.1891. 
Sodium [3-(5-methylsulfonyl-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 9-(4-
chlorobenzamido)-3,5,9-trideoxy-5-fluoroacetamido-D-glycero--D-galacto-2-
nonulopyranosid]onate (18). Prepared from 22b (9.6 mg, 19.2 µmol) and 26k (8.0 mg, 28.7 
µmol) according to general procedure C. Yield: 15 mg, 66%. D20 -20.4 (c 0.60, MeOH); 1H 
NMR (500 MHz, CD3OD): δ = 1.64 (t, J = 12.0 Hz, 1H, H-3a), 2.32 (p, J = 7.1 Hz, 2H, H-2"), 
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2.82 (t, J = 7.4 Hz, 2H, H-3"), 2.88 (dd, J = 4.8, 12.3 Hz, 1H, H-3b), 3.12 (s, 3H, CH3), 3.43-
3.50 (m, 2H, H-7, H-9a), 3.77-3.86 (m, 3H, H-4, H-6, H-9b), 3.90 (m, 1H, H-5), 4.04 (td, J = 
3.1, 8.3 Hz, 1H, H-8), 4.42 (t, J = 6.9 Hz, 2H, H-1"), 4.67 (A of AB, J = 12.3 Hz, 1H, H-1'a), 
4.84 (d, J = 46.9 Hz, 2H, CH2F), 4.94 (B of AB, J = 12.3 Hz, 1H, H-1'b), 7.28 (s, 1H, CHar), 
7.42 (d, J = 8.5 Hz, 2H, CHar), 7.53 (d, J = 8.6 Hz, 1H, CHar), 7.64 (dd, J = 1.7, 8.6 Hz, 1H, 
CHar), 7.80 (d, J = 8.5 Hz, 2H, CHar), 7.94 (s, 1H, CHar), 8.14 (d, J = 1.4 Hz, 1H, CHar); 13C 
NMR (126 MHz, CD3OD): δ = 22.8 (C-3"), 31.7 (C-2"), 42.7 (C-3), 44.7 (C-9), 45.5 (CH3), 
50.9 (C-1"), 53.7 (C-5), 59.1 (C-1'), 69.7 (C-4), 71.7 (C-8), 72.5 (C-7), 74.0 (C-6), 81.1 (d, J = 
183 Hz, CH2F), 102.2 (C-2), 113.2, 116.8, 120.4, 120.9, 125.5, 126.7, 128.3, 129.8, 130.2, 
131.8, 134.6, 138.7, 140.7, 147.0 (C-Ar), 169.4, 172.2, 172.3 (3 CO); HRMS: m/z calcd for 
C33H37ClFN6Na2O11S M+Na+: 825.1709, found: 825.1709. 
Sodium [3-(5-nitro-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 9-benzamido-
3,5,9-trideoxy-5-fluoroacetamido-D-glycero--D-galacto-2-nonulopyranosid]onate (19). 
Prepared from 22a (15 mg, 30 µmol) and 26o (12 mg, 45 µmol) according to general 
procedure C. Yield: 3.7 mg, 16%, yellow solid. []D20 -20.6 (c 1.00, MeOH); 1H NMR (500 
MHz, D2O): δ = 1.64 (t, J = 12.1 Hz, 1H, H-3a), 2.16-2.23 (m, 2H, H-2"), 2.61 (dd, J = 6.5, 
11.9 Hz, 2H, H-3"), 2.69 (dd, J = 4.8, 12.5 Hz, 1H, H-3b), 3.34 (dd, J = 8.3, 14.0 Hz, 1H, H-
9a), 3.52 (dd, J = 1.3, 8.6 Hz, 1H, H-7), 3.73 (m, 1H, H-4), 3.77-3.91 (m, 3H, H-6, H-8, H-
9b), 3.95 (t, J = 10.1 Hz, 1H, H-5), 4.25-4.36 (m, 3H, H-1'a, H-1"), 4.55 (B of AB, J = 12.2 
Hz, 1H, H-1'b), 4.92 (m, 1H, CH2F), 7.04 (s, 1H, CHar), 7.23 (d, J = 9.0 Hz, 1H, CHar), 7.33 (t, 
J = 7.7 Hz, 2H, CHar), 7.43 (t, J = 7.4 Hz, 1H, CHar), 7.58 (s, 1H, CHar), 7.61 (d, J = 7.4 Hz, 
2H, CHar), 7.78 (dd, J = 1.9, 8.9 Hz, 1H, CHar), 8.06 (d, J = 1.8 Hz, 1H, CHar); 13C NMR (D2O, 
126 MHz):  = 28.9 (C-3"), 40.2 (C-2"), 42.5 (C-9), 50.0 (C-1"), 51.1 (C-5), 57.0 (C-1'), 67.8 
(C-4), 69.8 (C-7), 70.0 (C-8), 72.0 (C-6), 79.6 (d, J = 190 Hz, CH2F), 101.9 (C-2), 111.0, 
116.8, 125.0, 126.0, 126.7, 128.4, 131.9, 133.3 (C-Ar); HRMS: m/z calcd for 
C32H35FN7Na2O11 [M+Na]+: 758.2174, found: 758.2176. 
Sodium [3-(5-nitro-1H-indol-3-yl)-propyl-[1,2,3]triazole-4-yl-methyl 9-(4-chloro-
benzamido)-3,5,9-trideoxy-5-fluoroacetamido-D-glycero--D-galacto-2-
nonulopyranosid]onate (20). Prepared from 22b (18.3 mg, 36.4 µmol) and 26o (13.3 mg, 
54.6 µmol) according to general procedure C. Yield: 19 mg, 70%. D20 -21.6 (c 1.00, 
MeOH); 1H NMR (500 MHz, CD3OD): δ = 1.65 (t, J = 11.9 Hz, 1H, H-3a), 2.30 (p, J = 7.1 Hz, 
2H, H-2"), 2.80 (t, J = 7.4 Hz, 2H, H-3"), 2.87 (dd, J = 3.9, 12.1 Hz, 1H, H-3b), 3.44-3.52 (m, 
2H, H-7, H-9a), 3.78-3.95 (m, 4H, H-4, H-5, H-6, H-9b), 4.03 (m, 1H, H-8), 4.43 (t, J = 6.8 
Hz, 2H, H-1"), 4.68 (A of AB, J = 12.2 Hz, 1H, H-1'a), 4.80 (m, 1H, CH2F), 4.94 (B of AB, J = 
12.2 Hz, 1H, H-1'b), 7.27 (s, 1H, CHar), 7.42 (dd, J = 8.8, 11.0 Hz, 3H, CHar), 7.79 (d, J = 8.5 
Hz, 2H, CHar), 7.97 (s, 1H, CHar), 8.01 (dd, J = 2.1, 9.0 Hz, 1H, CHar), 8.48 (d, J = 2.1 Hz, 
2  Results and Discussion 
   
- 119 - 
1H, CHar); 13C NMR (126 MHz, CD3OD): δ = 22.7 (C-3"), 31.7 (C-2"), 42.6 (C-3), 44.7 (C-9), 
51.0 (C-1"), 53.8 (C-5), 59.0 (C-1'), 69.6 (C-4), 71.7 (C-8), 72.4 (C-7), 74.0 (C-6), 81.1 (d, J = 
183 Hz, CH2F), 102.0 (C-2), 112.6, 116.8, 117.7, 118.0, 127.3, 128.0, 129.8, 130.2, 134.5, 
138.8, 141.4, 142.4 (C-Ar) 169.4, 172.2, 172.3 (3 CO); HRMS: m/z calcd for 
C32H34ClFN7Na2O11 M+Na+: 792.1784, found: 792.1787. 
Surface Plasmon Resonance. The SPR measurements were performed on a 
Biacore 3000 surface plasmon resonance based optical biosensor (Biacore AB, Sweden). 
Sensor chips (CM5), immobilization kits, maintenance supply and HBS-EP (10 mM HEPES 
pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% v/v surfactant P20) were purchased from 
Biacore AB. CM5 chips were preconditioned prior to usage by injecting a series of 
conditioning solutions. A flow rate of 50 µL/min was used and 2 × 20 µL of 50 mM NaOH, 10 
mM HCl, 0.1% SDS and 100 mM H3PO4 were injected. The carboxyl groups on the CM5 
chip were activated for 10 min with a 1:1 mixture of 0.1 M N-hydroxysuccinimide (NHS) and 
0.1 M 3-(N,N-dimethylamino)propyl-N-ethylcarbodiimide (EDC) at a flow rate of 10 µL/min. 
Polyclonal goat anti-human IgG (Fc specific) was purchased from Sigma (I2136, Sigma-
Aldrich Chemie GmbH, Buchs, Switzerland). A sample and a reference surface were 
prepared sequentially or in parallel. For immobilizing, a 30 µg/mL solution of the polyclonal 
antibody diluted in acetate buffer (10 mM sodium acetate, pH 5.0) was then injected over the 
activated surface for 10 min at a flow rate of 10 µL/min. Densities around 13,000 to 14,000 
RU were achieved. Flow cells were blocked with a 10 min injection of 1 M ethanolamine, pH 
8.0. For capturing, MAGd1-3-Fc solution (expressed and purified as described[24]) was diluted 
to a 30-40 µg/mL concentration using HBS-EP. MAGd1-3-Fc was injected at a flow rate of 1 
µL/min for 10 min. The surface was equilibrated overnight at a flow rate of 5 µL/min, 
achieving densities around 3,500 to 4,000 RU. Tenfold dilution series were freshly prepared 
in eluent buffer immediately before use. All binding experiments were conducted at 25 °C at 
a flow rate of 20 µL/min. The samples were injected over 1 min followed by 1 min 
dissociation. Each sample was measured in duplicates for each concentration, using a 
randomized concentration order. Several buffer samples were injected before the first 
concentration, and one blank between each concentration, which were used for the double 
blank referencing during data processing. Double referencing was applied to correct for bulk 
effects and other systematic artifacts. Data processing and equilibrium binding constant 
determinations were accomplished with Scrubber (BioLogic Software, Version 1.1g or 2.0c). 
Kinetic data were simultaneously fit using the non-linear regression program Clamp or 
Scrubber 2.0c. 
CMC determination. 10 mM stock solutions of the samples were prepared in 
DMSO. Then, a dilution series in DMSO was prepared by a Hamilton Microlab Star robot 
(Hamilton AG, Bonaduz, Switzerland) and 5 µL of each well were transferred into buffer 
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(0.05 M MOPSO, pH 6.5) to yield 50 µL of the 12 desired concentrations (between 0 and 1 
mM). Before starting the experiment, the Delta-8 instrument (Kibron Inc., Espoo, Finland) 
used for the CMC determination was calibrated with water. Then, the surface tension of 
each of the 12 dilutions was measured and the results were analyzed with the Vector 
software (Kibron, version 4.02). The assay used for CMC determination was performed at F. 
Hoffmann-La Roche Ltd. (Basel).  
Isothermal Titration Calorimetry. ITC experiments were performed using a VP-ITC 
instrument from MicroCal, Inc. (GE Healthcare, Northampton). The measurements were 
performed at 25 °C. Injections of 10 µL ligand solutions were added from a computer 
controlled 300 µL microsyringe at an interval of 5 min into the sample cell solution of MAGd1-
3-Fc (cell volume 1.4523 mL) with stirring at 307 rpm. A control experiment was performed, 
where the identical ligand solutions were injected into buffer without protein. The 
enthalpogram showed negligible heat development, resulting from dilution effects. The 
assay buffer was HBS-E (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, pH 7.4). The 
concentration of MAG was between 5 and 9 µM (determined by HPLC[32]) and 100 µM 
antagonist solution was injected. The experimental data were fitted to a theoretical titration 
curve (one site binding model) using Origin version 7 software (MicroCal, Northampton), with 
∆H° (enthalpy change), KA (association constant), and N (number of binding sites) as 
adjustable parameters. The quantity c = Mt(0) KD–1, where Mt(0) is the initial macromolecule 
concentration, is of importance in titration microcalorimetry. The experiments were 
performed with c values of 8-30. Thermodynamic parameters were calculated from equation 
(1), 
 G  H TS  RT lnKD  RT lnKA (1) 
where ∆G°, ∆H°, and ∆S° are the changes in free energy, enthalpy, and entropy of binding, 
respectively, T is the absolute temperature, and R is the universal gas constant (8.314 J 
mol–1 K–1).[33] 
Molecular Modeling. Molecular-dynamic simulations (MD) using Desmond,[28] were 
performed to check the stability of the proposed binding modes along with the kinetic 
aspects of the binding. The complexes were simulated during 4.0 ns at 300 K using explicit 
solvent (TIP3P water) and sampled at 1.2 ps intervals. Those frames were then analyzed for 
hydrogen-bond contribution,  stacking and the 1 –NO2Lys 67 interactions to complex 
stabilization. 
Hapten binding assay. Hapten inhibiton assays were performed with wild type and 
mutant MAG Fc-chimeras using immobilized fetuin as target as previously described.[24b] 
Essentially, Fc-chimeras complexed with alkaline phosphatase coupled anti-Fc antbodies 
were allows to bind to fetuin immobilized in microtitre plates in the presence of increasing 
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concentration of inhibitors and IC50 values determined from the resulting inhibition curves. 
At least three independent titrations were performed with triplicate each. 
Expression & purification of mutant. MAGd1-3-Fc mutant K67A was generated by 
site directed mutagenesis with the QuikChange Kit (Stratagene, La Jolla, CA, USA) 
according to the manufacture’s instructions using the plasmid encoding Siglec-4d1-3-Fc wt as 
a template and the following primer pair: 5’-
CAATAGTCCCTACCCCGCGAACTACCCACCGGTG-3’ and 5’-
CACCGGTGGGTAGTTCGCGGGGTAGGGACTATTG-3’. CHOLec1 cells stably secreting 
MAGd1-3-Fc K67A or CHOLec3.2.1.8 cells expressing MAGd1-3-Fc wt proteins were 
maintained in chemically defined Ex-Cell® media (Sigma-Aldrich, München, Germany) 
supplemented with 8 mM glutamine at 8 % CO2 and 37°C and purified as described.[2]4 
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Isothermal Titration Calorimetry. 
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Figure S1: Enthalpogram of compound 1 with MAGd1-3 Fc. 
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Figure S2: Enthalpogram of compound 5 with MAGd1-3 Fc. 
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Figure S3: Enthalpogram of compound 19 with MAGd1-3 Fc. 
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Compound Purity. 
 
HPLC data for the target compounds  
  
HPLC system: Agilent 1100 with UV detection (190-410 nm). A: Water + 0.1% formic acid; 
B: acetonitrile + 0.1% formic acid.  
Method A: Column: Waters Atlantis dC18, 3µm, 4.6  75mm; gradient: 5% B  70% B over 
20 min; flow rate: 0.5 ml/min. 
Method B: Column: Waters Atlantis  dC18, 3µm, 4.6  75mm; gradient: 5% B  95% B 
over 22 min; flow rate: 0.5 ml/min. 
 
Table S1. HPLC data for the target compounds 
 
 
 Formula Method Retention time Purity 
2 C32H37N6NaO9 A 12.97 97 
3 C33H39N6NaO10 A 11.34 97.5 
4 C36H41N6NaO10 A 13.03 97 
5 C39H40ClN6NaO10 A 15.25 95 
6 C33H36F3N6NaO9 A 14.43 96 
7 C33H38N7NaO11 A 13.70 98 
8 C34H40N7NaO11 A 14.32 98 
9 C33H37ClN6NaO10 A 18.98 98.5 % 
10 C32H34Cl2FN6NaO9 A 20.18 97.1 % 
11 C32H34ClF2N6NaO9 A 19.55 97.3 % 
12 C33H37ClFN6NaO9 A 19.88 97.3 % 
13 C32H34Cl2FN6NaO9 A 20.00 95.7 % 
14 C35H41ClFN6NaO9 B 14.42 95.0 % 
15 C35H39ClFN6NaO9 A 14.13 96.8 % 
16 C32H34Cl2FN6NaO9 A 19.57 95.7 % 
17 C33H34ClN7NaO9 A 18.92 98.1 % 
18 C33H37ClFN6NaO11S A 17.78 100 % 
19 C32H35FN7NaO11 A 13.50 97 % 
20 C32H34ClFN7NaO11 B 18.03 99.8 % 
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HPLC-traces of compounds 2 - 20 
 
 
 
 
 
 
 
 
 
O
COONa
O
HO
AcHN
OH
OHH
N
O
N N
N
NH
2
O
COONa
O
HO
AcHN
OH
OHH
N
O
N N
N
NH
O
4
O
COONa
O
HO
AcHN
OH
OHH
N
O
N N
N
NH
3
OMe
2  Results and Discussion 
 
- 128 - 
 
 
 
 
 
 
 
O
COONa
O
HO
AcHN
OH
OHH
N
O
N N
N
NH
CF3
6
O
COONa
O
HO
AcHN
OH
OHH
N
O
N N
N
N
NO2
7
O
COONa
O
HO
AcHN
OH
OHH
N
O
N N
N
NH
5
O
Cl
2  Results and Discussion 
 
- 129 - 
 
 
 
 
 
 
 
 
O
COONa
O
HO
AcHN
OH
OHH
N
O
N N
N
N
NO2
8
O
COONa
O
HO
FAcHN
OH
OHH
N
O
N N
N
NH
Cl
10
Cl
O
COONa
O
HO
FAcHN
OH
OHH
N
O
N N
N
NH
OCH3
9
2  Results and Discussion 
 
- 130 - 
 
 
 
 
 
 
 
 
 
 
O
COONa
O
HO
FAcHN
OH
OHH
N
O
N N
N
NH
12 CH3
Cl
O
COONa
O
HO
FAcHN
OH
OHH
N
O
N N
N
NH
F
11
Cl
O
COONa
O
HO
FAcHN
OH
OHH
N
O
N N
N
NH
13
Cl
Cl
2  Results and Discussion 
 
- 131 - 
 
 
 
 
 
 
O
COONa
O
HO
FAcHN
OH
OHH
N
O
N N
N
NH
14
Cl
O
COONa
O
HO
FAcHN
OH
OHH
N
O
N N
N
NH
15
Cl
O
COONa
O
HO
FAcHN
OH
OHH
N
O
N N
N
NH
16
Cl
Cl
2  Results and Discussion 
 
- 132 - 
 
 
 
 
 
 
 
 
O
COONa
O
HO
FAcHN
OH
OHH
N
O
N N
N
NH
17
Cl
CN
O
COONa
O
HO
FAcHN
OH
OHH
N
O
N N
N
NH
18
Cl
SO2Me
O
COONa
O
HO
FAcHN
OH
OHH
N
O
N N
N
NH
19
NO2
2  Results and Discussion 
 
- 133 - 
 
 
 
 
O
COONa
O
HO
FAcHN
OH
OHH
N
O
N N
N
NH
20
NO2
Cl
2  Results and Discussion 
 
- 134 - 
 
1H NMR spectra for the target compounds in CD3OD or D2O. 
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2.2.2 CD22 – Siglec-2 
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2.3 Thermodynamics of Glycomimetics Binding to Bacterial Lectins 
2.3.1 FimH 
2.3.1.1 Flexibility of Mannosidic Aglycones Favors Binding 
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Introduction 
Urinary tract infections (UTI) are among the most common infections, affecting each 
year millions of people, particularly women.[1,2] The main cause of UTI are 
uropathogenic strains of E. coli (UPEC) which adhere to urothelial cells by the 
interaction of receptors, the so-called FimH lectins, located on the top of their pili.[3] 
Their host cells, the urothelial cells, form the superficial cell layer of the bladder and 
contain oligomannosides as part of the glycoprotein uroplakin A.[4,5] These 
oligomannosides are potent ligands of FimH and therefore establish the first contact 
between bacteria and urothelial cells, which is a prerequisite for the infectious 
cascade to take place. 
Various FimH ligands consisting of an D-mannopyranoside linked to a 
hydrophobic aglycone have been reported.[6,7] The mannose moiety establishes a 
firm network of H-bonds with FimH, whereas the aglycone takes advantage of the 
hydrophobic interactions offered by the side chain of three amino acids lining the 
entrance to the mannose binding pocket. [8] According to two tyrosines (Tyr48 & 137) 
and one isoleucine (Ile52) this entrance is called tyrosine gate.[9] Among the reported 
ligands, n-butyl- and n-heptyl -D-mannopyranoside (1 and 2) exhibit nanomolar 
affinities,[10] although their aglycones contain 4 and 7 rotatable bonds, respectively. 
Since these aglycones form hydrophobic contacts with the tyrosine gate leading to at 
least a partial loss of conformational flexibility, substantial entropy costs upon binding 
are expected.[11-14] Nevertheless, when the n-heptyl chain in 2 was replaced by a 
less flexible aglycone, e.g. a biphenyl (3) affinity surprisingly remained 
unchanged.[15] To rationalize this unexpected result, we present in this 
communication the thermodynamic binding properties of the FimH ligands 1 – 3 as 
well as molecular dynamics simulations of their complex with the carbohydrate 
recognition domain of FimH.    
 
OHOHO
OH
OH
O
OHOHO
OH
OH
O
OHOHO
OH
OH
O
1 2 3
 
Figure 1. n-Butyl- (1) and n-heptyl -D-mannopyranoside (2) reported to exhibit nanomolar affinities[10] 
and biphenyl -D-mannopyranoside (3)[15] surprisingly with a binding affinity similar to 2. 
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Results and Discussion 
A series of mannosidic FimH antagonists with aglycones of different flexibility were 
synthesized (Figure 1). The binding affinities were determined by isothermal titration 
calorimetry (ITC) and the competitive binding assay.[16] The results are shown in 
Table 1. A typical ITC experiment is summarized in Figure 2.  
 
Table 1. rIC50 values were determined with the competitive binding assay,[16] calculated relative to n-
heptyl -D-mannopyranoside (2), and compared to rKD values obtained from the ITC experiments. 
Confidence interval (95%)[17] of the fit for ITC experiments revealed 12 to 22% deviations for KD and 
below 1% deviations for N and ∆H°.  
FimH 
Antagonist rIC50 rKD N KD [nM] 
∆G° 
[kJ mol–1]
∆H° 
[kJ mol–1] 
–T∆S° 
[kJ mol–1] 
∆Cp [kJ 
mol–1 K–1]
1 4.0 4.6 1.02 121 –39.5 –36.6 –2.9 –0.94 
2 1.0 1.0 1.04 ± 0.04 26.2 ± 5.0 –43.3 ± 0.5 –42.3 ± 1.4 –1.1 ± 1.5 –0.90 
3 1.4 0.9 1.06 ± 0.01 23.8 ± 1.7 –43.5 ± 0.1 –43.4 ± 1.4 –0.1 ± 1.6 –0.97 
 
 
Figure 2. A typical result of ITC titration with n-heptyl -D-mannopyranoside (2) and FimH-CRD. The 
top panel shows the recorded change in heat in units of µcal s–1 as a function of time for successive 
injections of ligand (raw data). The bottom panel shows the integrals of the peaks (black squares) 
from the top panel plotted against the molar ratio of the binding process together with a line of best fit, 
used to estimate ∆H°, KD, and N. 
 
For both methods low nanomolar binding affinities were found. Three additional 
rotatable bonds are introduced at the aglycone going from butyl to heptyl (12). 
Since these are usually at least partially restrained upon binding, increased entropic 
costs are expected. [11-14] The binding affinity towards FimH increased when the alkyl 
chain was lengthened (12) as also shown in previously published affinity data.[10] 
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Surprisingly, a closer look into the thermodynamics revealed that only the enthalpic 
contribution got more favorable with little changes in the entropic term. Additionally, 
the term itself was almost negligible for both compounds. A possible explanation is 
that the heptyl aglycone (2) remains flexible upon binding but experience increased 
van-der-Waals contact with the tyrosine gate. In addition, solvent reorganization 
compensates for the entropy penalty arising for the loss of flexibility. In fact, it is 
known that flexible inhibitors can bind with high affinities because of reduced 
entropic penalties.[11,18-20]  
To gain further insight, we synthesized compound 3 with a constrained biphenylic 
aglycone. Surprisingly, the binding affinity and their thermodynamics of interaction 
were comparable to the compound with the flexible heptyl aglycone. Moreover, the 
change in heat capacity (∆Cp) was almost identical for all three compounds, 
indicating small differences in solvent restructuring and surface areas buried upon 
binding.[21,22] A crystal structure of a biphenyl -D-mannopyranoside with a carboxylic 
ester in the 3’-position of the biphenyl moiety suggests that the biphenyl aglycone 
does not bind within the tyrosine gate (in-docking mode, Figure 3a) but favors π-π-
stacking with Tyr48 (out-docking mode, Figure 3b).[15] Taken together, this indicates 
that compensation phenomena could allow compounds 2 and 3 to exhibit near-
identical thermodynamic properties while binding in different modes. 
 
 
Figure 3. Surface representation of FimH crystal structures (a) co-crystallized butyl -D-
mannopyranoside (1)[10] and (b) co-crystallized methyl 4’-(-D-mannopyranosyloxy)-biphenyl-3-
carboxylate[15] (comparable to 3). 
 
To verify the stated hypotheses, a series of 10 ns molecular-dynamics (MD) 
simulations were performed, revealing that a substantial part of ligand/tyrosine gate 
mobility could be retained upon binding (Figure 4). For further insight, relative 
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binding free energy changes (averaged over ensembles of MD snapshots) were 
calculated using the MM-GBSA (molecular-mechanics generalized Born surface 
area) approach (as implemented in Prime[23]). This method is reported to achieve 
good accuracy for various molecular systems at a fraction of the computational 
expense required by more sophisticated approaches.[24] An additional advantage 
was the possibility of decomposing the obtained values into specific energy 
contributions (Table 2). 
 
 
Figure 4. Distributions of aglycone and tyrosine conformers for superimposed (mannose heavy 
atoms) MD frames of respective simulations. 
 
Table 2. Selected data (average MM-GBSA values) obtained from ensembles of MD snapshots for 
respective   FimH antagonists.  
FimH 
Antagonist 
G [kcal mol–1] GSolv. [kcal mol–1] GEle. [kcal mol–1] GvdW [kcal mol–1] 
1 –64.5 ± 5.8 19.6 ± 2.4 –41.9 ± 7.5 –19.1 ± 2.8 
2 –76.3 ± 6.1 20.7 ± 2.5 –41.1 ± 6.9 –23.4 ± 2.9 
3 –73.0 ± 5.7 18.7 ± 2.6 –36.9 ± 6.8 –25.3 ± 2.7 
 
These results provide valuable context to both the ITC data and the driving forces 
behind the binding modes. Specifically, when moving from compound 1 to 2, we can 
observe a more unfavorable solvent contribution (likely related to the higher 
desolvation penalty of the latter), overcompensated by van der Waals interactions 
originating from a larger hydrophobic interface between aglycone and protein. 
Moving on to compound 3 reveals a less favorable electrostatic contribution – 
possibly due to the rigidity of the compound influencing the H-bond network quality – 
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balanced out by a smaller desolvation penalty and further improved interactions of 
the aglycone.  
Though the computational approach reports total changes in free energy, it does not 
fully account for conformational entropy shifts occurring upon binding of highly 
flexible compounds. This limitation along with lack of polarization effects, are 
reported[24] as the main reasons for the overly large values and ranges of the 
calculated energies. To compensate for this, changes in the mobility of ligand 
aglycones and tyrosine gate residues (expected to vary the most between respective 
systems) were quantified based on MD-conformer distributions (see methods 
section). The obtained absolute –TS data (1.7, 2.6 and 1.6 kcal mol–1 for 
compounds 1, 2, and 3, respectively) supports initial assumptions about n-heptyl -
D-mannopyranoside (2) paying the biggest penalty due to its number of rotatable 
bonds. Nevertheless these costs are much smaller than one would expect from fully 
constraining a ligand and two flexible side chains, again confirming that a substantial 
part of their mobility is being preserved. With respect to the experimental data, this 
could also mean that the solvation entropy gain, originating from displacing water 
from the mannose-binding pocket, overcompensates the cost of only partially 
restraining ligand and protein. 
 
Summary and Conclusion 
The present thermodynamic study reveals that flexibility is not always accompanied 
with an entropic penalty. A series of mannopyranosides with aglycones of different 
flexibility have been investigated. The n-heptyl aglycone (2) bound with higher affinity 
compared to the n-butyl aglycone (1) because of an increased enthalpic contribution 
without any entropic penalty. Interestingly, compound 3 with the constrained 
biphenylic aglycone exhibited an identical thermodynamic signature compared to 
compound 2 with the flexible heptyl chain although the binding geometry is different. 
In some cases, flexibility is not a disadvantage.  
 
Experimental Procedure 
Cloning of FimH-CRD. The plasmid pfimHs-trc, encoding FimH lectin domain 
(FimH-CRD, 1-156 amino acids[25]), was kindly provided by R. Glockshuber (ETH Zürich, 
Switzerland). For the periplasmic expression of FimH-CRD the plasmid pfimHs-trc was 
transformed into the protease-deficient E. coli strain HM 125.[26]  
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Protein Expression and Purification. E. coli HM 125 expressing FimH-CRD were 
grown at 30 °C with vigorous shaking (300 rpm) in M9 minimal medium[27] supplemented 
with 2 mM MgSO4, 0.1 mM CaCl2, 0.4% glycerin, and 100 μg.mL–1 ampicillin. When an 
OD600 of 0.8 was reached, the cells were induced with 1 mM IPTG (isopropyl -D-1-
thiogalactopyranoside) and further cultivated for 16 h at 30 °C and 300 rpm. Then the cells 
were cooled on ice for 5 min and harvested by centrifugation at 5´000 rpm for 20 min at 4 
°C. The pellet was suspended in a cold solution of 50 mM TrisHCl, pH 7.5, 150 mM NaCl, 5 
mM EDTA, 1 mg mL–1 polymyxin B sulfate and stirred for 2 h at 4 °C. After centrifugation at 
11´000 rpm for 20 min at 4 °C, the supernatant (periplasmic extract) was acidified by the 
addition of 0.11 volumes of 1 M acetic acid solution pH 4.5 and dialyzed at 4 °C against a 10 
mM acetic acid solution pH 4.5. The acidified extract was applied to a UNO-S® column 
attached to a BioLogic FPLC system (BioRad, Reinach BL, Switzerland) that was pre-
equilibrated with a 10 mM acetic acid solution pH 4.5. The flow through was collected and 
adjusted to pH 8 with a 2 M TrisHCl solution and applied to a UNO-Q® column attached to a 
BioLogic FPLC system (BioRad, Reinach BL, Switzerland). The column was pre-equilibrated 
with a 40 mM TrisHCl solution pH 8. The flow through containing FimH-CRD was dialyzed 
against 20 mM HEPES, 150 mM NaCl, and 1 mM CaCl2, pH 7.4 overnight at 4 °C. The 
protein solution was concentrated by ultrafiltration (5 kDa cut off) and gelfiltrated on a Bio-
Prep SE-100/17 column attached to a BioLogic FPLC system (BioRad, Reinach BL, 
Switzerland). The protein purity was verified by SDS–PAGE. At 4 °C, aliquots of the protein 
could be stored for up to 3 months. For long-term storage, the protein was frozen at −80 °C. 
  Competitive Binding Assay. The competitive binding assay was carried out as 
previously described by Rabbani et al.[16]  
Isothermal Titration Calorimetry. ITC experiments were performed using a VP-ITC 
instrument from MicroCal, Inc. (GE Healthcare, Northampton) after vacuum degassing of the 
samples. The measurements were performed at 25 °C and for ∆Cp determination 
additionally at 10 and 37 °C. Injections of 3 to 14 µL ligand solutions (150 µM) were added at 
an interval of 10 min into the sample cell solution containing FimH-CRD (8 to 23 µM, sample 
cell volume 1.4523 mL) with stirring at 307 rpm. Protein concentration was determined by 
HPLC-UV against a BSA standard.[28,29] The quantity c = Mt(0) KD–1 where Mt(0) is the initial 
macromolecule concentration, is of importance in titration microcalorimetry. The c-values 
were between 90 and 1050. Because the smallest reliable volumes were injected, sigmoidal 
shaped curves were detected. Control experiments injecting ligand solution into buffer 
without protein showed that the heats of dilution were small and constant. The assay buffer 
was: 10 mM HEPES, 150 mM NaCl, and 1 mM CaCl2, pH 7.4 (HBS-Ca). For compound 3, a 
final concentration 2.5% DMSO was necessary to dissolve the ligand. In this case, the 
protein solution was adjusted to 2.5% DMSO final concentration. Control experiments with 
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compound 2 in presence of 2.5% DMSO revealed identical results when compared to 0% 
DMSO. Baseline correction and peak integration were accomplished using the software 
Origin 7 as described by the manufacturer (OriginLab, Northampton). The first injection was 
always excluded from data analysis because it usually suffers from sample loss during the 
mounting of the syringe and the equilibration preceding the actual titration. A three-
parameter (N, KD and ∆H°, stoichiometry, dissociation constant, and change in enthalpy) 
nonlinear least-square data fitting was performed in an Excel (Microsoft) spreadsheet using 
the Solver add-in (Frontline System)[17,30] according to binding isotherms published by 
Ziegler and Seelig.[31]  
Thermodynamic parameters were calculated from the equation (1) and (2),  
   G  H TS  RT lnKD  RT lnKA (1) 
 
  
Cp  HT2  HT1(T2 T1)
    (2) 
where ∆G°, ∆H°, ∆S°, and ∆Cp are the changes in free energy, enthalpy, entropy, and heat 
capacity of binding, respectively, T is the absolute temperature, and R is the universal gas 
constant (8.314 J mol–1 K–1).  
Molecular Modeling. For all simulations a 1.69 Å resolution crystal structure (PDB 
code 1UWF) of the FimH-CRD was used. Flexible docking was performed using Glide.[32] 
Poses were selected based on docking scores and protein–ligand interaction energies 
calculated with the OPLS 2005 force field.[33] Molecular dynamics simulations were carried 
out with Desmond.[34] Each MD (preceded by executing a built–in relaxation protocol) was 
run for 10 ns in 300 K with 1.2 ps intervals for writing energy and trajectory data. All 
simulations were evaluated using the Simulation Quality Analysis script. Corresponding 
images were generated using Maestro[35,36] and VMD.[37] MM-GBSA calculations were 
performed on ensembles of minimized MD snapshots (834 per simulation). Gs were 
obtained as average values, taking into account the local internal strains of the ligand and 
residues within 6.0 Å. Conformational entropies for chosen system components were 
obtained through RMSD-based MD (free and in-complex simulations) snapshot clustering 
(Desmond Trajectory Clustering). A cutoff of 1.0 Å between clusters was used. The results, 
corresponding to the population of unique conformational states, were used to calculate 
corresponding entropies similar to the approach of D’Aquino et al.[38] by using the standard 
formula: 
 
S  pi ln pi
i
  
where pi is the probability of state i and R is the universal gas constant. Resulting values 
were normalized to 45 states for each component. 
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2.3.1.2 Ortho-Substituted Biphenyl Aglycones 
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3 Summary 
Most of the lectins are characterized calorimetrically for the first time except FimH[1] 
and an indirect thermodynamic determination of E-selectin binding to ESL-1.[2] All 
these interactions enrich the dataset with variable thermodynamic fingerprints. A 
typical carbohydrate-lectin interaction was found for physiological ligands and mimics 
interacting with DC-SIGN that are enthalpically favorable interaction largely 
compensated by an entropic penalty that result in a micromolar binding affinity. In 
contrast, carbohydrates binding to E-selectin are entropically favored and as well in 
the micromolar range. The other carbohydrate-lectin interactions that were 
investigated exhibit nanomolar binding affinities. All these interactions are 
enthalpically driven with variable entropic contribution ranging from unfavorable for 
CD22 ligands, over negligible to unfavorable contributions for MAG and FimH 
antagonists. Overall, the thermodynamics among the investigated lectins are very 
divers and gave insights into the driving force of interactions. 
 
References 
[1] M. Durka, K. Buffet, J. Iehl, M. Holler, J. F. Nierengarten, J. Taganna, J. Bouckaert, S. P. 
Vincent, Chem. Commun. 2011, 47, 1321-1323; M. Almant, V. Moreau, J. Kovensky, J. 
Bouckaert, S. G. Gouin, Chem. Eur. J. 2011, 17, 10029-10038. 
[2] M. K. Wild, M. C. Huang, U. Schulze-Horsel, P. A. van der Merwe, D. Vestweber, J. Biol. 
Chem. 2001, 276, 31602-31612. 
 
 
4  Appendix 
- 205 - 
Table 1. Experiment index for chapter 2.1.1.1 and 2. Binding thermodynamics of E-selectin antagonists determined by ITC at 25 °C (HBS-Ca buffer) 
compared to rIC50/IC50 values from competitive binding assay where BW69669 was used as reference compound.  
Structure Ligand IC50 [µM] rIC50) KD [µM] rKD [µM] 
∆G° 
[kJ mol–1] 
∆H° 
[kJ mol–1] 
–T∆S° 
[kJ mol–1] N c-value 
O
O
OH
OH
HO
O
COONa
O
O
OH
HO
O
HO
O
HO
AcHN
HO OH
OH
NHAc
OH
OCH3
Methyl sLex
2.1.1.1 1 
2.1.1.2 1 
  
943.4 
 
–17.3 +5.9 –23.2 1 0.2 
811.7 –17.6 +4.9 –22.5 1 0.1 
Mean ± SD 875.4 ± 138.5 12.9 ± 3.7 877.5 ± 93.1 14.9 –17.5 ± 0.2 +5.4 ± 0.7 –22.9 ± 1.1 1  
O
O
OH
OH
HO
O
O
CO2Na
OAcHN
HO
OH
OH
O
OH
HO
O
HO
NHAc
HO
OSE
OH
FB119 822.8 ± 162.3 12.4 ± 2.4 885 15 –17.4 +5.9 –23.3 1 0.2 
O
OH
OH
HO
O
COONa
O
O
OH
HO
O
HO
O
HO
AcHN
HO OH
OH
 
FB89 
2.1.1.1 3 
312.5 ± 
479.1 4.4 ± 2.4 316.5 5.4 –20.0 –0.5 –19.5 1  0.6 
O
OH
OH
HO
O
COONa
O
O
OH
HO
O
HO
O
HO
AcHN
HO OH
OH
 
FB87 
2.1.1.1 4 60.3 ± 15.2 0.59 ± 0.28 37.6 0.64 –25.3 +0.9 –26.2 0.94 3.0 
O
OH
OH
HO
O
O
O
OH
HO
O
HO
NaO O
HO
 
FB321 43.0 ± 16.8 0.66 ± 0.05 62.9 1.1 –24.0 –5.9 –18.1 0.98 1.8 
O
OH
OH
HO
O
O OAcHN
HO
OH
OH
O
OH
HO
O
HO
HO
NHO
 
FB109 311.8 ± 107.8 3.6 ± 0.3 414.9 7.0 –19.3 +5.2 –24.5 1 1.0 
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Structure Ligand IC50 [µM] rIC50) KD [µM] rKD [µM] 
∆G° 
[kJ mol–1] 
∆H° 
[kJ mol–1] 
–T∆S° 
[kJ mol–1] N c-value 
O
O
OH
OH
HO
O
COONa
O
O
OH
HO
O
HO
OH
NHAc
O SiMe3
 
FB289 344.5 ± 154.5 4.4 ± 0.9 107.3 1.8 –22.7 –0.8 –21.9 1 1.0 
O
O
OH
OH
HO
O
COONa
O
O
OH
HO
O
HO
OH
NHAc
O
 
FB329 
2.1.1.1 5 
233.4 ± 
69.2 3.5 ± 0.3 259.7 4.4 –20.5 –2.2 –18.3 1 0.9 
O
OH
OH
HO
O
COONa
O
O
OH
HO
O
HO
 
BW69669
2.1.1.1 6 
2.1.1.2 2 
  
62.1 
 
–24.0 –5.0 –19.0 0.99 1.5 
55.9 –24.3 –5.5 –18.8 0.87 1.2 
Mean ± SD 61.4 ± 13.6 1 59.0 ± 4.4 1 –24.2 ± 0.2 –5.3 ± 0.4 –18.9 ± 0.6 0.93 ± 0.08  
O
OH
OH
HO
O
COOH
O
O
OH
HO
O
HO
 
DS4115 
2.1.1.1 2 
2.1.1.2 3 
  
17.2  
 
–27.2 –5.7 –21.5 0.97 4.8 
19.7 –26.9 –5.9 –21.0 0.97 4.2 
Mean ± SD 13.7 ± 3.3 0.18 ± 0.02 18.5 ± 1.8 0.31 –27.1 ± 0.2 –5.8 ± 0.1 –21.3 ± 0.4 0.97 ± 0.01  
O
O
OH
OH
HO
O
COONa
O
O
OH
HO
O
HO
OH
 
CGP77175 A   
30.3  
 
–25.7 –7.8 –17.9 1.13 4.4 
29.6 –25.8 –7.4 –18.4 1.17 2.9 
Mean ± SD 17.5 ± 6.9 0.29 ± 0.07 30.0 ± 0.5 0.51 –25.8 ± 0.1 –7.6  ± 0.3 –18.2 ± 0.4 1.15 ± 0.03  
O
OH
OH
HO
O
COONa
O
O
O
HO
O
HO
O
 
BW534 
2.1.1.2 4 8.7 ± 0.1 0.09 ± 0.01 4.8  –30.3 –7.2 –23.1 1.17 4.6 
O
OH
OH
HO
O
COONa
O
O
O
HO
O
HO
O
F
 
BW510 
2.1.1.2 6 7.4 ± 1.5 0.08 ± 0.01 3.6 0.06 –31.1 –11.3 –19.8 1.08 11 
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Structure Ligand IC50 [µM] rIC50) KD [µM] rKD [µM] 
∆G° 
[kJ mol–1] 
∆H° 
[kJ mol–1] 
–T∆S° 
[kJ mol–1] N c-value 
O
OH
OH
HO
O
COOH
O
O
O
HO
O
HO
O
 
DS0565 
2.1.1.2 7 5.2 ± 1.0 0.05 ± 0.01 8.6 0.15 –28.9 –11.6 –17.3 1.04 8.7 
O
OH
OH
HO
O
COONa
O
O
O
HO
O
HO
O
 
GMI1077 
2.1.1.2 5   
4.3 
 
–30.6 –13.0 –17.6 0.95 10.5 
4.0 –30.8 –12.1 –18.7 0.97 10.1 
3.8 –31.0 –12.0 –19.0 1.08 8.0 
Mean ± SD 6.7 ± 2.0 0.07 ± 0.01 4.0 ± 0.3 0.07 –30.8 ± 0.2 –12.4 ± 0.6 –18.4 ± 0.7 1.00 ± 0.07  
E-selectin 
monomer     –31.2 –11.8 –19.4 1.14 19.7 
O
OH
OH
HO
O
COOH
O
O
O
HO
O
HO
O
 
DS0567 
2.1.1.2 8 6.1 ± 1.7 0.06 ± 0.02 2.1 0.04 –32.5 –12.7 –19.8 1.11 35.7 
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Table 2. Experiment index for chapter 2.1.1.1 and 2. rIC50/IC50 values from competitive binding assay for E-selectin antagonists (HBS-Ca buffer) whith 
BW69669 was used as reference compound.  
Structure Ligand IC50 [µM] rIC50 
O
OH
OH
HO
O
COONa
O
O
OH
HO
O
HO
 
BW69669 61.4 ± 13.6 1.0 
O
OH
OH
HO
O
COONa
O
O
OAc
HO
O
HO
O
HO
AcHN
HO OH
OH
CO2Me
 
FB124 57.9 1.0 
O
OH
OH
HO
O
O
O
OH
HO
O
HO
HO
O NHMe
 
FB298 336.2 ± 170 3.5 ± 2.7 
O
OH
OH
HO
O
O
O
OH
HO
O
HO
BnHN O
HO
 
FB320 146.8 2.7 
O
OH
OH
HO
O
COONa
O
O
OH
HO
O
HO
 
FB333 1423 22.0 
O
OH
OH
HO
O
COOH
O
O
OH
HO
O
HO
 
FB341 77.5 ± 22.4 1.5 ± 0.3 
 
 
 
 
Structure Ligand IC50 [µM] rIC50 
O
OH
OH
HO
O
COOH
O
O
OH
HO
O
HO
FB344 629.3 14.7 
COONa
O
O
O
O
O OH
OH
HO
HO
HO
NH
O
BW570 7.8 ± 0.6 0.08 ± 0.01 
O
OH
OH
HO
O
CO2Na
O
O
NH
HO
O
HO
O
BW585 11.0 ± 0.6 0.15 ± 0.05 
O
OH
OH
HO
O
CO2Na
O
O
NH
HO
O
HO
O
BW588 7.3 ± 0.6 
0.10 ± 
0.03 
O
O
OH
OH
HO
O
O
CO2Na
OHN
HO
OH
OH
O
OH
HO
O
HO
NHAc
HO
O
OH
HO
O
SiMe3 GG-2-109 497.5 ± 62.4 7.1 ± 1.7 
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Table 3. Experiment index for chapter 2.1.2. Binding thermodynamics of DC-SIGN antagonists determined by ITC at 25 °C (HBS-Ca buffer) compared to 
rIC50/IC50 values from competitive binding assay (determined by Meike Scharenberg) where phenyl Lea was used as reference compound.  
Structure Ligand rIC50 KD [nM] rKD 
∆G° 
[kJ mol–1] 
∆H° 
[kJ mol–1] 
–T∆S° 
[kJ mol–1] N c-value 
O
O
O
O
OH
O
O OH
OHHO
NHAcOH
OHHO
HO
 
Phenyl Lea 
2.1.2 1  
553 KL –18.6 –29.4 +10.8 1 0.14 
610 KL –18.4 –26.6 +8.3 1 0.08 
Mean ± SD 1 582 ± 40 1 –18.5 ± 0.1 –28.0 ± 2.0 +9.5 ± 2.1 1  
O
O
O
O
OH
O
O OH
OHHO
NHAcOH
OHHO
HO
 
methyl Lea 
2.1.2 2 2.9 ± 0.5 735 1.3 –17.9 –27.9 +10.0 1 0.12 
OO
O
O
OH
HO
HO
OH
OH
OH
HO
 
KM65 
2.1.2 4 1.8 ± 0.5 645 1.1 –18.2 –31.4 +13.2 1 0.09 
OO
O
O
HO
HO
OH
OH
OH
HO
 
KM153 
2.1.2 5 4.7 ± 1.0 1277 2.2 –16.5 –29.7 +13.2 1 0.04 
OHO
O
HO
OH
OH
 
KM151 
2.1.2 6  1073 1.8 –16.9 –34.4 +17.5 1 0.03 
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Table 4. Experiment index for chapter 2.2.1.1 and 2. Binding thermodynamics of MAGd1-3-Fc antagonists determined by ITC at 25 °C (HBS-E buffer) 
compared to KD values from SPR (determined by Stefanie Mesch). 
Structure Ligand KD [nM] SPR 
KD [nM] 
ITC 
∆G° 
[kJ mol–1] 
∆H° 
[kJ mol–1] 
–T∆S° 
[kJ mol–1] N 
c-
value 
O
CO2Na
O
H
N
OH
OH
HO
O
Cl
F
FHN
O
F
SM5FAc 
2.2.1.1 5 500 
142 –39.1 –39.2 +0.1 1.02 151.8 
106.3 –39.8 –43.3 +3.5 0.91 33.9 
Mean ± SD  124.2 ± 25.2 –39.5 ± 0.5 –41.3 ± 2.9 +1.8 ± 2.4 0.97 ± 0.08  
O
O
O
OO
O
O
OH
AcHN
HO COONa
HO
AcHN
OH
OH
HOHO
AcHN
HO
COONa
OH
OH
OH
OH O CH3
AcHN COOMe
2.2.1.1 13a  
2900 –31.6 –22.5 +9.1 0.77 5.9 
1200 –33.8 –24.9 +8.9 0.89 12.3 
Mean ± SD  2100 ± 1200 –32.7 ± 1.6 –23.7 ± 1.7 +9.0 ± 0.1 0.83 ± 0.08  
O
CO2Na
OAcHN
H
N
OH
OH
HO
O
N N
N
N
H
NO2
SH281/ 
JXH144 
2.2.1.2 1 
190 
 
610 –35.5 –33.4 –2.1 1.01 14.8 
568 –35.7 –34.6 –1.1 0.91 10.9 
Mean ± SD  582.3 ± 18.7 –35.6 ± 0.1 –34.0 ± 0.9 –1.6 ± 0.7 0.96 ± 0.07  
O
CO2Na
OAcHN
H
N
OH
OH
HO
O
N N
N
N
H
O
Cl
JXH158 
2.2.1.2 5 75 
118.0 –39.6 –52.0 +12.4 0.93 19.2 
146.2 –39.1 –51.8 +12.7 0.88 23.7 
Mean ± SD  132.1 ± 19.9 –39.3 ± 0.4 –51.9 ± 0.1 +12.6 ± 0.2 0.91 ± 0.04  
O
CO2H
OFAcHN
H
N
OH
OH
HO
O
N N
N
N
H
NO2
SM432 
2.2.1.2 19 50 
207 –38.2 –32.9 –5.3 0.97 30.4 
136 –39.2 –32.1 –7.1 1.13 47.8 
Mean ± SD  171.5 ± 50.2 –38.7 ± 0.7 –32.5 ± 0.6 –6.2 ± 1.3 1.05 ± 0.11  
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Table 5. Experiment index for chapter 2.2.2. Binding thermodynamics of CD22d1-3-Fc antagonists determined by ITC at 25 °C (HBS-E buffer) compared to KD 
values from SPR (determined by Stefanie Mesch). 
Structure Ligand KD [nM] SPR 
KD [nM] 
ITC 
∆G° 
[kJ mol–1] 
∆H° 
[kJ mol–1] 
–T∆S° 
[kJ mol–1] N c-value 
H
N
HO
O
COOH
O
OH
OHHN
S
O
O
NO2
F
FO
Cl
 
DM-N3 
2.2.2 9k 110 131.4 –39.3 –54.8 +15.5 0.96 85 
AcHN
HO
O
COOH
O
OH
OHHN
O
 
SMC-9-4 
2.2.2 13a 800 
592 –35.6 –72.8 +37.2 0.93 3.0 
909 –34.5 –73.9 +39.4 0.98 3.1 
Mean ± SD  750.5 ± 224.2 –35.1 ± 0.8 –73.4 ± 0.8 +38.3 ± 1.6 0.96 ± 0.04  
AcHN
HO
O
COOH
O
OH
OHHN Cl
ClO
 
SM-2-26-2 
2.2.2 13b 100 
64.1 –41.1 –81.1 +40.0 0.93 64.8 
81.3 –40.4 –76.5 +36.1 0.95 34.4 
101.5 –39.9 –83.1 +43.2 0.92 15.3 
Mean ± SD  82.3 ± 18.7 –40.5 ± 0.6 –80.2 ± 3.4 +39.7 ± 3.6 0.94 ± 0.02  
H
N
HO
O
COOH
O
OH
OHHN
S
O
O
NO2
Cl
ClO
 
SM-2-31 
2.2.2 17a n.b. 
H
N
HO
O
COOH
O
OH
OHHN
S
O
O
NO2
Cl
ClO
HO
 
SM-2-16 
2.2.2 17b 60 
86.1 –40.3 –60.8 +20.5 1.08 32.5 
73.0 –40.8 –62.3 +21.5 1.06 19.2 
Mean ± SD  79.6 ± 9.3 –40.6 ± 0.4 –61.6 ± 1.1 +21.0 ± 0.7 1.07 ± 0.01  
H
N
HO
O
COOH
O
OH
OHHN
S
O
O
NO2
Cl
ClO
N
 
SM-2-18 
2.2.2 17c 110 
122.0 –39.5 –81.4 +41.9 0.96 14.8 
182.8 –38.5 –85.3 +46.8 0.93 13.1 
Mean ± SD  152.4 ± 43.0 –39.0 ± 0.7 –83.4 ± 2.8 +44.4 ± 3.5 0.95 ± 0.02  
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Table 6. Experiment index for chapter 2.3.1.1 and 2. Binding thermodynamics of FimH-CRD antagonists determined by ITC at 25 °C (HBS-Ca buffer) 
compared to rIC50/IC50 values from competitive binding assay (determined by Said Rabbani) where n-Heptyl -D-mannopyranoside was used as reference 
compound. 
Structure Ligand rIC50 KD [nM] rKD 
∆G° 
[kJ mol–1] 
∆H° 
[kJ mol–1] 
–T∆S° 
[kJ mol–1] N c-value  
OHOHO
OH
O
OH
 
n-Heptyl -D-
manno-
pyranoside 
(HM) 
2.3.1.1 2 
2.3.1.2 1 
 
1 
22.4 
 
–43.7 –42.6 –1.1 1.06 1052 KL 
16.9 –44.4 –42.6 –1.8 1.05 519 KL 
19.8 –44.0 –42.4 –1.6 1.09 520 KL 
22.7 –43.6 –43.1 –0.5 1.08 454 KL 
25.9 –43.3 –41.5 –1.8 1.09 375 KL 
26.1 –43.4 –39.1 –4.3 1.01 458 KL 
28.3 –43.1 –42.4 –0.7 1.01 399 KL 
31.8 –42.8 –43.9 +1.1 1.01 314 KL 
29.8 –43.0 –42.4 –0.6 1.04 342 KL 
30.2 –42.9 –43.5 +0.6 1.02 348 RP 
27.4 –43.2 –40.4 –2.8 1.02 365 KL 
33.5 –42.7 –43.1 +0.4 0.98 412 KL 
Mean ± SD  26.2 ± 5.0 1 –43.4 ± 0.5 –42.3 ± 1.4 –1.1 ± 1.5 1.04 ± 0.04   
OHOHO
OH
OH
 
1,5–Anhydro 
mannitol 39 
705 
 
–35.1 –38.0 +2.9 1.08 33 RP 
892 –34.5 –39.9 +5.4 1.05 26 RP 
Mean ± SD  798 ± 132 30 –34.8 ± 0.4 –39.0 ± 1.3 +4.2 ± 1.8 1.05 ± 0.03   
OHOHO
OH
O
OH
 
MM 34 
1123 
 
–34.0 –30.7 –3.3 1.12 19 KL 
1298 –33.6 –31.5 –2.1 1.00 18 RP 
Mean ± SD  1211±124 46 –33.8 ± 0.3 –31.1 ± 0.6 –2.7 ± 0.8 1.06 ± 0.08   
OHOHO
OH
O
OH PLJ01234A 
2.3.1.1 1 4.0 121 4.6 –39.5 –36.6 –2.9 1.02 93.6 KL 
OHOHO
OH
O
OH
COOH  
AV277 1.2 
40.2 
 
–42.2 –42.7 +0.5 1.02 281 KL 
50.6 –41.6 –41.4 –0.2 1.03 216 KL 
Mean ± SD  45.4 ± 7.4 1.7 –41.9 ± 0.4 –42.1 ± 0.9 0.2 ± 0.5 1.03 ± 0.01   
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Structure Ligand rIC50 KD [nM] rKD 
∆G° 
[kJ mol–1] 
∆H° 
[kJ mol–1] 
–T∆S° 
[kJ mol–1] N c-value  
OHOHO
OH
HN
OH
O  
OS429 3.6 59.1 2.3 –41.3 –43.0 +1.7 1.02 191 KL 
OHOHO
OH
O  
JXH@031 (2–
deoxy HM) 147 4953 189 –30.3 –12.5 –17.8 1.02 7.1 KL 
OHOHO
OH
O
OH
 
PLJ01192A 
(2.5% DMSO) 
2.3.1.1 3 
 
1.4 
22.6 
 
–43.6 –42.4 –1.2 1.05 449 KL 
25.0 –43.4 –44.4 +1.0 1.06 420 RP 
Mean ± SD  23.8 ± 1.7 0.91 –43.5 ± 0.1 –43.4 ± 1.4 –0.1 ± 1.6 1.06 ± 0.01   
OHOHO
OH
O
OH
ONa
O  
PLJ01238A 
2.3.1.2 4b 0.20 14.1 0.54 –44.8 –47.3 +2.5 1.00 688 KL 
OHOHO
OH
O
OH
ONa
O
F
 
PLJ01175B 
2.3.1.2 14a 0.58 
9.2 
 
–45.9 –51.6 +5.7 1.01 1120 KL 
11.7 –45.3 –49.9 +4.6 1.00 829 KL 
Mean ± SD  10.5 ± 1.8 0.40 –45.6 ± 0.4 –50.8 ± 1.2 +5.2 ± 0.8 1.00 ± 0.01   
OHOHO
OH
O
OH
ONa
O
Cl
 
TK05 
2.3.1.2 5b 0.09 
3.7 
 
–48.1 –55.5 +7.4 1.01 2784 KL 
4.6 –47.6 –54.3 +6.7 1.01 2109 KL 
Mean ± SD  4.2 ± 0.6 0.16 –47.9 ± 0.4 –54.9 ± 0.9 +7.0 ± 0.5 1.01   
OHOHO
OH
O
OH
Cl
Cl
O
ONa
 
TK23 
(0.6% DMSO)  
12.9 
 
–45.0 –53.2 +8.2 1.02 713 KL 
22.7 –43.6 –56.0 +12.4 1.03 604 KL 
Mean ± SD  17.8 ± 6.9 0.49 –44.3 ± 1.0 –54.6 ± 2.0 +10.3 ± 3.0 1.03 ± 0.01   
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Structure Ligand rIC50 KD [nM] rKD 
∆G° 
[kJ mol–1] 
∆H° 
[kJ mol–1] 
–T∆S° 
[kJ mol–1] N c-value  
OHOHO
OH
O
OH
ONa
O
Me
 
PLJ01179B 
2.3.1.2 14b 0.16 4.8  –47.5 –56.2 +8.7 0.99 2146 KL 
OHOHO
OH
O
OH
ONa
O
CN
 
PLJ01224A 
2.3.1.2 14f 0.58 7.4 0.28 –46.4 –55.0 +8.6 1.01 1311 KL 
OHOHO
OH
O
OH
ONa
O
OMe
 
PLJ01178B 
2.3.1.2 14d 0.08 
7.7 
 
–46.3 –52.5 +6.2 1.02 1338 KL 
10.9 –45.4 –51.0 +5.6 1.02 890 KL 
Mean ± SD  9.3 ± 2.3 0.35 –45.9 ± 0.6 –51.8 ± 1.1 +5.9 ± 0.4 1.02   
OHOHO
OH
O
OH
ONa
O  
PLJ01181B 
2.3.1.2 14e 1.09 6.9 0.26 –46.6 –46.7 +0.1 1.01 1493 KL 
OHOHO
OH
O
OH
ONa
O
CF3
 
PLJ01194B 
2.3.1.2 14c 0.15 3.2 0.12 –48.5 –58.5 +10.0 1.00 3219 KL 
OHOHO
OH
O
OH
N
 
PLJ01005A 2.0 
249 
 
–38.0 –36.8 –1.2 0.98 44 KL 
651 –35.3 –34.5 –0.8 1.09 19 KL 
Mean ± SD  450 ± 284 17 –36.7 ± 1.9 –35.7 ± 1.6 –1.0 ± 0.3 1.04 ± 0.08  
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Structure Ligand rIC50 KD [nM] rKD 
∆G° 
[kJ mol–1] 
∆H° 
[kJ mol–1] 
–T∆S° 
[kJ mol–1] N c-value  
OHOHO
OH
O
OH
N
N
N
COOH  
PLJ01066A 0.29 
5.4 
 
–47.2 –57.1 +9.9 0.92 1733 KL 
1.5 –50.3 –51.7 +1.4 1.03 6333 KL 
Mean ± SD  3.5 ± 2.8 0.13 –48.8 ± 2.2 –54.4 ± 3.8 +5.6 ± 6.0 0.98 ± 0.08   
OHOHO
OH
O
OH
N
N
N
N
MHa31 1.1 189 7.2 –38.4 –37.2 –1.2 1.02 61 KL 
OHOHO
OH
O
OH
S
O
O NH  
PLJ01089A 12.8 
2.4 
 
–49.2 –52.6 +3.4 0.98 3704 KL 
4.6 –47.6 –49.4 +1.8 0.91 1641 KL 
Mean ± SD  3.5 ± 1.6 0.14 –48.4 ± 1.1 –51.0 ± 2.2 +2.6 ± 1.1 0.95 ± 0.05   
OHOHO
OH
O
OH
N
O
O  
PLJ01076A 0.22 
6.4 
 
–46.8 –53.3 +6.5 1.13 1320 KL 
3.4 –48.3 –53.6 +5.3 1.05 1903 KL 
Mean ± SD  4.9 ± 2.1 0.19 –47.6 ± 1.1 –53.5 ± 0.2 +5.9 ± 0.8 1.09 ± 0.06   
OHOHO
OH
O
OH
Cl
N
O
O  
PLJ01128A 
 
0.70 
 
1.1 
 
–51.1 –56.5 +5.4 1.00 8355 KL 
1.8 –50.1 –52.0 +1.9 1.01 3839 KL 
Mean ± SD  1.5 ± 0.5 0.06 –50.6 ± 0.8 –54.3 ± 3.2 +3.7 ± 2.4 1.01 ± 0.01   
 
 
 
